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ABSTRACT

FUNCTIONAL CONSEQUENCES OF CYTOSINE METHYLATION IN MITOCHONDRIAL
DNA CATALYZED BY DNA METHYLTRANSFERASE 1
Lisa Sale Shock, B.A.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2011
Major Advisor: Shirley M. Taylor, PhD
Associate Professor, Department of Microbiology and Immunology

Cytosine methylation of mitochondrial DNA (mtDNA) was first described several
decades ago, but neither the mechanism generating this modification nor its functional
significance was known. Because mitochondrial dysfunction is a hallmark characteristic of
numerous human diseases, including neurological and cardiovascular disease, aging and cancer,
this dissertation addressed whether epigenetic modification of mtDNA regulates mitochondrial
function. We show that mtDNA contains not only 5-methylcytosine (5mC), but also 5hydroxymethylcytosine (5hmC), suggesting that previous reports likely underestimated the
degree of epigenetic modification within the mitochondrial genome. We questioned how these
modifications were generated by looking for mitochondrial isoforms of the nuclear-encoded
DNA methyltransferases. We found that an isoform of the most abundant mammalian
methyltransferase, DNA methyltransferase 1 (DNMT1) translocates to mitochondria, driven by

an in-frame mitochondrial targeting sequence (MTS) located upstream of the nuclear DNMT1
translational start site. This MTS is highly conserved across mammalian species, and directs a
heterologous protein to the mitochondria. To investigate the function of mitochondrial DNMT1
(mtDNMT1), we created a cell line that carries a tandem-affinity purification (TAP) tag at the Cterminus of a single endogenous human DNMT1 allele. Using the DNMT1-TAP cell line, we
showed that mtDNMT1 specifically binds mtDNA in a manner that is proportional to CpG
density, proving its presence in the mitochondrial matrix. mtDNMT1 exhibits CpG-specific
methyltransferase activity in vitro that is resistant to trypsin-treatment of intact mitochondria, but
moderately susceptible to pharmacologic inhibition by the nucleoside analog 5-aza-2’deoxycytidine (5-aza-dC). NRF1 and PGC1α, transcription factors that activate nuclear-encoded
mitochondrial proteins in response to oxidative stress, were observed to up-regulate expression
of mtDNMT1. Loss of p53, a tumor suppressor gene known to help control mitochondrial
metabolism, also results in a striking increase in mtDNMT1 expression, and this up-regulation of
mtDNMT1 appears to modify mitochondrial transcription in a gene-specific fashion. Our data
suggests roles for mtDNMT1 in both the establishment and maintenance of cytosine methylation
(from which 5hmC is presumably derived) and in the regulation of mitochondrial transcription.
We propose that the enzymes responsible for epigenetic modification of mtDNA have potential
as therapeutic targets, with relevance to a broad spectrum of human disorders.

Chapter 1: Introduction and Overview

I.

Overview of mitochondrial structure and function
Mitochondria are considered to be the “powerhouse of the cell” for their essential role in

electron transport and oxidative phoshorylation, which provide the majority of cellular energy (1,
2). These unique organelles, however, are more than just a powerhouse (2). Mitochondria are
also involved in a number of other key cellular processes, including cell signaling,
differentiation, metabolism, apoptosis, control of the cell cycle, and control of cell growth (1-3).
Mitochondrial dysfunction contributes to the progression of various human pathologies,
including neurodegenerative disorders, cardiac disease, aging and cancer (1-3). The involvement
of mitochondria in such a wide range of diseases has made them an attractive therapeutic target
among researchers spanning numerous fields.
Early studies on mitochondrial function used isolated systems, and focused on the
organelle as an essential, yet autonomous, element of the cell. However, more recent findings
strongly favor the view that mitochondria function as a cooperative, integrated system, highly
involved in crosstalk with the nucleus and other components of the cell (1-4). Evidence
supporting this crosstalk is based on the observation that a majority of the genes required for all
of the mitochondria’s biological functions are encoded by the nuclear genome (1-4).
Structurally, the mitochondrion is rather complex and unusual. It is comprised of two
membranes that separate four distinct compartments, each with its own subset of functions
(Figure 1-1). The outer mitochondrial membrane is composed of half lipid, half protein (5). It

1

Figure 1-1: Cartoon of the organellar structure of a mitochondrion. Mitochondria are
composed of two membranes (the outer and the inner membrane), which separate two aqueous
compartments: the intermembrane space and the matrix. The matrix contains multiple copies of
mitochondrial DNA (mtDNA). This compartmentalization assists the organelle in subdividing its
many functions.

2

serves as the outermost barrier of the organelle, with a topology dotted by transmembrane
channels, making it permeable to molecules less than 10 kDa in weight (5). The inner
mitochondrial membrane is only about 20% lipid, 80% protein, making it a much denser barrier.
The inner membrane’s characteristic impermeability allows the formation of a proton-motive
force, which drives ATP synthesis. Separating the outer and inner membranes is the aqueous
intermembrane space. Its protein components are 100% nuclear in origin, and many contain Nterminal targeting signals that direct their import and translocation into mitochondria (6). The
matrix is also an aqueous compartment, housing mitochondrial DNA (mtDNA) and ribosomes,
and serves as the site for mitochondrial transcription, translation, and ATP synthesis.
Import of nuclear-encoded precursor proteins into mitochondria is most frequently driven
by N-terminal targeting sequences that are recognized by receptors on the outer mitochondrial
surface. Once imported through the mitochondrial outer membrane, targeting sequences then
serve as sorting signals, directing the precursor protein to its destination (6, 7). Either during
translocation, or shortly thereafter, the targeting sequences are cleaved by the mitochondrial
processing peptidase (MPP) to yield their final functional form (6, 7).

II.

General features of mtDNA, including mtDNA methylation
Part of what makes mitochondria so unique is that these organelles contain their own

genetic system and the means for translating proteins encoded on the mitochondrial genome.
Mammalian mitochondrial DNA exists as a 16.5kb double-stranded circular molecule. Despite
its small size, mtDNA represents ~1% of a cell’s total genomic DNA, because mtDNA is present
in two to ten copies per mitochondrion, and 103-104 copies per cell (Figure 1-2) (1, 4).
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Figure 1-2: Schematic diagram highlighting general features of mtDNA. tRNA genes (red
bars, single-letter code) intersperse the protein-coding and rRNA genes on both the H-strand
(dark blue) and L-strand (light blue). Positions of amplicons used in MeDIP and mitochondrial
gene expression studies (Chapter 2) are represented by dashed white lines. HSP1, heavy strand
promoter 1; HSP2, heavy strand promoter 2; LSP, light strand promoter.
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The mitochondrial genome exhibits an extreme economy in its organization: it is
relatively small in size, and contains no introns or non-coding regions. Both strands of
mitochondrial DNA are used to encode a total of 13 proteins, present in the respiratory chain
complexes, 2 rRNAs and 22 tRNAs (Figure 1-2), by far an insufficient collection of proteins to
allow for complete functioning of the organelle. As mentioned above, the vast majority of
“mitochondrial” proteins, including those required for mtDNA replication and transcription, are
encoded in the nucleus and transported into the mitochondria.
In contrast to the nuclear genome, mtDNA is not complexed with histones. However,
mtDNA is present in stable protein-containing complexes called nucleoids, each containing
multiple copies of mtDNA bound to a complex mixture of proteins, including the mtDNA
polymerase (POLG), Twinkle helicase and various transcription factors (8, 9). These mtDNA
nucleoids are thought to function in a manner similar to nuclear histones by packaging between
five and seven copies of mtDNA each into a restricted diameter of only 70nm (9). This
compaction property of nucleoids therefore contributes to mtDNA segregation and heritable
transmission of mitochondrial genomes into daughter mitochondria during fusion and fission (810).
Mitochondrial nucleoid complexes are proposed to exist in two zones: 1) the core
complex, which contains mtDNA actively undergoing replication and/or transcription, associated
with appropriate POLG and mtRNA polymerase (mtRNAP) proteins, and 2) the peripheral
complex, containing mtDNA and natively-bound proteins that are not efficiently crosslinked to
the DNA, including heat-shock protein 60kDa (Hsp60) and AAA-domain ATPase/protease 3A
(ATAD3A) (9). Among the most abundant components of mtDNA nucleoid core complexes is
mitochondrial transcription factor A (TFAM) (8, 9). A number of recent studies have reported
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levels of TFAM in sufficient quantities to coat the entire mitochondrial genome, supporting its
proposed role in binding, bending and compacting mtDNA into distinct foci (10, 11), and
protecting mtDNA from oxidative damage (12), in addition to its role as a mitochondrial
transcription factor (10).
Isolation of mitochondrial replicative intermediates from mouse L cells using dye-CsCl
gradients and electron microscopy suggested a model in which mtDNA replication originates at
the origin of replication of the heavy strand (OH), upon formation of a displacement loop (Dloop) (4). This D-loop exists as a triplex structure containing a short daughter heavy (H)-strand
RNA, which remains stably associated with the parental strand, serving as a primer to initiate Hstrand synthesis (4). Once initiated, synthesis of the H-strand proceeds unidirectionally for the
entire length of the molecule. Upon completing approximately three-fourths of the H-strand,
synthesis of the L-strand begins at its origin (OL), and continues in the opposite direction. Once
replication has traversed the full length of the molecule in both directions, both H- and Ldaughter strands are converted to covalently-closed circles and super-helical turns are added,
forming traditional super-helical mtDNA (4).
Studies performed decades ago first reported the presence of 5-methylcytosine (5mC)modified residues in mtDNA. These early findings were controversial because of technical
limitations and it was considered likely that the modifications measured were reflective of
contaminating nuclear DNA. Using methylation-sensitive restriction endonuclease cleavage and
nearest-neighbor analysis, these groups reported low levels of methylation restricted to CpG
dinucleotides (only 3-5% of CpGs were methylated), in the mitochondria of several species (1517). This methylation was described as “nonrandom”, meaning that, while certain sites were
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most frequently modified, different sites were found to be methylated to a different extent (16,
17).
Interestingly, methylation is not the only feature mtDNA shares with nuclear DNA.
Mitochondrial DNA was also found to exhibit an underrepresentation of CpG dinucleotides
(termed “CpG suppression”) to nearly the same extent as the nuclear genome (18). The phrase
“CpG suppression” refers to the general rarity of CpG dinucleotides within DNA, compared to
the random expected frequency. 5mC, which occurs in the mammalian genome almost
exclusively at CpG dinucleotides, is a known mutational “hotspot”, as it can be spontaneously
deaminated to thymidine. Thus, CpG suppression is thought to be reflective of a functional
significance of 5mC residues and lends further support to the idea that mtDNA was at some time,
or is now, methylated.
Although the presence of mtDNA methylation has been known for quite some time, it has
remained surprisingly underexplored. Thus, the remainder of the overview on epigenetic
mechanisms and their roles in regulating gene expression will focus on what is known about
these processes in the nuclear compartment, and consider whether these mechanisms might also
operate in mitochondria.

III.

Epigenetic regulation of gene expression in the nucleus
There is a clear and well-established role for genetics in human disease, but nuclear

genetic information is packaged in a complex chromatin structure and the information content
extends beyond the sequences of genes (Figure 1-3A). The term epigenetics refers to the extra
layer of instructions that influences gene activity without altering the DNA sequence. Epigenetic
modifications exist in three main forms: 1) DNA methylation, 2) histone modifications, and 3)

7

nucleosome positioning (Figure 1-3B). Mechanistically, each of these mechanisms induces
dynamic and dramatic changes in chromatin structure, thereby dictating gene expression and
inheritance (19). Epigenetic modifications have fundamental roles in normal development and
biology, and are often among the first factors to become dysregulated in disease. Although
epigenetic modifications are somatically heritable, they are also reversible, making them the
subject of intense investigation as therapeutic targets (20, 21). Aberrations to the epigenetic
landscape have been demonstrated in cancer, diabetes, aging, and a number of neurological
disorders (21).
While the human genome is essentially the same in all of our cells, the epigenome differs
in a tissue-specific fashion, and can be influenced by a cell’s environmental cues. Thus,
epigenetics provides a platform for the generation of multiple different phenotypes arising from
the same genotype (22). The tissue-specificity of epigenetic marks contributes to cellular
differentiation and, when aberrantly placed, can lead to neoplastic transformation with
characteristics specific to the host organ (22, 23). Epigenetic mechanisms also have a “nurture”
component, such that changes to cellular environmental conditions, including physical, chemical
or dietary influences, can induce a stable, heritable epigenomic response (24). This gene-
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Figure 1-3: Structural organization and packaging of nuclear genetic material. (A) The
organization of DNA within the chromatin structure: (i) A short region of DNA double helix; (ii)
DNA is wound around a histone octamer, forming nucleosomes separated by short stretches of
linker DNA; (iii) nucleosomes condense to form a packed chromatin fiber; (iv) chromatin fibers
are further folded into higher-order structures; (v) the full mitotic chromosome. (B) Euchromatic
and heterochromatic states of chromatin. (i) Euchromatin, represented by a transcriptionally
active gene with an open chromatin structure, sparse DNA methylation (green circles), and
activating histone marks (blue circles). The transcriptional machinery is shown present at the
promoter, represented by a complex of green ovals. (ii) Heterochromatin, represented by a
transcriptionally silenced gene with closed chromatin structure, dense DNA methylation (orange
circles), and repressive histone marks (yellow circles). Adapted from figures by Felsenfeld G,
Groudine M (2003) Nature and Feinberg AP (2007) Nature.
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environment interaction in early development is thought to be linked to disease outcomes later in
life (24).
DNA methylation is probably the most well-studied of epigenetic mechanisms. DNA
methylation is the result of a stable chemical alteration of the DNA, and can have long-term
consequences on gene activity. It was first suggested by Riggs (25) and Holliday and Pugh (26)
that patterns of DNA methylation vary in different cell types, and that these methylation patterns
are capable of altering gene expression profiles. It was hypothesized that the mechanisms
underlying these effects on gene expression acted through modulation of DNA binding by
transcription factors or other proteins (25, 26). Molecular studies have confirmed these initial
hypotheses, demonstrating that the covalent addition of a methyl group to the DNA changes the
facade of the major groove, altering accessibility by DNA binding proteins (27, 28). Although
DNA methylation is generally associated with gene silencing, in actual fact, depending on
whether a positive or negative regulatory element is affected, DNA methylation can act to either
increase or decrease transcription (27). The precise function of methylation depends on the
sequence context surrounding the modified residue, and its proximity relative to the
transcriptional start site of the adjacent gene (27).
Post-translational modifications (PTMs) of histone proteins, collectively, comprise
another mechanism influencing the recruitment of effector protein complexes that regulate
transcription (28). Histone modifications include acetylation, methylation, phosphorylation,
SUMOylation and ubiquitination (29). The majority of these modifications decorate either the Nor C-terminal histone tails; however, some localize to the globular domains of the histone
proteins (28). Whereas both acetylation and methylation involve the addition of small chemical
groups, SUMOylation and ubiquitination add larger, more bulky groups that can presumably
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have a more profound impact on chromatin structure. It was first thought that histone PTMs
could be classified by their consistent behavior as either positive or negative marks, however, the
functions of individual histone modifications are neither easily definable nor predictable. Rather,
like DNA methylation, the consequences of each mark are highly dependent on the specific
residues and contexts in which they are added (28).
The coordinated effects of DNA methylation and histone modification result in an
“epigenetic code,” a mosaic pattern of factors regulating gene expression at the transcriptional
level. The combination of modifications can either work directly, by influencing local chromatin
structure, or indirectly, through the recruitment of effector molecules (28). Chromosomes have
two structurally and functionally distinct chromatin topographies, distinguishable by the
positioning of nucleosomes along the chromatin fiber. The term “euchromatin” has been
assigned to the active transcriptional state, whereby chromatin is dotted by acetylated histones
and devoid of methylation (Figure 1-3B). This open configuration allows for the recruitment of
activating factors, and accessibility to DNA by the transcriptional machinery. In contrast, the
term “heterochromatin” refers to the transcriptionally inert state of chromatin that adopts a
closed, compact configuration, preventing access by the transcriptional machinery.
Heterochromatin is characterized by an abundance of DNA cytosine methylation, and
hypoacetylation of histones. The prevailing thought is that these epigenetic marks function
cooperatively, to either activate gene expression or to establish repression (28); in this way, the
dynamic state of chromatin is regulated by two opposing sets of epigenetic marks for fine-tuned
control.
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IV.

Dynamics and mechanisms of DNA methylation and demethylation
DNA methylation arises through the covalent addition of a methyl group to the 5’

position of a cytosine, and occurs almost exclusively at CpG dinucleotides within the
mammalian genome. CpG dinucleotides are under-represented in mammalian DNA, due in part
to the mutagenic pressure of spontaneous 5-methylcytosine (5mC) deamination, yet vertebrate
genomes contain the highest levels of 5mC modifications in the animal kingdom (30). In
humans, approximately 70-80% of all CpG dinucleotides are methylated, meaning that 5mC
accounts for approximately 1% of all DNA bases (31).
Although they represent long-term heritable marks, DNA methylation patterns exhibit
striking temporal and spatial variation. During early development, the paternal pronucleus
undergoes a distinct phase of demethylation, which erases the existing methylation pattern and
essentially reprograms the genome (30, 32). The somatic DNA methylation pattern is established
by a wave of de novo methylation just before implantation, and that pattern is then propagated
during DNA replication throughout development of the organism (30, 33). DNA methylation
patterns in somatic cells and the adult organism are stable, except for a distinct subset of genes
that undergo selective demethylation when their expression is needed, as in the demethylation of
imprinted genes in primordial germ cells (32). It is thought that DNA methylation patterns are
maintained between cell generations by a mechanism based on semi-conservative replication,
whereby the parental pattern is copied onto the nascent DNA strand (34).
Mammals exhibit a distinct bimodal pattern of methylation, with hypermethylation of
CpG dinucleotides sparsely distributed throughout the genome, and hypomethylation of “CpGislands,” which are short stretches of CG-dense sequence surrounding the promoter regions of
genes (Figure 1-4). Methylated CpGs throughout the body of a gene are thought to contribute to
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Figure 1-4: Roles of DNA methylation in normal development and disease states. DNMT1
functions normally to faithfully maintain the established pattern of methylation throughout DNA
replication. When functioning abnormally, as in cases of over-expression, DNMT1 has been
shown to methylate DNA de novo, and appears to drive tumor progression. The mechanisms
forcing these dramatics shifts in DNA methylation remain to be understood, but it is apparent
that the factors involved would be extremely relevant therapeutic targets. Adapted from figure by
Taylor, S.M. (2006) Cell Science Reviews.
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genomic stability, whereas the absence of methylation at CpG-island-associated promoters
supports transcription and expression of the adjacent genes. Cells undergoing transformation to a
neoplastic phenotype exhibit the opposite methylation profile: global hypomethylation, leading
to genomic instability and hypermethylation of CpG-island-associated promoters, resulting in
transcriptional silencing (22, 23).
The enzymatic reaction of DNA methylation is catalyzed by a family of DNA (cytosine5) methyltransferases (DNMTs), whose individual roles will be discussed in more detail below.
These enzymes require the aid of cofactor and methyl group donor, S-adenosyl-ʟ-methionine
(SAM) and rely on the steric relief of base-flipping the target cytosine out of the DNA backbone
(35, 36). The DNMTs exert a nucleophilic attack on the carbon-6 position of the target cytosine.
This attack is performed by a thiol group positioned within the ProCys active site of the enzyme,
and results in the formation of a covalent complex between the DNMT and the cytosine C-6
position. Formation of the covalent intermediate activates the carbon-5 position of the target
cytosine for electrophilic attack, which leads to the transfer of a methyl group from SAM to the
C-5 position of the cytosine (35). The covalent reaction intermediate is resolved when the 5-6
double bond is reformed and the DNMT is released by β-elimination (36). The active site
cysteine residue has been shown to be essential for both covalent complex formation with the
target cytosine residue, and catalysis of the DNMT enzyme (37, 38).
The requirement for DNA methylation in normal mammalian development is
demonstrated by a number of key studies which showed that pharmacological inhibition of DNA
methylation by nucleoside analogs of cytidine (5-aza-cytidine and 5-aza-deoxycytidine) induced
striking phenotypic changes in cultured mouse cells (39, 40). Multinucleated myotubes, a
characteristic of contractile striated muscle cells, adipocytes and chondrocytes were all observed
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to arise from cultures of 10T1/2 and NIH/3T3 mouse cells treated with the cytidine analogs (39).
The resultant changes in the differentiated state of treated cells were traced back to changes in
the methylation patterns of their DNA (40). Subsequent deletion of the genes encoding the
DNMT enzymes resulted in an approximate 3-fold reduction in genomic 5mC levels (41). While
ES cells carrying the deletions could survive in culture without obvious defects in viability or
proliferation, knockout mice exhibited severe developmental abnormalities, and died early in
development (41, 42).
Just as there are mechanisms in place to add methyl groups to DNA, the process of DNA
demethylation also has been examined at both the genome-wide and locus-specific levels (43).
However, the precise mechanism underlying removal of 5mC has been under intense debate. For
years researchers sought an active demethylase, and several reports claimed to have identified
known proteins with secondary demethylating functions (43). Many hypothesized that such a
demethylation reaction could occur through a base excision repair-like process, in which the
5mC base is excised and replaced with an unmethylated cytosine (43, 44). Active DNA
demethylation has been well-characterized in plants, and involves a group of 5mC-specific DNA
glycosylases that initiate base excision repair of 5mC to unmethylated cytosines (44).
The recent discovery of 5-hydroxymethylcytosine (5hmC) residues in mammalian DNA
sparked speculations that 5hmC could represent an intermediate in either active or passive
demethylation of mammalian DNA (45, 46). Earlier this year, a study described a two-step
mechanism mediated by the ten-eleven translocase (TET) family of methylcytosine oxygenases,
whereby 5mC residues are first converted to 5hmC residues through oxidation by the TET1
protein. 5hmC residues are then deaminated by the activation-induced deaminase
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(AID)/apolipoprotein B mRNA-editing enzyme complex (APOBEC) family of deaminases to
form uracil, which is repaired by the base excision repair pathway (47).
The predominant mechanism for generation of 5hmC modification is thought to be
through oxidation of 5mC residues by the TET1 protein, although other mechanisms have been
suggested, including the direct addition of an aldehyde to DNA by DNMT1 (Figure 2-15) (4648). It is curious that, through two alternate mechanisms, DNMT1 could be responsible both for
generating 5mC modifications and removing them by initiating demethylation, but this level of
mechanistic fine-tuning has been described for other enzymes participating in “suicide”
inhibition of their own activity, such as acetylcholinesterase (49).
5hmC was first identified in brain and liver tissues extracted from several species, and
estimated by thin layer chromatography to represent approximately 15% of the total number of
cytosines within the rat genome (50). This is far greater than the estimated frequency of 3-6% for
5mC residues among cytosine bases within the normal mammalian genome (51), but is likely
either an artifact, or a reflection of the tissue-specificity of the 5hmC modification, as the highest
levels of 5hmC are undoubtedly found in the brain (52). More recent enzymatic quantitations of
5hmC levels in genomic DNA from murine embryonic stem cells estimate that the modified base
occurs at around 0.3% of cytosines (53). Also unlike 5mC, 5hmC is enriched at gene promoters
and CpG islands, and co-localizes with euchromatin, which promotes high levels of transcription
(54). Thus, the distribution of 5hmC modifications also demonstrates a bimodal pattern, but
opposite to that for 5mC, which further supports the idea that 5hmC is derived from pre-existing
5mC modifications (46, 54).
Just as the presence of 5mC can have either direct or indirect effects on transcription,
5hmC is also thought to influence local chromatin structure by two potential means: 1) recruiting
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5hmC-specific proteins or 2) preventing binding by 5mC-binding proteins (52). Studies have
shown that some 5mC-specific binding proteins, including methyl-CpG binding protein 2
(MeCP2), and methyl-binding domain proteins, MBD1, MBD2 and MBD4, do not recognize
5hmC residues (55, 56). Additionally, certain restriction endonucleases, including the MspI and
HpaII isoschizomer can distinguish between 5mC and 5hmC modifications at the internal
cytosine within their 5’-CCGG-3’ target restriction site when first modified by βglucosyltransferase (52). However, methods for specific detection and quantitation of 5hmC are
still lacking; the vast majority of methods commonly employed to map and measure DNA
methylation, such as classical sodium bisulfite sequencing, cannot distinguish between 5mC and
5hmC modifications (53, 56).

V.

Roles of the DNA methyltransferase (DNMT) enzymes
While several members of the family of DNA methyltransferase homologs are known to

exist (Figure 1-5), only three have DNA methyltransferase activity: DNMT1, DNMT3a and
DNMT3b. The de novo methyltransferases, DNA methyltransferase 3a (DNMT3a) and DNA
methyltransferase 3b (DNMT3b), are thought to establish the pattern of methylation on
unmethylated DNA during early embryogenesis (34). That pattern is then faithfully maintained
throughout subsequent rounds of DNA replication by the most abundant mammalian
methyltransferase, DNA methyltransferase 1 (DNMT1) (34). DNMT2 is a tRNA
methyltransferase, and DNMT3L does not have any catalytic activity, but is thought to function
as a regulatory factor, interacting with and stimulating methylation by DNMT3a (34, 57).
All DNA (cytosine-5) methyltransferases share similarities in sequence and structure. All
(except for DNMT2) consist of two major domains: the N-terminal regulatory domain, and the
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Figure 1-5: Basic molecular structures of for the family of DNMT enzymes. (A) The
structure of DNMT1 consists of two domains: the N-terminal regulatory domain and the smaller
C-terminal catalytic domain. The regulatory domain contains binding sites for PCNA (PCNA)
and other proteins, a nuclear localization signal (NLS), a replication foci targeting sequence
(RFTS), CXXC Zn-finger domains (Zn-binding) and bromo-associated homology (BAH)
domains. The catalytic domain contains conserved motifs (black bars labeled with roman
numerals), each with specific functions contributing to enzymatic activity. Motif IV is the active
site; motifs VIII and X bind the target cytosine residue. The N-terminal and C-terminal domains
are separated by a LysGly (KG repeat) hinge region. (B) Organization of structural domains and
conserved motifs among the DNMT enzymes. The C-terminal domains for all other DNA
(cytosine-5) methyltransferases share strong amino acid sequence homology and conserved
motifs. The N-terminal domains are highly variable across the DNMTs. Adapted from figure by
Hermann A, Gowher H, Jeltsch A (2004) Cell Mol Life Sci.
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C-terminal catalytic domain. Like bacterial DNMTs, DNMT2 lacks the large N-terminal domain
(Figure 1-5). The regulatory domain serves to facilitate interactions with numerous proteins and
binds to DNA (57). The catalytic domain, on the other hand, serves as the active center of the
enzyme, and houses the conserved motifs characteristic of all eukaryotic and prokaryotic
cytosine-5 DNMTs. Motifs I, II and III form a binding pocket for SAM; motif IV contains the
ProCys dipeptide initiating the methyl transfer reaction; motifs V, VII and IX are involved in
preserving the structure of the target recognition domain; motifs VI, VIII and X form the binding
pocket for the cytosine substrate (Figure 1-5) (36, 57).
The initial hypothesis that de novo and maintenance methylation were two distinct
processes arose from observations by Lei, et al. (58). They used homologous recombination to
delete the only known DNA methyltransferase gene at the time (now known as DNMT1), and to
their surprise, the DNMT-null cells retained low but stable levels of 5mC and DNMT activity.
These results suggested that not only was an independently-encoded DNMT present in
mammalian cells, but it contained enzymatic activity capable of methylating exogenouslyintroduced unmethylated DNA in vivo (58). Upon closer examination of the EST database, a
total of four human EST clones were found to contain the highly conserved DNA (cytosine-5)
methyltransferase motifs (59). Two of these clones shared a high degree of sequence similarity,
but differed from DNMT1 and DNMT2; these were subsequently named DNMT3a and
DNMT3b, although they are encoded by separate genes (59). Both DNMT3a and DNMT3b were
found to be highly expressed in undifferentiated murine embryonic stem cells, but barely
detectable in differentiated embryoid bodies and adult tissues (59). DNMT1, on the other hand,
is fairly ubiquitously expressed in mammalian cells, but has been shown to be indispensable for
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proper differentiation and survival of differentiated cells (60). Thus, the expression patterns for
these enzymes correlate with their proposed roles as de novo or maintenance methyltransferases.
Additional genetic studies confirmed that DNMT3a and DNMT3b were responsible for
establishment of the methylation profile (42). Embryonic stem (ES) cells carrying homozygous
deletions in either DNMT3a or DNMT3b displayed no change in their ability to methylate
unmethylated proviral DNA, however, targeted disruption of the active site in both genes
(DNMT3a-/-, DNMT3b-/-) prevented de novo methylation activity (42). Similarly, mice carrying
a double mutation for both enzymes exhibited a more severe phenotype than either individual
deletion, suggesting an overlap in functions among the DNMTs (42).
As their names suggest, the catalytically active DNMTs work quite differently on DNA
substrates. DNMT3a and DNMT3b both prefer unmethylated DNA, but DNMT3a modifies
DNA in a distributive manner (61), while DNMT3b is processive in its activity (62). This
difference in mechanism is thought to be related to the specific function for each enzyme. For
instance, DNMT3a has been shown to establish methylation patterns at single copy genes, which
requires recruitment for each methylation event (63), while DNMT3b methylates regions of high
CG content within pericentromeric repeats, which is benefited by a processive mechanism (35).
DNMT1 initially garnered the name “maintenance methyltransferase” because it strongly prefers
hemi-methylated DNA substrates, although it is quite active on unmethylated DNA, with a faster
catalytic rate, in fact, than either of the “de novo” DNMTs (64). DNMT1 has also been shown to
co-localize with sites of active DNA replication and associate with the replication machinery,
observations which both support its role of copying the parental methylation pattern onto the
daughter DNA strand (57).
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Due to the dynamic nature of DNA methylation and the apparent differences in
mechanism and function of the DNMT enzymes, it has long been accepted that two distinct
methylation processes (de novo versus maintenance methylation) are responsible for generation
and establishment of the DNA methylation profile. However, recent literature proposes a new
model for DNA methylation, suggesting that the roles of DNMTs may not be as mutually
exclusive as previously thought (65). Among the first suggestions of cooperativity among the
enzymes came from Bert Vogelstein’s laboratory, which genetically disrupted first DNMT1 and
then DNMT3b in a human colon cancer cell line (66). Interestingly, cells lacking either DNMT1
or DNMT3b alone retained a substantial level of genomic methylation, and methylation-induced
gene silencing of repetitive DNA sequences, and imprinting and tumor suppressor genes (66).
However, deletion of both DNMT1 and DNMT3b in double knockout (DKO) cells resulted in
approximately 95% reduction in DNA methylation levels, and almost complete loss of
methyltransferase activity (66). It should be noted that the strategy behind generation of these
DNMT1 knockout (KO) cell lines involved targeted disruption of the N-terminus, replacing
exons 3-5 with a hygromycin resistance cassette. It was later discovered that these DNMT1
“knock-outs”, were actually hypomorphs, and contained alternatively-spliced, truncated versions
of the DNMT1 protein that retained in vitro catalytic activity (67). Interestingly, however, among
the sites that underwent complete demethylation in the DKO cells was the CpG-island promoter
of DNMT3a2, which is a variant of DNMT3a (67), and its up-regulation in cells deplete of the
other DNMTs may represent some sort of compensatory mechanism to maintain sufficient levels
of methylation for cell survival.
Descriptions of cooperation between the DNMTs were substantiated by others who
reported an interaction, nuclear co-localization, and some degree of communication between the
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de novo enzymes, DNMT3a and DNMT3b, and the maintenance enzyme, DNMT1 as they
facilitated methylation spreading (68, 69). Interestingly, recent reports described striking
differences in binding affinities of the DNMTs to select regions of chromatin; DNMT1
interacted more with linker DNA, while DNMT3a and DNMT3b were both tightly anchored on
nucleosomes (70). Although the DNMTs demonstrate this apparent distinction in their
interaction with DNA at the chromatin level, it suggests that they may in fact be compensating,
or “covering for” each other by methylating sites missed by the other enzyme(s) (70).
Collectively, a closer examination of the specific activities of each DNMT enzyme on
different DNA substrates, their unique interactions with chromatin, and the results of genetic
studies disrupting the DNMTs alone or in combination, have led researchers to conclude that it is
the differences in the functional properties of these enzymes that drives their cooperation.
Classifying the DNMTs as either all “de novo” or all “maintenance” is therefore an oversimplification. Certain aspects of each DNMT are required at different times throughout
development, and along DNA of variable sequence contexts to achieve the same general end.
These aspects are exploited by nature to achieve the best possible cooperative mechanism for
ensuring proper maintenance of DNA methylation.

VI.

DNA methyltransferase 1 (DNMT1) expression and regulation
Because DNA methylation exerts such fine-tuned control over gene expression, it should

be expected that the cellular levels and activity of the major methyltransferase, DNMT1, are also
tightly controlled. DNMT1 is the largest and most abundant of the mammalian DNMTs (Figure
1-5), with coding sequence totaling over 1600 amino acid residues, and producing a protein of
approximately 185kDa in size, which is roughly three times larger than its prokaryotic
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counterpart (57). The unique tripartite structure of DNMT1 is thought to be the result of a fusion
of three distinct genes, one of which is an ancestral prokaryotic methyltransferase and believed
to give rise to the C-terminal catalytic domain (71). The N-terminal domain itself exhibits a
bipartite structure, with two distinct regions: one dispensable for enzymatic activity, the other
essential, although they encode redundant nuclear localization signals (Figure 1-5, RFTS and
NLS) (71).
Also within the N-terminal domain of DNMT1 is a replication focus targeting sequence
(RFTS), located between amino acids 110-307, that directs the enzyme to sites of active DNA
replication in the nucleus of the cell (Figure 1-5) (35, 72). The localization of DNMT1 is highly
cell cycle-dependent, as its co-localization with replication foci occurs only during S-phase;
during all other stages of the cell cycle, DNMT1 exhibits a diffuse nuclear distribution (72). Two
bromo adjacent homology (BAH) domains are located within the N-terminal regulatory domain
of DNMT1. These are commonly found in chromatin-associated proteins and have been
proposed to serve as protein-protein binding sites within DNMT1 (35, 57). In close proximity to
the RFTS and BAH are a number of other protein binding domains, including a proliferating cell
nuclear antigen (PCNA) interacting domain, which also facilitates its recruitment to the DNA
replication fork and sites of DNA repair (57). Histone deacetylase 1 and 2 (HDAC 1 and 2),
DNA methyltransferase associated protein 1 (DMAP1) and retinoblastoma tumor suppressor
(Rb) also all have binding sites within the N-terminal domain of DNMT1, which link processes
of DNA methylation, histone deacetylation and a growth regulatory pathway (35, 57). Lastly, the
center of the N-terminal domain of DNMT1 contains a cysteine-rich Zn2+ binding region,
comprised of two CXXCXXC clusters with two isolated cysteines, that strongly resembles zincfinger binding domains of other proteins (73). This region was examined for its DNA binding
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properties and found to be essential for the methyltransferase activity of DNMT1, demonstrating
that the N-terminal domain of the protein cooperates with the C-terminal, catalytic domain (73).
The C-terminal domain of DNMT1 is the active center of the enzyme, containing the
active site that is absolutely required for enzymatic function (Figure 1-5). As mentioned above,
the C-terminal domain is not catalytically active in isolation; it requires the presence of at least
the majority of the N-terminal domain to assist in its function through an allosteric activation
mechanism (57, 74).
Several amino acids residues of the DNMT1 protein have been shown to be altered by
post-translational modifications, each with unique consequences dependent on where the
modification occurs. For instance, Akt kinase-mediated phosphorylation of Ser209 within the
nuclear localization signal of the N-terminal domain increases nuclear translocation of DNMT1
from the cytosol (75). Phosphorylation of Ser514 and Ser515 are thought to play roles in
targeting of the enzyme to replication foci and allosteric activation of methyltransferase activity,
respectively (76, 77). Although post-translational modifications are common events, modulating
the activity, localization, stability and interactions of the proteins they modify, the PTMs for
DNMT1 remain largely unexplored.
As briefly discussed previously, there is a cell cycle component to regulation of DNMT1
expression and activity. Evidence for this type of control stems from findings that cellular levels
of DNMT1 transcript and protein are positively correlated with cell proliferation (78). DNMT1
expression was minimal in G0/G1 and peaked late in S-phase of synchronized mouse cells (78).
The timing of these fluxes in DNMT1 levels aligned with levels of DNA synthesis, suggesting
that DNA methylation and replication are co-regulated by the cell cycle.
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A current subject of intense investigation is the regulation of DNMT1 function through
binding by accessory proteins, with one of particular interest: ubiquitin-like, containing PHD and
RING finger domains 1 (UHRF1). UHRF1, also known as Np95 in mouse and ICBP90 in
human, has been shown to be required for maintenance of DNA methylation patterns in
mammalian cells, a result of its direct interaction with DNMT1 (79). UHRF1 contains a set and
ring-associated (SRA) domain that exhibits strong hemi-methylated DNA binding properties.
UHRF1 also binds DNMT1, and is therefore thought to play a role in tethering DNMT1 to sites
of hemi-methylated CpGs, facilitating the faithful propagation of the established methylation
pattern by DNMT1 (79). It has also recently been reported that, unlike MeCP2 or the methylbinding domain proteins, UHRF1 recognizes and binds to 5hmC residues with a similar affinity
to 5mC (80). It will be interesting to see if an interaction between UHRF1 and the TET family of
proteins is revealed, and what role, if any, UHRF1 may play in DNA demethylation.
Aberrations to the DNA methylation profile have been considered early events in
tumorigenesis (81). Numerous reports described elevated levels of DNMT1 in tumor cells, 43000-fold higher than in non-tumor cells, and the change in DNMT1 expression was shown to
positively correlate with cancer stage progression (81, 82). Higher DNMT1 expression was also
paired with abnormal methylation activity: greater overall genomic methylation and de novo
methylation activity (83). However, upregulation of DNMT1 is not equivalent to dysregulation
of DNMT1. Rather, aberrations to the DNA methylation pattern and distribution, not simply
increases in methylation levels, are found in diseased states.

25

VII.

Summary and Objectives

Our laboratory has intensely pursued the molecular mechanisms underlying the
dysregulation of the most abundant mammalian DNA methyltransferase, DNMT1, as they relate
to the aberrant DNA methylation patterns of diseased cells. A great deal is known about
epigenetic mechanisms and their regulatory effects on transcription of the nuclear genome, but
the field of mitochondrial epigenetics severely lacks exploration. The early findings that
mitochondrial DNA contains 5-methylcytosine residues in CpG dinucleotide contexts, much like
the nuclear genome, provided a simple analogy for the role this modification might play in
mitochondria. Additionally, the absence of a known mitochondrial methyltransferase opened the
door for one of the catalytically active nuclear-encoded enzymes to fill that role. The studies
described throughout this dissertation were aimed at identifying and characterizing the DNA
methyltransferase responsible for mtDNA methylation, quantifying its methylation activity, and
understanding the role of DNA methylation in regulating mitochondrial function.
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Chapter 2: Identification, Regulation and Function of Mitochondrial DNMT1 (mtDNMT1)

INTRODUCTION
I.

Mitochondrial transcription
The D-loop regulatory region of mtDNA contains the bi-directional promoters for

initiation of both heavy and light strand transcription, and serves as the site for assembly of
transcription initiation complexes (Figure 2-1). Transcription of the light strand begins at a single
promoter, appropriately called light-strand promoter (LSP). RNA synthesis covers the entire
length of the light strand, generating a single transcript that is processed to produce 1 mRNA and
8 of the 22 tRNAs (1). Unlike the light strand, transcription of the heavy strand is initiated at two
adjacent promoters, HSP1 and HSP2. Transcription starting at HSP2 generates a long, polygenic
message that is processed to produce 12 mRNAs, 14 tRNAs and both of the 2 rRNAs (1).
Transcription from HSP1 is dedicated solely to the production of the 2 rRNAs, to support the
mitochondrion’s need for high-level production of rRNA, relative to mRNA (1).
The driving force behind mitochondrial transcription is the mitochondrial RNA
polymerase (POLRMT). Perhaps surprisingly, POLRMT is encoded on the nuclear genome, and
gains access to the mitochondrial compartment via a cleavable, N-terminal mitochondrial
targeting sequence (MTS). Related to the T7 family of bacteriophage polymerases, human
POLRMT complexes with mitochondrial transcription factor B2 (mtTFB2) to form the core,
two-component mitochondrial transcription machinery (Figure 2-1) (13). Other factors, including
the human mitochondrial transcription factor A (TFAM), were once thought to be included in the
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Figure 2-1: Schematic representation of mitochondrial transcription from HSP1, HSP2 and
LSP. The H-strand of mtDNA is shown in dark blue; the L-strand is in light blue; tRNAs are
represented by red bars and labeled by their single-letter code. Transcription initiation
complexes, consisting of mitochondrial RNA polymerase (POLRMT) and mitochondrial
transcription factor B2 (mtTFB2), assemble at bidirectional promoters within the D-loop.
Transcripts initiating at LSP or HSP2 can traverse the entire mtDNA template, whereas those
initiating at HSP1 terminate at a transcription terminator (Term, yellow bar), located within the
tRNAL(UUR) gene. Adapted from figure by Scarpulla R (2008) Physiol Rev 88: 611-638.
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repertoire of proteins and transcription factors comprising the transcriptional apparatus.
However, it has recently been shown that TFAM is, instead, dispensable as part of the core
machinery (13).
TFAM is a high-mobility-group (HMG)-box protein, also encoded on the nuclear
genome, and shares homology with a group of HMG-box proteins involved in the maintenance
and architecture of DNA in nuclear chromatin (84). Like HMG-box proteins in the nucleus,
TFAM binds to specific recognition sites within the core promoter of mtDNA, a region which
lies between the LSP and two HSPs, and functions to unwind mtDNA, making it more accessible
to transcriptional machinery (1, 3). In addition to binding at specific sites, TFAM has also been
reported to coat the entire mitochondrial genome, contributing to its maintenance and
stabilization (1, 3, 14). TFAM knockout mice exhibit embryonic lethality paired with a drastic
reduction in mtDNA content, substantiating its essential role in mtDNA maintenance (14).
Termination of transcription occurs at a strong bi-directional terminator located within
the tRNALeu gene, which lies between the end of the 16S rRNA gene and the first protein-coding
unit on the heavy strand, NADH dehydrogenase subunit 1 (ND1) (1). This 28 nucleotide
consensus site is bound by the mitochondrial termination factor 1 (mTERF1) (1). Interestingly,
mTERF1 not only binds the termination site, but also HSP1, stimulating transcription, and thus
coupling initiation and termination events (Figure 2-1) (1, 3). When mTERF1 binds both sites
simultaneously, it results in looping-out of the DNA, forming a transcription bubble to maintain
a high rate of rRNA synthesis (1).
Transcription of the mitochondrial genome is thought to be co-regulated with nuclear
components of the respiratory chain complexes (1, 3). In mammals, oxidative stress results in
stabilization of peroxisome proliferator activated receptor γ-coactivator 1α (PGC1α), which
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activates the transcription of several nuclear-encoded transcription factors, including nuclear
respiratory factor 1 (NRF1). PGC1α and NRF1 form a complex that in turn up-regulates
transcription of TFAM, mtTFB1 and mtTFB2, as well as multiple members of the mitochondrial
respiratory chain complexes (1, 3). This coordinated series of activation events ultimately serves
to stimulate mitochondrial biogenesis as a protective cellular response (1).

II.

Import of nuclear-encoded proteins into mitochondria
Of the approximately 1500 proteins present in mitochondria only about 1% originate

from within the mitochondrial compartment (85). The other 99% of “mitochondrial” proteins are
encoded by the nuclear genome, synthesized on ribosomes in the cytosol, and transported into
mitochondria using complex translocase machinery (85). There are several major protein import
pathways, each with distinct features based on the protein’s ultimate submitochondrial
destination, but for simplicity, our discussion will be limited to the presequence pathway (85).
The presequence pathway is the most common route of import. It relies on a specific
mitochondrial targeting signal (MTS), encoded within the sequence of the transported protein, to
be recognized by receptors on the outer mitochondrial membrane (Figure 2-2). The protein gains
entry into the mitochondrial compartment by first passing through the translocase of the outer
membrane (TOM) complex. The TOM machinery contains a highly conserved core component:
the Tom40 integral membrane protein, which forms a β-barrel structure and serves as the channel
through the outer membrane. The Tom20 subunit of the TOM complex recognizes the MTS of
the preprotein and directs the protein to the Tom22 receptor, which then sends it through the
Tom40 channel. Other, smaller Tom proteins are involved in the overall stability of the complex,
and participate in the transfer of preproteins from one subunit to another (85).
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Figure 2-2: Characteristics of a mitochondrial targeting sequence (MTS). N-terminal,
cleavable presequences are the classical types of mitochondrial targeting sequences, and can be
grouped into three general classifications based on where they direct the attached protein within
mitochondria: matrix, inner membrane, intermembrane space. MPP, mitochondrial processing
peptidase; IMP, inner membrane peptidase. Adapted from figure by Chacinska A, et al. (2009)
Cell 138: 628-644.
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Once inside the outer membrane, the MTS becomes important for relaying information
about where the preprotein should be directed. There are three general classes of mitochondrial
presequences, based on the final destination of the protein: matrix, inner membrane and
intermembrane space (Figure 2-2) (85). These signals are typically 15-50 amino acids in length,
and form positively-charged amphipathic α helices (6, 7, 85). Upon import, most presequences
are proteolytically cleaved by the mitochondrial processing peptidase (MPP). Most N-terminal
presequences direct their attached proteins to the matrix, unless they contain a hydrophobic
sorting signal located immediately downstream of the MTS (85). This hydrophobic sorting signal
serves to arrest translocation by anchoring the precursor protein within the inner membrane. For
intermembrane space proteins, the inner membrane peptidase (IMP) generally cleaves the
precursor protein just downstream of the hydrophobic anchor sequence, forming a smaller
mature protein (85).
Traversing the inner membrane is considerably more complicated, as it involves the
translocase of the inner membrane (TIM) complex, the presequence associated motor (PAM) and
two energy sources: ATP and the electrochemical membrane potential (85). Like the TOM
complex, the TIM complex contains a highly conserved core module, consisting of a Tim50
receptor protein, a Tim23 channel-forming protein, and Tim17, which recruits PAM and plays a
role in sorting of preproteins. Although not part of the core machinery, Tim21 also plays a
critical role in import, working with Tim50 and Tim23 to aid in transient interaction between the
TOM and TIM complexes, and facilitate translocation of preproteins through the outer and inner
membranes (85). Once through the inner membrane, preproteins are bound by Tim44 and the
central subunit of the PAM motor, mtHsp70, to be driven into the mitochondrial matrix (85).
PAM requires hydrolysis of ATP to drive transfer of preproteins into the matrix. The negative
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charge on the matrix side of the membrane potential also helps preproteins cross through the
inner membrane by exerting an electrophoretic effect on the presequences, which carry an
overall positive charge (85).
Either during or just after translocation of the preprotein into the matrix, the
mitochondrial processing peptidase (MPP) removes the presequence. This allows the mature
protein to fold into its active, folded form (85).

III.

Regulation of DNMT1 by p53 in the nucleus
p53 is a tumor suppressor protein, encoded by one of the most frequently mutated genes

in cancer. p53 functions as a DNA sequence-specific transcription factor and is highly sensitive
to DNA damage and general conditions of cellular stress. When activated by stress, p53 becomes
stabilized and can trigger apoptosis or p53-dependent cell cycle arrest (86). Most p53-mediated
effects have been attributed to its function in the nucleus; however, p53 has also been detected in
mitochondria, and proposed to influence mtDNA copy number, mitochondrial respiration and
overall mitochondrial function (86-88).
Studies performed by Erica Peterson in our laboratory described a link between p53
status and regulation of DNMT1 expression (89). A sequence matching the consensus p53
recognition site was found within the genomic sequence for DNMT1, upstream of the
translational start site (Table 2-1). Binding of p53 to the DNMT1 locus was demonstrated both in
vitro, by electrophoretic mobility shift assay (EMSA), and in vivo by chromatin
immunoprecipitation (ChIP) assays (89). Deletion of p53 in both human tumor and normal
mouse cell lines induced a 3- to 6-fold increase in DNMT1 expression at both the mRNA and
protein levels (89), suggesting that p53 serves to repress DNMT1 transcription through a
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Table 2-1: Consensus sequences for putative p53 binding sites within the MTS for DNMT1.

p53
consensus
Mouse
Human
Chimp
Rat
Cow

RRRCWWGYYY
GCGCATGCGC
GCGCATGCGT
GCGCATGCGT
GCGCATGCGC
GCGCATGCGC

N(0-13)
15
7
7
9
12
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RRRCWWGYYY
TAGCATGGTC
GGGCATGGCC
GGGCATGGCC
GGGCATAGCAT
GAGCCAGTTCC

Base Pair
Position
-163 to -130
-207 to -181
-207 to -181
-163 to -134
-205 to -173

mechanism that involves its direct DNA binding to the DNMT1 promoter. Studies described
below extended these original observations to examine the effects of p53-mediated regulation of
DNMT1 in the mitochondrial compartment.

IV.

Objectives
Several nuclear-encoded genes involved in mitochondrial function, including PGC1α, are

regulated by DNA methylation (90). Conversely, it has been suggested that mitochondria are
able to influence cytosine methylation levels in the nucleus by modulating the flux of one-carbon
units for the generation of S-adenosyl-ʟ-methionine, the methyl group donor in the DNA
methylation reaction (91). Thus, epigenetic regulation of nuclear gene expression appears to have
a mitochondrial component. The presence of cytosine methylation in mtDNA, without a known
mitochondrial methyltransferase, led us to ask whether this epigenetic modification might play a
role in the coordinated regulation of mitochondrial gene expression from both nuclear and
mitochondrial genomes.

MATERIALS AND METHODS
Materials
HCT116 p53+/+ and HCT116 p53-/- cells were obtained from Dr. Bert Vogelstein, Johns
Hopkins University (Baltimore, MD). Primary MEFs were prepared from E12.5-E13.5 mouse
embryos. HCT116 neoS cells were obtained from American Type Culture Collection (ATCC,
Manassas, VA). Protein G sepharose beads (cat# 17-0618-01) were purchased from GE
Healthcare (Uppsala, Sweden). DNA substrates used in β-glucosyltransferase assay were
synthesized in the presence of dCTP, 5m-dCTP or 5hm-dCTP and purchased from Active Motif
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(Carlsbad, CA). DNA oligo primers (25nmoles) were designed using OligoAnalyzer software
from Integrated DNA Technologies (IDT, Coralville, IA) and purchased from Invitrogen
(Carlsbad, CA), unless described otherwise. Quantitect SYBR Green Mastermix (cat# 204145)
was purchased from Qiagen and used for all qPCR analysis. A Bioruptor water bath sonicator
(Diagenode, Denville, NJ) was used to shear gDNA to a range of 400-700bp fragments. BioRad
DNA Engine Peltier thermal cyclers, fitted with Chromo 4 Real-Time Fluorescence Detector
attachments were used for all studies involving qPCR. Real-time qPCR data was analyzed with
Opticon Monitor 3 Software. Beckman centrifuges (Palo Alto, CA) were used for all differential
centrifugation studies: Beckman J6-MI, fitted with JS 4.2 rotor, Beckman J2-HC, fitted with JA17 rotor, and Beckman Optima L-80 XP Ultracentrifuge, fitted with 50-TI rotor. Antibodies were
purchased from Active Motif (Carlsbad, CA), Abcam (Cambridge, MA), Sigma (St. Louis, MO),
Upstate Biotechnology (Billerica, MA), Santa Cruz (Santa Cruz, CA), Imgenex (San Diego,
CA), Pierce (Rockford, IL), Invitrogen (Carlsbad, CA), and received as a gift from Dr. Andrew
Larner (VCU), and will be discussed individually below.

Methods
Cell Culture
WT and p53-/- MEFs were grown at 37°C in 10% CO2, in DMEM medium
(Gibco/Invitrogen) supplemented with 10% FBS. HCT116neoS cells were grown at 37°C in 5%
CO2, in RPMI 1640 medium (Gibco/Invitrogen) supplemented with 10% FBS. HCT116 p53+/+
and HCT116 p53-/- cells were grown at 37°C in 5% CO2, in RPMI 1640 medium
(Gibco/Invitrogen) supplemented with 10% FBS. All cell media were obtained from
Gibco/Invitrogen and FBS was obtained from Gemini.
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For experimental consistency and because DNMT1 is cell-cycle regulated (78, 92), all
experiments were set up using cells treated identically in the days leading up to an experiment.
Cells were fed 24 hrs prior to plating and split and seeded into appropriate dishes or flasks 24 hrs
prior to harvest. Cells were harvested approximately 24 hrs after plating to ensure that the
majority of cells were still in S-phase, and expressing the maximal level of DNMT1.

Subcellular fractionation – Preparation of Crude and Percoll-purified mitochondria, and
cytosolic isolation
Cells from 3-4 sub-confluent 150mm dishes were washed twice with 2mL of cold 1x
PBS, pH 7.4, and placed on ice. While still on ice, cells were scraped in 2mL of 1x PBS using
sterile cell scrapers. Cells were transferred to a pre-weighed 15mL conical tube (BD Falcon, cat
# 352096), pelleted and weighed to obtain the whole cell pellet weight. The whole cell pellet
from approximately 50-60 million cells was resuspended in 3mL of mitochondrial
homogenization buffer (0.25M sucrose, 10mM Tris-HCl, pH7.0, 1mM EDTA, pH 6.8)
containing complete protease inhibitors (Complete EDTA-free Protease Inhibitor Cocktail
tablets, Roche, cat # 11873580001, 1 tablet/25mL homogenization buffer). An aliquot (5-10%)
of this resuspended cell volume was retained in a separate tube to generate the whole cell lysate,
prepared by pelleting the cells (900xg, 5 minutes, 4°C), obtaining a pellet weight, and
resuspending the whole cell pellet in SDS Lysis buffer (62.5 mM Tris pH 6.8, 5% glycerol, 2%
SDS, 5% β-mercaptoethanol, and 1x complete protease inhibitor cocktail (Roche)) at a volume
7.5x the pellet weight. The remainder of the resuspended cell volume (90-95%) was transferred
to a pre-chilled 7mL glass dounce homogenizer (Wheaton) and incubated on ice for 5 minutes to
allow the cells to swell in the hypotonic homogenization buffer. Resuspended cells were
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subjected to three rounds of 15 dounce strokes, followed by centrifugation at 900xg (2,200rpm)
in a Beckman J6-MI centrifuge for 5 minutes at 4°C, each time separating the post-nuclear
supernatant (containing mitochondrial and cytosolic fractions) from the nuclear/unbroken cell
fraction. This pellet was resuspended in another 3mL of mitochondrial homogenization buffer to
repeat douncing. After three rounds of douncing, the collected post-nuclear supernatant fraction
was again centrifuged at 900xg for 5 minutes at 4°C to pellet any contaminating
nuclear/unbroken cells. The entire post-nuclear supernatant fraction was then transferred to a
14mL round-bottom tube (BD Falcon, cat # 352059) and centrifuged at 10,000xg (9,000rpm) in
a Beckman J2-HC centrifuge for 15 minutes at 4°C to pellet the mitochondria. The mitochondrial
pellet was washed 2-3 times with 1mL of mitochondrial homogenization buffer, centrifuging at
10,000xg in a tabletop microfuge for 5 minutes at 4°C. The final mitochondrial pellet was
weighed, and will be referred to as a “Crude” mitochondrial preparation.
A Percoll gradient was constructed; 6.55mL Percoll (Amersham, cat # 17-0891-02) was
mixed with 2.2mL of 2.55M sucrose, 12.25mL of TE, pH 7.4, and ddH2O to a total volume of
21mL, in a 50mL conical tube. This solution was mixed well, and 10mL was aliquoted into two
50TI Beckman Ultracentrifuge tubes (cat # 344085). The crude mitochondrial pellet was
resuspended in 1mL of mitochondrial homogenization buffer with complete protease inhibitors,
and overlaid onto the Percoll by gently pipetting the resuspended mitochondria down the side of
the tube. Samples were centrifuged at 60,000xg (30,000rpm) in a Beckman Ultracentrifuge for
45 minutes at 4°C. Following high-speed centrifugation, mitochondria could be seen to form a
hazy white band that migrated near the center of the gradient. This band was conservatively
transferred into new 14mL round-bottom tubes, and washed 2-3 times with 2-3mL of
mitochondrial homogenization buffer, spinning at 10,000xg for 15 minutes at 4°C in the
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Beckman J2-HC after each wash. The final Percoll-purified mitochondrial pellet was weighed,
and will be referred to as a “Percoll-purified” mitochondrial preparation.
The cytosolic fraction was obtained by collecting the post-mitochondrial supernatant
following high-speed centrifugation to pellet mitochondria (10,000xg, 15 minutes, 4°C in
Beckman J2-HC, described above). An equal volume of ice-cold 20% TCA was added to the
post-mitochondrial supernatant, mixed well, and incubated on ice for 30 minutes. Cytosolic
proteins were pelleted at 6,000xg (7,500rpm in Beckman J2-HC centrifuge) for 15 minutes at
4°C, washed 2-3 times with 3-5mL of ice-cold acetone, each time spinning at 7,500rpm for 5
minutes at 4°C to collect the pellet. After the last wash, the cytosolic pellet was allowed to airdry on ice for approximately 5 minutes, before being dissolved in SDS lysis buffer (described
below) for direct analysis by immunoblot.

Methyl-DNA Immunoprecipitation (MeDIP) using purified mtDNA
The specificity of both 5mC and 5hmC antibodies for their respective cytosine
modifications was verified by Prashant Thakkar using defined DNA substrates synthesized in the
presence of dCTP, 5m-dCTP, or 5hm-dCTP (Active Motif).
Mitochondria were isolated from 50-60 million HCT116 cells, as described above. The
mitochondrial pellet was washed twice with 1mL of mitochondrial homogenization buffer with
complete protease inhibitors (Complete EDTA-free Protease Inhibitor Cocktail tablets, Roche),
and once with 1mL of mitochondrial homogenization buffer in the absence of protease inhibitors.
To washed mitochondrial pellets, formaldehyde crosslinking solution (11% formaldehyde,
50mM HEPES, pH 8.0, 100mM NaCl, 1mM EDTA, 0.5mM EGTA) was added to 1/10th the
final volume, and incubated for 15min at 37°C. Crosslinking was terminated by adding glycine
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to a final concentration of 125mM and incubating at room temperature for 10min. Crosslinked
mitochondria were pelleted by centrifugation at 10,000xg for 5min at 4°C, and washed once with
1mL of cold 1x PBS, pH 7.4. Mitochondrial pellets were split into two 1.5mL microcentrifuge
tubes and re-pelleted by centrifugation, then lysed in 1mL mtIP Lysis buffer (0.5% Triton X-100,
300mM NaCl, 50mM Tris-HCl, pH 7.4, 100µg/mL leupeptin, 200µM PMSF, complete protease
inhibitor cocktail). The mitochondrial lysate was pipeted up and down several times to mix
thoroughly and incubated on ice for 15min with occasional inversion of the tubes, to allow
complete lysis.
Crosslinked mitochondrial DNA was sonicated using the Diagenode Bioruptor water bath
sonicator at the highest pulse, cycling between 30sec on and 30sec off, for two rounds of 15min
each. DNA fragmentation was assessed on a 1% TAE-EtBr agarose gel to verify proper shearing
to an average of 400bp. Sonicated DNA (10µL) was run alongside 1µg of unsonicated gDNA.
Crosslinks were reversed by adding 0.5% SDS and incubating samples overnight at 65°C.
Sonicated DNA was precipitated by adding 1/10th volume (30µL) of 3M NaOAc, 30µg of
UltraPure Glycogen (Invitrogen, cat # 10814010), and 2 volumes (600µL) of 100% ethanol per
sample, followed by incubation at -80°C for approximately 2 hrs. Precipitated DNA was
centrifuged at high speed in a microfuge for 15 minutes at 4°C. The DNA pellet was washed
once with 1mL of 70% ethanol and allowed to air dry on the benchtop for approximately 5
minutes. DNA pellets were resuspended in 200µL HPLC H2O with 50µg/mL of RNase A
(Sigma, cat # R5503), and samples were incubated at 37°C for 1 hr. 100µg/mL Proteinase K
(1µL of 20mg/mL stock, Bioline, cat # BIO-37037) and 0.25% SDS were added to each tube,
and mixed well. DNA samples were incubated at 37°C overnight for complete digestion of RNA
and

protein

contaminants.

Digested

DNA
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was

subjected

to

two

rounds

of

phenol/chloroform/isoamyl alcohol extraction (Invitrogen, cat # 15593031), and precipitated as
described above. Precipitated DNA was resuspended in 500µL of 10mM Tris, pH 8.0. DNA was
quantitated using the ND-1000 NanoDrop spectrophotometer, and 4µg purified mtDNA was
used as input into each MeDIP assay. The DNA was denatured by boiling for 10 minutes, and
then immediately cooled on ice for 10 minutes. An aliquot (51µL) of 10x IP buffer (100mM
NaPO4, pH 7.0, 1.4M NaCl, 0.5% Triton X-100) and 2µg of each antibody for IP were added to
the denatured DNA sample, and incubated at 4°C overnight with end-over-end rotation. A total
of three conditions were examined for each DNA sample: Nonspecific IgG (-) control (Millipore,
cat # 12-371), 5mC antibody (Active Motif, cat # 39649), and 5hmC antibody (Active Motif, cat
# 39770).
Lambda DNA (New England BioLabs, cat # N3011L) was sonicated using a Diagenode
Bioruptor water bath sonicator at the highest pulse for 2 cycles of 15 minutes each, with 1 minute
on and 1 minute off. After each cycle, the tubes were removed from the sonicator, tapped to mix
and quickspun to collect all DNA at the bottom of the tubes.
Protein G sepharose beads (GE Healthcare, cat # 17-0618-01) at a volume of 20µL per
sample, per condition, were pipeted using a 2-200µL tip with the end cut off and pelleted by
centrifugation at 4,500rpm for 5 minutes at 4°C in a tabletop microfuge, to remove the 70%
ethanol resuspension mix. The beads were washed with 400µL of 1x PBS-0.1% BSA solution
three times, incubating the beads with rotation for 5 minutes at 4°C and spinning at 4,500rpm for
5 minutes at 4°C. At the end of the third wash, the volume of pelleted beads was estimated, and
an equal volume of 1x IP buffer was added to make a 50% bead slurry. BSA (5µg per 30µL of
50% slurry) and sonicated lambda DNA (5µg per 30µL of 50% slurry) were added to the bead
slurry and incubated for 3 hours at 4°C with rotation to block the beads and prevent non-specific
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IgG binding. After blocking, the beads were again washed with 1x PBS-0.1% BSA as described
above, and the pellet was resuspended in an equal volume of 1x IP buffer, and mixed by tapping
the tube.
Approximately 20µL of blocked, washed bead slurry was added to each tube containing a
DNA-antibody complex. These samples were incubated for 2 hours at 4°C with rotation to allow
DNA-antibody-Protein G bead complexes to form. Beads were collected by centrifuging at
4,500rpm for 5 minutes at 4°C, and washed three times, each with 500µL 1x IP buffer for 10
minutes at 4°C with rotation, and spinning at 4,500rpm for 2 minutes at 4°C. After the third
wash, the beads were resuspended in 250µL of Proteinase K digestion buffer (50mM Tris, pH
8.0, 10mM EDTA, 0.5% SDS), and mixed by tapping the tube. Seventy µg of Proteinase K
(3.5µL of 20mg/mL stock, Bioline, cat # BIO-37037) was added to each sample, and incubated
for 3 hours at 50°C with shaking to disrupt the antibody-Protein G bead interactions.
Immunoprecipitated DNA was extracted with 250µL of Phenol:Chloroform:Isoamyl alcohol
(25:24:1), and precipitated using 1/10th volume (25µL) of 3M NaOAc, 40µg of UltraPure
Glycogen (2µL of 20µg/µL stock, Invitrogen, cat # 10814010), and 3 volumes (750µL) of 100%
ethanol per sample. The DNA pellet was allowed to air-dry at room temperature for
approximately 5 minutes, resuspended in 75µL TE buffer, pH 8.0, and stored at -20°C.
Quantitative PCR using Quantitect SYBR Green mastermix and mitochondrial-specific
primers (see Table 2-2 for primer sequences and Figure 2-2 for a map of primer positions along
mtDNA) was performed to measure the level of enrichment of mtDNA sequences in
immunoprecipitated material pulled down by each antibody: anti-5mC, anti-5hmC or nonspecific
IgG. Absolute amounts of immunoprecipitated mtDNA were quantitated using a standard curve
of purified mtDNA, and expressed relative to input.
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Table 2-2: Mitochondrial primer sequences.

Species

Primer Set

Mouse
Human

mMTS
hMTS

Mouse

mtDNMT1
Total
DNMT1
β-Actin
mtDNMT1
Total
DNMT1
β-Actin

Human

Mouse

ND1
ATP6
ND6
COX1
18S rRNA

Human

ATP6
COX2
12S
16S-1

Mouse

16S-2
16S-3
ATP6/COX3
ATP6
12S
2

Human

Forward

Reverse

Amplification of Mitochondrial Targeting Sequences
5'-ATGCGCACTCCCTTCGGGCATAG-3'
5'-CTTGCAGGTTGCAGACGACAG-3'
5'-ATGAATGAATGCCTCGGGCAC-3'
5'-CTCGGAGGCTTCAGCAGACGC-3'
Quantitation of DNMT1 Abundance
5'-ACTCTCTTGCCCTGTGTGGTACATG-3'
5'-TCTTTCCAAGTCTTTGAGCCGCC-3'
5'-TCAGAGCTGTTCTGTCGTCTGCAA-3'
5'-GACCCAGATCATGTTTGAGACC-3'
5'-TCCCTGGGCATGGCCGGCTC-3'

5'-TCTTTCCAAGTCTTTGAGCCGCC-3'
5'-ATCAGAATGCCTGTGGTACGAC-3'
5'-CTCTTTCCAAATCTTGAGCCGCC-3'

5'-TCCGAGATGCCGGCGCGTACC-3'
5'-CCACGAAACTACCTTCAACTCC-3'

5'-CTCTTTCCAAATCTTGAGCCGCC-3'
5'-TCATACTCCTGCTTGCTGATCC-3'

Mitochondrial Gene Expression
5'-CAGGATGAGCCTCAAACTCCA-3'
5'-ATTCCCATCCTCAAAACGCC-3'
5'-AGTTATGTTGGAAGGAGGGATTGG-3'
5'-TCGCAATTCCTACCGGTGTC-3'
5'-GTCTGTGATGCCCTTAGATG-3'

5'-CGGCTCGTAAAGCTCCGA-3'
5'-TGTTGGAAAGAATGGAGACGGT-3'
5'-TACCCGCAAACAAAGATCACCCAG-3'
5'-CGTGTAGGGTTGCAAGTCAGC-3'
5'-AGCTTATGACCCGCACTTAC-3'

Mitochondrial MeDIP (5mC and 5hmC)
5'-ATTCAACCAATAGCCCTGGCCG-3'
5'-ACGTAGGCTTGGATTAAGGCGAC-3'
5'-ACAGATGCAATTCCCGGACGTC-3'
5'-TGGGCATGAAACTGTGGTTTGCTC-3'
5'-AGTTCACCCTCTAAATCACCACG-3'
5'-TGACTTGGGTTAATCGTGTGACC-3'
5'-ACCTTACTACCAGACAACCTTAGCC-3'
5'-TAGCTGTTCTTAGGTAGCTCGTCTGG-3'
qPCR Quantitation of 5hmC
5'-AAAAGAGGGACAGCTCTTCTGGAACG-3'
5'-CGGTTTCTATCTATTTACGATTTCTCCC-3'
5'-CCCACCAACAGCTACCATTAC-3'
5'-ATTCAACCAATAGCCCTGGCCG-3'
5'-AGTTCACCCTCTAAATCACCACG-3'
5'-GAGACAAGTCGTAACATGGTAAG-3'
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5'-TCGTTTAGCCGTTCATGCTAGTCC-3'
5'-GCCACCCTAATAACCTTCTCTAGG-3'
5'-CTAGACCTGATGTTAGAAGGAGGG-3'
5'-ACGTAGGCTTGGATTAAGGCGAC-3'
5'-TGACTTGGGTTAATCGTGTGACC-3'
5'-GGGTAAGGTTTGCCGAGTTCCT-3'

β-Glucosyltransferase Assay – Relative quantitation of 5hmC levels
The sequence-specific detection of 5hmC at GlaI restriction sites was determined using
the Quest 5hmC Detection kit (Zymo Research, cat # D5416), according to manufacturer’s
specifications. GlaI restriction enzyme was purchased separately from SibEnzyme (Russia, cat #
E494), supplied with 10x SEB Reaction Buffer. Either purified mtDNA or total cellular DNA
(80ng) was used as starting template. Unmethylated, fully methylated and fully
hydroxymethylated control DNAs supplied by Active Motif were used to validate the assay. The
assay relies on the fidelity of a series of modifying and restriction enzymes, and the sensitivity of
qPCR to detect even small differences in the availability of full-length template DNA.
Template DNA from HCT116 cells or MEFs was first incubated with the bacterial
methylase, M.SssI (New England Biolabs, cat # M0226S) to methylate all unmethylated CpG
dinucleotides, and GpC methyltransferase M.CviPI (New England BioLabs, cat # M0227S) to
methylate all GpC dinucleotides within the template. Then, DNA was incubated with βglucosyltransferase (β-gt) to add a bulky glucosyl moiety to all naturally-occurring 5hmC
residues. Finally, template DNA was digested with GlaI enzyme, which cleaves only when the
cytosines within its restriction site are either fully methylated or fully hydroxymethylated. GlaI
cannot cleave its target sequence when it has been glucosylated, so modification by β-gt affords
the protection of a 5hmC residue from GlaI cleavage. Modified, digested DNA was used as
template in qPCR with primers specific to various regions along the mitochondrial genome (see
Table 2-2). The level of enrichment of 5hmC was normalized to the input signal for each
amplicon.
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Bioinformatic analyses of the DNMT1 mitochondrial targeting sequence
The mitochondrial targeting sequences for DNMT1 were located using UCSC Genome
Browser software (http://genome.ucsc.edu/) by querying the reference sequence (“RefSeq”) of
DNMT1 for the promoter/upstream region as far as 500 bases upstream of the coding sequence.
In all species for which the 5’ flanking sequence of DNMT1 was available, the retrieved
genomic

sequence

was

copied

and

pasted

into

the

ExPasy

Translate

tool

(http://www.expasy.ch/tools/dna.html) to convert the nucleotide sequence into its predicted
protein sequence. Once translated, the appropriate 5’ to 3’ frame was selected such that the
sequence downstream of the nuclear translational start (labeled ATG3 in Figure 2-6) matched the
known protein sequence for DNMT1 (… MPARTAPARV …). The correct frame of the entire
translated sequence for DNMT1, starting at each upstream ATG, was consecutively copied and
pasted into the MitoProt II query box (http://ihg.gsf.de/ihg/mitoprot.html) to predict whether a
protein originating at each of the putative upstream start sites translocates to the mitochondria.
Mitochondrial targeting sequences for DNMT1 in all available species were analyzed for the
presence

of

transcription

factor

binding

sites

using

MatInspector

software

(http://www.genomatix.de/en/index.html).

Cloning of MTS and confocal microscopy
The mitochondrial targeting sequences for both human and mouse DNMT1 were
amplified by PCR, against random-primed cDNA templates, starting at ATG1 and ending just
upstream of ATG3 using primers as described in Table 2-2. PCR products were separated on a
1% TAE agarose gel stained with ethidum bromide, and visualized by UV transillumination. The
desired PCR products (~160bp for mouse, ~300bp for human) were excised from the gel using a
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clean razor blade, the gel slice was weighed, and the PCR product was purified using the Wizard
SV gel and PCR Clean-up System (Promega, cat # A9282), according to manufacturer’s
instructions. Purified PCR products were cloned into the Vivid Colors pcDNA 6.2/EmGFP
mammalian expression vector (Invitrogen, cat # K359-20) with an in-frame C-terminal GFP tag.
Dr. Shirley Taylor transfected these vectors into NIH/3T3 mouse lung fibroblasts or HCT116
human colon carcinoma cells grown on poly-L-lysine-coated glass coverslips. Transfections were
performed using Polyjet liposomes (SignaGen, cat # SL100688) for HCT116 cells, or Amaxa
MEF1 Nucleofector Kit (Lonza, cat # VPD-1004) for NIH/3T3 cells. Both transfection reagents
were used according to the manufacturer’s instructions. GFP fluorescence was observed at 24hrs
post-transfection to verify expression of the GFP-tagged constructs and to estimate transfection
efficiency. At 48hrs post-transfection, Dr. Shirley Taylor fixed cells with 4% paraformaldehyde
and stained with 25nM MitoTracker Red CMXRos (Molecular Probes, M-7512) for 45 minutes
at 37°C. Stained coverslips were washed 3 times with 1x PBS, pH 7.4 and mounted onto glass
slides with ProLong Gold antifade reagent with DAPI (Invitrogen, cat # P-36931). Mitochondrial
localization was visualized using a Leica TCS-SP2 AOBS confocal scanning microscope. All
confocal microscopy was performed by Dr. Shirley Taylor.

RT-PCR to detect transcript for mtDNMT1
Total RNA was isolated from both HCT116 cells and MEFs using TRIzol Reagent
(Invitrogen, cat # 15596-026), according to manufacturer’s instructions. RNA was treated with
amplification-grade DNaseI (Invitrogen, cat # 18068015) to remove any gDNA contamination,
and reverse-transcribed with the SuperScript III First-Strand Synthesis system (Invitrogen, cat #
18080051) using oligo-d(T) primers, following the manufacturer’s protocols. Endpoint PCR to
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detect a mature transcript for the mitochondrial isoform of DNMT1 was performed using
HotStarTaq Plus Master Mix (Qiagen, cat # 203645). Sense primers placed across ATG1
(mouse) or ATG2 (human) were paired with an antisense primer that crossed the exon 1-2
boundary by four nucleotides (Ex1-2 asn Mod, Table 2-2). Minus RT template control reactions
were run alongside +RT template reactions for each primer set. PCR products were separated on
a 1% TAE agarose gel stained with ethidium bromide and visualized by UV transillumination.

SDS-PAGE and immunoblotting of subcellular fractions
Each subcellular fraction (whole cell lysate, cytosolic and mitochondrial) was collected in
a pre-weighed 1.5mL microcentrifuge tube, and weighed to calculate the appropriate volume of
SDS Lysis Buffer (62.5mM Tris-HCl, pH 7.5, 5% glycerol, 2% SDS, 5% β-mercaptoethanol, 1x
complete protease inhibitor cocktail (Roche)) to add to each sample. SDS Lysis buffer was added
at 7.5x the whole cell pellet weight, and 10x the cytosolic and mitochondrial pellet weights.
Whole cell and cytosolic lysates were passed through a 21G needle fitted with 1mL syringe
approximately 20 times to shear the gDNA and create a homogeneous mixture. Lysates were
aliquoted and stored at -80°C until use.
Protein concentrations were calculated using a Bradford Protein assay (BioRad, cat #
500-0006) against a standard curve generated by absorbance values measured for known
concentrations of BSA (Fisher, cat # 23210) read at 595nm. Protein was loaded onto SDS-PAGE
gels to approximate equal cell equivalents, so that an equal signal for each compartment-specific
antibody was obtained (whole cell lysate: 75µg, cytosolic lysate: 25µg, mitochondrial lysate:
18µg). The appropriate amount of total protein from each cell fraction was diluted in an equal
volume of Laemmli sample buffer (BioRad, cat # 161-0737) plus 5% β-mercaptoethanol, boiled
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for 5 minutes, and quickly spun to collect the samples. SDS-PAGE 4-15% gradient gels (BioRad
4-15% Tris-HCl Ready gel, cat # 161-1158) were assembled in a Mini-PROTEAN
electrophoretic box unit (BioRad, model # 422 ElectroEluter), and the tank was filled with 1L of
1x running buffer (25mM Tris base, 250mM glycine, 0.1% SDS). Boiled lysate samples were
loaded into the wells alongside 10µL of the Precision Plus Dual Color pre-stained protein ladder
(BioRad, cat # 161-0374). Gels were resolved by electrophoresis at 150V for approximately 1hr.
Resolved proteins were transferred onto an Immobilon PVDF membrane (Millipore, cat #
IPVH00010), soaked in 100% methanol and sandwiched between 15 sheets of pre-cut Whatman
paper (3mm Chromatography paper, cat # 3030 917). Each sheet of Whatman paper was soaked
in 1x Towbin buffer (25mM Tris-HCl, pH 8.3, 192mM glycine, 10% methanol, 0.04% SDS) and
rolled smooth to remove any bubbles. The transfer sandwich was assembled in the center of the
bottom plate of the Hoefer Semi-dry Transfer apparatus (model # TE77). The top of the semi-dry
transfer apparatus was fitted squarely on top of the transfer sandwich and plugged into the
receptacle on the bottom unit. The transfer apparatus was connected to a power supply (BioRad
PowerPac Basic) and run at 80mA for 4hrs to transfer all proteins onto the PVDF membrane.
To prevent any nonspecific binding of the antibodies, the membrane was blocked in T20
StartingBlock blocking buffer (Fisher, cat # 37543), either for 1hr at room temperature or
overnight at 4°C, with gentle rocking on a platform shaker. Blots were washed with 1x TBS-T
(0.5M Tris-HCl, pH 7.5, 0.14M NaCl, 2.7mM KCl and 0.1% Tween 20) three times for 5
minutes each with vigorous shaking. Primary and secondary antibodies were diluted in
StartingBlock blocking buffer under the conditions optimized for each antibody (see Table 2-3).
Membranes were incubated in primary and/or secondary antibody for 1hr at room temperature
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Table 2-3: Optimal conditions for antibodies used in mitochondrial immunoblots.

Antibody
NDNMT1

Manufacturer

Species

Blocking
Buffer

Abcam

rabbit

StartingBlock

1:1000

1:10,000

VDAC

rabbit

1:4000

1:10,000

mouse

StartingBlock
5%
milk/TBS-T

1:10,000

1:10,000

H3K4me3

Sigma
*a gift from
Dr. Larner
Upstate
Biotechnology

rabbit

StartingBlock

1:1000

1:10,000

DNMT3a

Imgenex

mouse

StartingBlock

1:250

1:10,000

DNMT3b

Imgenex

mouse

StartingBlock

1:250

1:5000

GFP

Invitrogen

rabbit

StartingBlock

1:1000

1:10,000

Tubulin
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Primary
Dilution

Secondary
Dilution

Secondary
Antibody
goat antirabbit
goat antirabbit
goat antimouse
goat antirabbit
goat antimouse
goat antimouse
goat antirabbit

Protein
Size
(kDa)
185
32
60
17
120
110
varies

with gentle shaking. Following both primary and secondary antibody incubation, membranes
were washed with 1x TBS-T three times for 10 minutes each with vigorous shaking. All
secondary

antibodies

were

conjugated

with

horseradish

peroxidase

to

allow

for

chemiluminescent detection using the SuperSignal West Pico (Pierce, cat # 34080) and West
Dura (Pierce, cat # 34075) Chemiluminescent Substrate kits according to manufacturer’s
instructions. Blots were developed using autoradiography film (ISC Bioexpress, cat # F-90248X10) and a Konica SRX-101A developer.

Regulation of mtDNMT1 expression
NRF1 and PGC1α
Murine cDNA encoding NRF1 was obtained from ATCC (Manassas, VA) and re-cloned
into pDEST26/C-FLAG with an in-frame C-terminal Flag-tag. The plasmid containing PGC1α
was a gift from Dr. Gregorio Gil (Virginia Commonwealth University). HCT116 cells were
transfected using Polyjet liposomes (SignaGen, cat # SL100688) according to manufacturer’s
instructions. MEFs were transfected using the Amaxa MEF1 Nucleofector kit (Lonza, cat #
VPD-1004) according to manufacturer’s instructions. All cells were harvested 48 hrs after
transfection, and fractionated as described above, to make whole cell and mitochondrial lysates.
Aliquots of whole cell lysate (75µg) and mitochondrial lysate (18µg) were separated on 4-15%
gradient gels and transferred by semi-dry transfer method, exactly as previously described. Blots
were cut twice horizontally: once at the 50kDa marker, and once between the 20kDa and 25kDa
markers. Each strip was probed individually with the following antibodies: 50-250kDa with the
Abcam N-DNMT1 antibody (185kDa full-length DNMT1), 25kDa-50kDa with the VDAC
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antibody (Pierce, 32kDa), and 0-25kDa with the H3K4me3 antibody (Upstate Biotechnology,
17kDa). Blots were probed, washed, and developed as described previously.
p53
Total RNA was isolated and reverse transcribed as previously described from WT or p53
-/- MEFs. RT-qPCR was performed using Quantitect SYBR Green mastermix, and the same
primer sets as used in the studies to detect mtDNMT1 transcript in mouse (Table 2-2). The
ATG1 sense primer was paired with the Ex1-2 asn Mod primer to measure abundance of mRNA
encoding only mitochondrial DNMT1, while the ATG3 sense primer was paired with the Ex1-2
asn Mod primer to measure the abundance of total DNMT1 mRNA. Reactions were run in
triplicate and values were normalized to mouse β-actin.
WT and p53-/- MEFs were fractionated to generated whole cell, cytosolic and
mitochondrial lysates, as described previously. 75µg of whole cell lysate, 25µg of cytosolic
lysate and 18µg of mitochondrial lysate were separated on two identical 4-15% gradient gels and
transferred to PVDF membranes as previously described. The first blot was cut once horizontally
at the 25kDa marker, to probe the top portion (25-250kDa) for N-DNMT1 (Abcam), and the
bottom portion (<25kDa) for H3K4me3 (Upstate Biotechnology). The second identical blot was
cut once horizontally between the 37kDa and 50kDa markers, to probe the top portion (50250kDa) with a tubulin antibody (gift from Dr. Andrew Larner, VCU, 60kDa), and the bottom
portion (<50kDa) with a VDAC antibody (Pierce). Blots were probed, washed and developed as
previously described.
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Effects of mtDNMT1 over-expression on mitochondrial transcription
Total RNA was isolated from WT and p53-/- MEFs using TRIzol Reagent, and reverse
transcribed with the SuperScript III First Strand Synthesis System, both according to the
manufacturer’s instructions. In the first set of experiments, cDNA was synthesized using random
hexamers to obtain a more complete representation of the transcribed genome. In the second set
of experiments, strand-specific cDNA was synthesized using complementary primers located
within the ATP6 gene: ATP6sn for light strand cDNA synthesis, and ATP6asn for heavy strand
cDNA synthesis. For both experiments, changes in mitochondrial gene expression between the
two cell lines were measured using primers specific to four different regions of the mitochondrial
genome, 3 on the heavy strand: ATP6, COX1 and ND1, and one on the light strand: ND6. Primer
sequences are listed in Table 2-2, and their location is mapped on the mitochondrial genome in
Figure 2-2. An Analysis of Variance (ANOVA) using least-square means was applied to
determine the statistical significance of differences in gene expression. A random-effects
ANOVA was performed using the statistical package JMP 7.0 (SAS). The least-squares mean for
each gene in WT and p53-/- MEFs was obtained, along with standard errors. Each dataset was
normalized to 18S rRNA expression. Three independent sets of biological samples were
analyzed for each gene, with triplicate technical repeats in each sample. The ANOVA model
included technical replicates as nested effects and biological replicates as random effects. The
corresponding 95% confidence intervals (C.I.) were obtained using statistical methods for
transformations (Delta method). Standard deviations (SDs) were computed using the formula:
SD = AVGsample/AVGinput x (√((SDsample/AVGsample)2+(SDinput/AVGinput)2))).
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RESULTS
5mC and 5hmC modifications are present in mtDNA
Early studies using thin-layer chromatography and nearest-neighbor analysis reported the
presence of 5mC in mtDNA (15-17), but there was doubt as to the purity of the mitochondrial
preparations and the sensitivity of the methods used in these early reports. Here, with newer and
more sensitive techniques, we not only confirm the presence of 5mC modifications in mtDNA,
but we also report for the first time, the existence of 5hmC-modified residues in mtDNA (Figure
2-3). MeDIP with antibodies specific to 5mC or 5hmC modifications was performed on mtDNA
made from isolates of highly-purified mitochondria. The immunoprecipitated DNA was probed
by qPCR to determine the presence and relative abundance of both types of modified bases
within DNA sequences specific to the mitochondrial genome. DNA immunoprecipitated with the
5mC antibody was enriched 10- to 20-fold for mtDNA over nonspecific IgG controls, across all
regions tested. Interestingly, we also observed a very strong (38- to 580-fold) enrichment of
mtDNA in material immunoprecipitated with the 5hmC antibody, relative to nonspecific IgG
controls. The apparent lower level of enrichment of mtDNA in 5hmC-immunoprecipitated
samples measured by primer 27 is likely a reflection of less efficient amplification of a longer
amplicon (833bp) from mtDNA sheared to an average of 400bp. However, the enrichment of
mtDNA in these samples is still a substantial 38-fold over nonspecific IgG controls. These were
extremely exciting results, as they suggested that earlier studies likely underestimated both the
degree and significance of epigenetic modification in the mitochondrial genome.
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Figure 2-3: qPCR detection of 5mC and 5hmC in mtDNA. (A) mtDNA immunoprecipitation
using an antibody directed against 5mC shows a 10- to 20-fold enrichment compared with IgG
controls. (B) mtDNA immunoprecipitation using an antibody directed against 5hmC
demonstrates substantial levels of this modified base in mtDNA (38- to 580-fold over IgG
controls). (A and B) Mitochondria were purified from HCT116 human colon carcinoma cells.
Mitochondrial-specific amplicons are labeled in Figure 1-2; Primers are listed in Table 2-2.
Prashant Thakkar performed all MeDIP and hydroxy-MeDIP analyses.
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β-Glucosyltransferase assay validates and quantifies 5hmC levels in mtDNA
We performed an independent assay to validate the presence of 5hmC residues in
mtDNA (Figures 2-4 and 2-5). The Quest 5hmC Detection kit from Zymo Research provided a
straightforward method for gaining quantitative information on the relative abundance of 5hmC
residues in a sequence-specific manner. We used phage T4 5hmC-β-glucosyltransferase (β-gt) to
determine the presence of 5hmC at GlaI restriction endonuclease cleavage sites. A series of
control experiments using defined DNA templates containing only unmethylated cytosine, 5mC
or 5hmC, confirmed that the GlaI restriction enzyme cleaved only sites that were fully
methylated or fully hydroxymethylated, but not those containing a glucosylated 5hmC moiety
(Figure 2-4). Thus, protection of mtDNA sequences from GlaI cleavage was afforded by
glucosylation of 5hmC residues by the β-gt enzyme, and this protection could be measured by
our ability to amplify across the GlaI cleavage site by PCR. The level of protection from GlaI
cleavage was assessed first by endpoint PCR, and then by qPCR (Figure 2-5). 5hmC
modifications were detected in three different amplicons from human mtDNA and two
amplicons from both mouse mtDNA and mouse gDNA. Amplicons containing two GlaI
restriction sites each (amplicons ATP6, 12S and 16S-3) showed approximately 50% protection in
comparison to amplicons with only a single GlaI cleavage site (amplicons 2 and 16S-2). This
suggests that there is a similar level of 5hmC at all restriction sites tested, since sequences
containing two cleavage sites could only be amplified with half the frequency as those containing
just one GlaI site. As an internal control, a mouse amplicon devoid of GlaI sites (ATP6/COX3)
did not show protection from GlaI cleavage, even after 5hmC glucosylation.
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Figure 2-4: β-glucosyltransferase assay for site-specific detection of 5hmC in mtDNA. (A)
Flowchart showing steps of β-glucosyltransferase assay. (B) Control DNA samples from the
Adenomatous polyposis coli (APC) promoter were amplified in PCR reactions containing dCTP,
5m-dCTP or 5hm-dCTP and used to validate the specificity of the Quest 5hmC Detection kit
(Zymo Research). DNA (150ng) was incubated in the presence or absence of βglucosyltransferase (β-gt) and methylase mixture (M.SssI and M.CviPI) as indicated, followed by
GlaI cleavage. Products of the reaction were resolved on a 3% NuSieve agarose gel. GlaI
cleavage was specific for methylated or hydroxymethylated DNA and was prevented by
glucosylation of 5hmC residues (lanes 7 and 8). Complete methylation by the methylase mixture
resulted in complete cleavage (lanes 1 and 2).
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Figure 2-5: Quantitation of site-specific 5hmC levels in mtDNA. (A and B) Endpoint PCR
demonstrates protection from GlaI cleavage of either 80ng of human mtDNA (A), or 80ng of
mouse mtDNA or mouse total gDNA (B), following incubation with β-gt and methylase mixture.
For each primer set, lane 1 represents input DNA, lane 2 represents (-) β-gt control and lane 3
represents (+) β-gt protection. Mouse amplicon ATP6/COX3 was expected to contain a single
GlaI restriction site, but showed protection both in the absence and presence of β-gt. DNA
sequence analysis verified the presence of a SNP deleting the restriction site (ACGT to ATGT).
The data demonstrate that this assay is applicable to both purified mtDNA and total genomic
DNA. (C) Enrichment of 5hmC in DNA samples was measured in triplicate and the average
enrichment was graphed relative to the input for each amplicon. Error bars signify the standard
deviation about the mean. 5hmC modifications were detected in all amplicons.
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Genomic sequence upstream of DNMT1 encodes a conserved mitochondrial targeting
sequence (MTS)
Having confirmed that mtDNA contains 5mC residues (from which 5hmC is also
presumably derived), we sought the enzyme(s) that may be responsible for these modifications.
We started by asking whether any of the known catalytically active mammalian DNA
methyltransferases might be targeted to mitochondria. Upon examination of the 5’ UTR and 5’
flanking genomic DNA upstream of the published transcriptional start sites for DNMT1, we
identified additional sequence (101 codons in human and 63 codons in mouse) containing no
termination codons, in frame with the ATG reported to be the primary translational start codon
for DNMT1 (Figure 2-6) (93). In these 5’ flanking sequences for both human and mouse
DNMT1, we have labeled the published nuclear translational start codons as “ATG3” because
there are two additional in-frame codons for methionine located upstream (Figure 2-6), each in a
moderate context for ribosome binding (94).
The MitoProt II algorithm (http://ihg.gsf.de/ihg/mitoprot.html) (95) predicted isoforms
for DNMT1 containing this additional N-terminal sequence in all mammalian species for which
the 5’ flanking sequence of DNMT1 was available. A protein produced from at least one of the
putative upstream ATG codons was predicted with very high probability to translocate to the
mitochondria (Table 2-4). The genome databases contained upstream sequences for human,
mouse, chimpanzee, rat and cow DNMT1, and in each species, one or more in-frame potential
start codons encoded a peptide with an extremely strong probability for mitochondrial
localization (Table 2-4). Although the sequence conservation between them is low, all of these
N-terminal extensions were predicted to form amphiphilic α-helices, a hallmark of other highlycharacterized mitochondrial targeting sequences (Figure 2-6) (6, 7, 85).
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Figure 2-6: Genomic sequence upstream of DNMT1 encodes a MTS. (A) Sequence encoding
an additional 101 in-frame amino acids, including two potential translation start ATG codons, is
present upstream of the published human DNMT1 start ATG (ATG3). (B) In mouse, 63 in-frame
amino acids are encoded upstream of the published translational start site, with two additional
potential translation start ATGs. Overlapping binding sites for p53 (underlined) and NRF1 (gray
box) are located across one of the two potential start ATG codons in both species. Published
transcription start sites for DNMT1 are indicated by horizontal arrows above the sequence.
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Table 2-4: Conservation of DNMT1 mitochondrial targeting sequence across mammalian
species.

Species
Mouse

Human

Chimp

Rat
Cow

ATG
number
ATG1
ATG2
ATG3*
ATG1
ATG2
ATG3*
ATG1
ATG2
ATG3*
ATG1
ATG2*
ATG1
ATG2
ATG3
ATG4
ATG5*

Position
upstream
of ATG*
+53aa
+45aa
-+101aa
+62aa
-+100aa
+62aa
-+53aa
-+97aa
+86aa
+67aa
+33aa
--

Probability of
Export to
Mitochondria
0.92
0.96
0.36
0.84
0.72
0.48
0.92
0.70
0.47
0.90
0.33
0.43
0.14
0.14
1.00
0.97

ATG* = Published translational start site
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The MTSs for human and mouse DNMT1 direct GFP to the mitochondria
We asked whether these upstream sequences directed an associated protein to a particular
subcellular compartment. We amplified human and mouse mitochondrial targeting sequences,
from ATG1 to just upstream of ATG3, and inserted them into the Vivid Colors pcDNA 6.2/CEmGFP-GW/TOPO mammalian expression vector, in frame with a C-terminal GFP tag. These
constructs were transfected into both NIH/3T3 mouse fibroblasts and HCT116 human colon
carcinoma cells. Confocal microscopy demonstrated clearly that both human and mouse leader
sequences targeted GFP to the mitochondria, as indicated by the distinct colocalization of
MitoTracker Red stain with GFP fluorescence (Figure 2-7). Stained mitochondria from
untransfected cells within the same visual field remained red in the merged images, serving as a
negative control for GFP expression. Additionally, a chloramphenicol acetyltranferase (CAT)GFP control plasmid remained cytosolic, and served as a negative control for nonspecific
mitochondrial localization. We observed a similar result in HCT116 cells. The ability of both the
human and mouse GFP-tagged constructs to operate across species indicates their functional
conservation.
HCT116 cells transfected with the Vivid Colors pcDNA 6.2/C-EmGFP-GW/TOPO
mammalian expression vector containing the cloned MTSs for human or mouse DNMT1 (the
same constructs used for the confocal microscopy studies, Figure 2-7) were fractionated,
separated on SDS-PAGE gels, and visualized by immunoblot. An antibody directed against the
GFP-tag showed the presence of GFP in the mitochondrial fraction of cells transfected with
either the human or mouse MTS, again demonstrating that these targeting sequences can operate
across species (Figure 2-8). Interestingly, two different sets of protein bands were detected for
GFP: the upper bands represent the intact translation products, carrying DNMT1 leader peptides
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Figure 2-7: The MTS for DNMT1 directs GFP to the mitochondria. Transiently-transfected
NIH/3T3 cells show distinct colocalization of GFP-tagged targeting sequences with MitoTracker
Red stain in the mitochondria. A CAT-GFP negative control plasmid does not localize to the
mitochondria. MTSs from both human and mouse operate across species, indicating their
functional conservation. Confocal images taken by Dr. Shirley Taylor.
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Figure 2-8: N-terminal peptides of mouse and human DNMT1 direct GFP to the
mitochondria. Mouse and human N-terminal MTSs from ATG1 to immediately upstream of
ATG3 were cloned in-frame to GFP and transiently transfected into HCT116 cells. Immunoblot
analysis with an anti-GFP antibody shows the presence of GFP in the mitochondrial fraction
(M). The upper bands represent intact translation product, carrying the DNMT1 MTS fused to
GFP (MTS-GFP), whereas the lower bands are the expected molecular mass of GFP after
proteolytic cleavage of the targeting peptides. W, whole cell lysate; M, mitochondrial lysate;
MTS, mitochondrial targeting sequence; VDAC, voltage-dependent anion channel.

63

fused to GFP, whereas the lower bands are the expected molecular mass of GFP after proteolytic
cleavage of the targeting peptides. Cells transfected with vector-only and CAT-GFP negative
controls were free of GFP in the mitochondrial fraction, indicating that translocation of GFP to
the mitochondria was specific to constructs containing a functional MTS. An antibody to VDAC
was used here as both a mitochondrial marker and a loading control, and an antibody to
H3K4me3 was used as a nuclear marker. This result, in conjunction with the immunoblots of
subcellular fractions from human and mouse cells (Figure 2-10), suggests that mtDNMT1, much
like many other nuclear-encoded mitochondrial proteins (6, 7, 85), undergoes proteolytic
processing upon entry into the mitochondrial compartment.

RT-qPCR detects mature transcripts capable of encoding MTSs in human and mouse
Using sense primers positioned over ATG1 (mouse) or ATG2 (human) and anti-sense
primers that overlap the exon 1-2 boundary by four nucleotides, endpoint RT-PCR detected
mature transcripts capable of encoding the N-terminal mitochondrial targeting peptide in both
human and mouse cell lines (Figure 2-9). No reverse transcriptase (“No RT”) cDNA templates
served as negative controls for PCR. These findings further supported the utilization of an
upstream transcription start site to generate a mitochondrial-specific isoform of DNMT1.

Immunoblots of subcellular fractions from human and mouse cell lines demonstrate the
presence of DNMT1, but not DNMT3a or DNMT3b, in the mitochondria
Immunoblots of subcellular fractions from mouse embryonic fibroblasts (MEFs) and
HCT116 human colon carcinoma cells showed the presence of DNMT1 in the highly purified
mitochondrial fraction (Figure 2-10). Neither DNMT3a nor DNMT3b could be detected. Both
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Figure 2-9: Detection of mature transcripts for mtDNMT1 in human and mouse. Mature
transcripts capable of encoding the upstream MTS are detected in both human and mouse cells.
No RT, no reverse transcriptase negative control.
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Figure 2-10: Detection of two protein species for DNMT1, and absence of the de novo
DNMTs (DNMT3a and DNMT3b) in mitochondria. (A) A DNMT1 antibody directed against
an N-terminal epitope (amino acids 1-10) detects two protein species in the mitochondrial
fraction, full-length DNMT1 (185 kDa, arrow) and a 60 kDa peptide. Immunoblots performed by
Erica Peterson. (B) DNMT3a or DNMT3b de novo DNA methyltransferases are not detected in
mitochondria. Antibodies against compartment-specific markers: voltage-dependent anion
channel (VDAC) (mitochondrial), tubulin (cytosolic) and H3K4me3 (nuclear) demonstrate the
purity of each subcellular fraction. W, whole cell lysate; C, cytosolic lysate; M, mitochondrial
lysate. For DNMT3b, the mitochondrial fraction was overloaded two-fold to exclude the
possibility of low levels of DNMT3b in the mitochondria.
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the full-length DNMT1 and a smaller peptide (~60kDa) are detected using an antibody directed
against an N-terminal epitope of DNMT1, suggesting that proteolytic processing of mtDNMT1
occurs upon entry into the mitochondrial compartment. Antibodies against compartment-specific
markers demonstrate the purity of each subcellular fraction. Voltage-dependent anion channel
(VDAC) is an outer mitochondrial membrane protein; an antibody against VDAC was used as a
mitochondrial marker. Histone H3 Lysine 4 trimethyl (H3K4me3) is a modified histone protein,
found only in the nucleus, so the H3K4me3 antibody was used as a nuclear marker. An antibody
to tubulin, which is a cytosolic protein, was used as a cytosolic marker. Absence of the nuclear
marker, H3K4me3, in the mitochondrial fraction indicated purity of this fraction from
contamination by nuclear material, which is the primary site of localization of DNA
methyltransferases.

mtDNMT1 expression is regulated by factors that respond to oxidative stress
MatInspector software (http://www.genomatix.de/en/index.html) predicted a binding site
for nuclear respiratory factor 1 (NRF1) within the MTS of both human and mouse DNMT1
(Figure 2-6). This consensus sequence was located over one of the upstream in-frame start
codons and was conserved in all other mammalian species examined for the presence of a MTS
(Table 2-5). Under conditions of oxidative stress, NRF1 works in conjunction with PGC1α,
which has been termed the “master regulator” of the response to oxidative stress, to up-regulate
multiple nuclear-encoded mitochondrial proteins (1, 3). Accordingly, we transiently transfected
NRF1, PGC1α, or both together, into HCT116 cells and fractionated transfected cells to analyze
changes in the levels of mtDNMT1 by immunoblot. A moderate increase in mtDNMT1
expression was seen in cells transfected with NRF1 or PGC1α alone, whereas cotransfection
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with both NRF1 and PGC1α resulted in a much more substantial increase in mtDNMT1
expression, relative to control (Figure 2-11). These results demonstrate that mtDNMT1 is a
bonafide nuclear-encoded mitochondrial protein, sensitive to regulation by transcriptional
activators that respond to oxidative stress.

Loss of p53 preferentially increases mtDNMT1 expression
Early studies performed by Erica Peterson in our laboratory identified a consensus p53
binding site that, when bound by p53, serves to repress DNMT1 transcription (Figure 2-6, Table
2-1) (89). This study reported a 3- to 6-fold increase in DNMT1 transcription following either
activation or genetic deletion of p53 in both HCT116 cells and MEFs (89). Because p53 is
known to regulate mitochondrial respiration (88), we questioned whether this tumor suppressor
protein affected mRNA expression of the mitochondrial DNMT1 isoform. Using RT-qPCR with
primers that distinguish the mitochondrial DNMT1 transcript from the total DNMT1 transcript
(Figure 2-9), we measured the relative abundance of mtDNMT1 and total DNMT1 in both WT
and p53-/- MEFs. The mitochondrial transcript comprises only 1-2% of the total DNMT1 mRNA
synthesized in log-phase WT MEFs. However, upon loss of p53, the relative abundance of the
mtDNMT1 transcript increased 6-fold, whereas the total DNMT1 mRNA increased only 3-fold.
This suggests a preferential up-regulation of the mitochondrial transcript in cells lacking p53
(Figure 2-12A).
Immunoblot analysis of subcellular fractions from both WT and p53-/- MEFs
recapitulated this phenomenon at the protein level (Figure 2-12B). Whole cell, cytosolic and
mitochondrial fractions from these isogenic cell lines were separated by SDS-PAGE, and probed
with antibodies directed against DNMT1 and appropriate compartment-specific controls. The
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Table 2-5: Consensus sequences for putative NRF1 binding sites within the MTS for
DNMT1.

NRF1
consensus
Mouse
Human
Chimp
Rat
Cow

YGCGCAYGCGCR
CGCGCATGCGCA
TGGGCATGGCCG
TGGGCATGGCCG
TGCGCATGCGCA
CGCGCATGCGCG
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Base Pair
Position
-164 to -153
-191 to -180
-191 to -180
-164 to -153
-205 to -194

Figure 2-11: Regulation of mtDNMT1 expression by NRF1 and PGC1α. HCT116 cells were
transiently transfected with recombinant NRF1 and PGC1α constructs and fractionated into
whole cell and mitochondrial fractions. Immunoblot analysis with an anti-DNMT1 antibody
shows that either NRF1 or PGC1α alone induce a modest up-regulation of DNMT1 in the
mitochondrial fraction. However, cells co-transfected with both NRF1 and PGC1α demonstrated
a substantial increase in mtDNMT1 expression. W, whole cell lysate; M, mitochondrial lysate.
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A

B

Figure 2-12: Regulation of mtDNMT1 expression by p53. (A) Loss of p53 selectively upregulates mtDNMT1 expression. Values represent mean +/- SD for two independent
experiments. WT, wild-type MEFs; P-, p53-null MEFs. (B) Immunoblot analysis of WT and
p53-/- MEFs shows a striking increase mtDNMT1 expression in p53-null cells. W, whole cell
lysate; C, cytosolic lysate; M, mitochondrial lysate.
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blots illustrate a striking increase in full-length DNMT1 expression in the mitochondrial fraction
of cells lacking p53. Interestingly, no change in the level of the 60kDa band was observed,
suggesting that this immunoreactive protein is either an artifact due to non-specific binding of
the antibody, or that cleavage of the full-length protein into the 60kDa species is limited by the
mitochondrial processing peptidase.

Up-regulation of mtDNMT1 is associated with gene-specific changes in mitochondrial
transcription
Using the same WT and p53-null isogenic MEF cell lines, we asked whether this drastic
overexpression of mtDNMT1 might be reflected in an alteration of mitochondrial transcription.
Prashant Thakkar in our laboratory used random hexamer-primed cDNA and RT-qPCR with
various primers specific to regions along the mitochondrial genome, and we observed an
interesting contrast of effects (Figure 2-13). Expression of NADH dehydrogenase subunit 6
(ND6), the only protein-coding gene on the light strand of mtDNA (Figure 1-2), was
significantly reduced in response to overexpression of mtDNMT1. This suggests a role for
methylation of mtDNA in repression of light-strand transcription, an effect that would mimic the
role DNA methylation plays in the nucleus. On the heavy strand, ATPase subunit 6 (ATP6) and
cytochrome c oxidase subunit 1 (COX1) were unaltered in their expression levels. However,
expression of NADH dehydrogenase subunit 1 (ND1), the first protein-coding region on the
heavy strand, immediately following the ribosomal RNA (rRNA) genes (Figure 1-2), was
significantly increased in response to elevated mtDNMT1. This increase in ND1 expression,
without changes in expression of ATP6 or COX1 located further downstream on the heavy
strand, suggests a gene-specific effect on mitochondrial transcription.
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Figure 2-13: Loss of p53/up-regulation of mtDNMT1 induces gene-specific effects on
mitochondrial transcription. Using random-hexamer-primed cDNA, gene-specific changes in
mitochondrial transcription were observed upon over-expression of mtDNMT1, relative to
nuclear 18S rRNA. To test for differences in expression of four mitochondrial genes across the
two cell lines, we applied an ANOVA using least-square means. ND1 and ND6 showed
significant differences in expression (P < 0.05). In p53-/- MEFs, ND1 mRNA expression was
significantly higher (mean = 1.73, SE = 0.18, 95% CI = 1.37, 2.09) than in WT MEFs (mean =
0.95, SE = 0.09, 95% CI = 0.76, 1.15). ND6 mRNA expression in p53-/- MEFs was significantly
lower (mean = 0.75, SE = 0.07, 95% CI = 0.59, 0.90) than in WT MEFs (mean = 1.14, SE =
0.11, 95% CI = 0.91, 1.38). Studies performed by Prashant Thakkar.
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To be sure that we were not masking any transcriptional effects by looking at the average
across both H and L strands of mtDNA, we modified our cDNA synthesis strategy to generate
only strand-specific-primed cDNA. The ATP6 gene was chosen as the region to initiate strandspecific cDNA synthesis because it was approximately equidistant from either region of interest
on the H (ND1) and L (ND6) strands. Using a sense primer within the ATP6 gene, we
synthesized only the light strand of mitochondrial cDNA; likewise, using an antisense primer
within the ATP6 gene, we synthesized only the heavy strand. Total RNA from WT and p53-/isogenic MEFs was used as the template for cDNA synthesis. RT-qPCR was performed using
primers for heavy-strand genes against heavy-strand template cDNA and primers for light-strand
genes against only light-strand template cDNA. Two new light strand primer sets were designed
against non-coding sequence complementary to ND4 (non-coding primer set “NC1”) and ND5
(non-coding primer set “NC2”) on the heavy strand, in order to get a more complete picture of
changes in transcription along the light strand (Table 2-2). Increased expression of mtDNMT1
appeared to differentially affect transcription initiating from HSP1 and HSP2. Transcription of
the ribosomal RNA genes, 12S and 16S rRNA, initiates from HSP1 on the heavy strand, and
showed contrasting effects (Figure 2-14A). No change in 12S rRNA expression was observed
between WT and p53-/- MEFs. However, a substantial decrease in expression of 16S rRNA was
observed upon loss of p53/up-regulation of mtDNMT1 (Figure 2-14A). Heavy strand transcripts
initiated at HSP2 all showed the same trend: expression of both ND1 and COX1 were
significantly up-regulated by overexpression of mtDNMT1 in p53-/- MEFs (Figure 2-14B). This
increase in ND1 is consistent with what we observed before using random hexamer-primed
cDNA, looking at an average of transcription from both strands (Figure 2-13). However, using a
modified cDNA synthesis strategy, we were able to see an increase in COX1 expression, which
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A

B

Figure 2-14: Loss of p53/up-regulation of mtDNMT1 induces additional gene-specific
effects on mitochondrial transcription. Total RNA from WT and p53-/- MEFs was used to
generate either random hexamer-primed cDNA (for nuclear 18S rRNA control) or gene-specificprimed cDNA with primers located within the ATP6 gene. Gene-specific changes in
mitochondrial transcription are again observed upon over-expression of mtDNMT1, relative to
nuclear 18S rRNA. NC1, non-coding region complementary to ND4 on the H strand; NC2, noncoding region complementary to ND5 on the H strand. Studies performed in collaboration with
Prashant Thakkar.
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was somehow masked before, by looking at the average across both strands. On the light strand,
looking at transcripts initiated at the light strand promoter (LSP), we saw increases in both NC1
and NC2 mRNA in response to mtDNMT1 overexpression (Figure 2-14). Interestingly, looking
only at the light strand, there was no change in ND6 transcription upon overexpression of
mtDNMT1 (Figure 2-14), which was not consistent with what we observed before (Figure 2-13).

DISCUSSION
Previous studies likely underestimated the level of epigenetic modification within the
mitochondrial genome
Cytosine methylation of the mitochondrial genome has remained largely overlooked, in
part because early reports using nearest-neighbor analysis indicated that this modification was
present at only 3-5% of CpG dinucleotides (17). This is well below the level of methylation
(~60-80% of CpG dinucleotides) seen in the nucleus (96, 97). The data presented here show a
10- to 20-fold enrichment of mtDNA sequences in immunoprecipitates using a 5mC antibody
(Figure 2-3A). This level of enrichment is somewhat lower than that usually obtained from total
gDNA (~100-fold for CpG islands), and likely reflects the CpG-sparse nature of the
mitochondrial genome, which does not contain CpG islands (17, 18). Additionally, our data
demonstrates the presence of 5hmC residues in mtDNA using two independent assays (Figures
2-3B, 2-4 and 2-5). Our data shows a 38-580-fold enrichment of mtDNA sequence in
immunoprecipitates using a 5hmC antibody, which is in striking contrast to the low level of
background signal in our nonspecific IgG controls (Figure 2-3A). Although we cannot use the
MeDIP assay with two antibodies of different specificities to accurately quantitate the frequency
of each type of modified residue, the β-glucosyltransferase assay is quantitative. However, this
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assay relies upon enzymatic digestion by GlaI, so the detection of 5hmC residues is only possible
at specific GlaI cleavage sites. While the β-gt assay can provide valuable information as to the
relative abundance of 5hmC residues within sequences containing a given number of GlaI
restriction sites (Figure 2-5), these sites are not representative of the entire mitochondrial
genome. Regardless, our findings that both 5mC and 5hmC residues exist within mtDNA suggest
that epigenetic modification of cytosines in the mitochondrial genome is likely to occur more
frequently than previously thought.

Profiles of 5mC- and 5hmC-modified residues across the mitochondrial genome
Mapping the location and distribution of 5mC or 5hmC residues in either the nuclear or
mitochondrial genomes is not yet technically feasible because the modified bases are
indistinguishable by bisulfite modification and sequencing (56, 98). However, MeDIP analysis of
specific DNA sequences, using antibodies specific for either modification can distinguish
between 5mC and 5hmC residues. While we cannot compare the level of enrichment of mtDNA
sequences we see with the 5mC antibody to that with the 5hmC antibody, we can compare across
regions immunoprecipitated with the same antibody. Our data illustrates that there are easily
detectable levels of both 5mC and 5hmC across all tested regions of the mitochondrial genome.
Primer set 27 is a particularly interesting case, as it overlaps the D-loop control region,
which contains the promoters responsible for initiating mtDNA transcription (Figures 1-2 and 23) (1, 3). The D-loop exists as a stable triple-helical structure, containing an RNA primer that is
required for initiation of mtDNA replication (1). We have found this region to be resistant to in
vitro methylation by M.SssI, a bacterial cytosine methyltransferase. It is therefore possible that
the kinetics of epigenetic modification in this region of the mitochondrial genome may be
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different from those in coding regions. For instance, the complex structure of the D-loop may
prevent access of mtDNMT1 to the DNA, or if mtDNMT1 can gain access, perhaps baseflipping of the target cytosine residue out of the DNA helix is prevented by the stability of the
triplex D-loop structure. Either of these hindrances would limit modification of cytosines within
the D-loop to 5mC. Additionally, if 5mC residues are required as precursors for 5hmC, then
limiting 5mC modification would also negatively impact the level of 5hmC in this region.
Nonetheless, both 5mC and 5hmC modifications are present in the amplicon containing the Dloop, albeit, perhaps to a lesser extent than other regions across the mitochondrial genome.

Possible mechanisms for generation of 5hmC
In the nucleus, 5hmC is generated from 5mC through the action of the ten-eleven
translocation (TET) family of methylcytosine oxygenases (46). There is not yet concrete
evidence regarding the presence or absence of these enzymes in mitochondria. We therefore
cannot rule out the possibility of a different mechanism for the generation of 5hmC in mtDNA,
including the covalent addition of 5-hydroxymethyl groups directly to DNA cytosine residues by
mtDNMT1, as described by Liutkeviciute and colleagues (Figure 2-15) (48). This mechanism
would require formaldehyde generated by mitochondrial mixed-function oxidases, which is
usually removed by aldehyde dehydrogenases as a protective measure against formaldehydeinduced oxidative damage (99). This uncharacteristic reaction would also require the baseflipping activity of DNMT1 to perform nucleophilic addition of an exogenous aldehyde to the C5
position of a target cytosine, rather than its naturally-catalyzed nucleophilic substitution reaction
(Figure 2-18). Using aldehydes, which lack an adenosyl anchor moiety and therefore are not true
“cofactors”, would be an atypical chemical reaction for DNMT1, which is normally considered

78

Figure 2-15: Mechanism for direct addition of a 5-hydroxymethyl group to cytosine by
DNMT1. Methylation by C-5 methyltransferases occurs via a direct nucleophilic SN2 attack of
the activated cytosine intermediate onto the cofactor, S-adenosylmethionine. This yields the
covalent methylated intermediate, and then 5mC. In an alternate mechanism, the activated
cytosine intermediate can undergo a nucleophilic addition reaction with an exogenous aldehyde.
This gives rise to a covalent coupled intermediate, and ultimately releases the 5hmC product.
Adapted from figure by Liutkeviciute, et al. (2009) Nat Chem Biol 5: 400-402.
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to be a cofactor-dependent enzyme (48). However, the mitochondrial matrix is a unique
environment, and may provide conditions that allow this reaction to proceed.
Alternatively, 5hmC may arise in a mitochondrial folate-dependent manner, as a
modification of dCMP by an enzyme analogous to that found in T-even bacteriophage. In
bacteriophage, the folate-dependent dCMP hydroxymethylase catalyzes the formation of 5hmdCMP from dCMP (100). 5hm-dCMP can be converted to 5hm-dCTP through the action of
deoxycytidylate kinases, and subsequently incorporated into bacteriophage DNA. Incorporated
5hmC residues can then be further modified by β-glucosyltransferase enzymes, in a reaction
identical to the one exploited in the β-glucosltransferase assay for sequence-specific detection of
5hmC in mtDNA. These mechanisms exist in T-even bacteriophage as a protective measure, to
ensure that phage DNA is not subjected to host-mediated restriction endonuclease cleavage. For
this to represent a viable mechanism for generation of 5hmC in mitochondria, a mitochondrial
enzyme with activity analogous to phage dCMP hydroxymethylase would be required, and
would not rely on the prior formation of 5mC.

Functional significance of mtDNA epigenetic modification
a. What are the possible functions of 5mC and 5hmC in mtDNA?
Overexpression of mtDNMT1, as seen in our p53-/- MEFs (Figure 2-12), results in an
asymmetric, gene-specific alteration in mitochondrial transcription patterns, suggesting diverse
roles for mtDNMT1 and cytosine modification in this organelle. Looking first at the results
obtained using strand-specific-primed cDNA (Figure 2-14), we observed decreased expression of
16S rRNA on the heavy strand when mtDNMT1 was overexpressed. This effect mimics what we
might expect to observe in the nucleus, where methylation status almost always inversely
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correlates with gene expression. However, increased expression of ND1 and COX1 on the heavy
strand, and NC1 and NC2 on the light strand suggest an opposite mode of action for methylation
of mtDNA. It could be that methylation of mtDNA serves to recruit the mitochondrial
transcription machinery, enhancing expression of methylated genes, rather than repressing them
as methylation does in the nucleus. Alternately, methylation could influence the structure of
mtDNA, such that either the methylation signal itself or binding by mitochondrial 5mC-specific
binding proteins opens the supercoiled configuration of mtDNA, inducing a more
transcriptionally-active state, much like acetylation promotes a more euchromatic state of nuclear
DNA.
Increases in transcription of ND1 and COX1 initiating at HSP2, with a concurrent
decrease in transcription of 16S rRNA from HSP1 suggests that the methylation-mediated effect
is rooted in transcription initiation. Perhaps mtDNA methylation differentially affects transcripts
originating at either H-strand promoter, providing an additional level of control of rRNA
transcript production relative to protein-coding mRNA in mitochondria.
However, random-hexamer-primed cDNA (Figure 2-13) shows no change in expression
of ATP6 or COX1 on the H-strand, but a significant increase in transcription of ND1, which is
consistent with the results obtained using strand-specific-primed cDNA. Transcription of all
three of these protein-coding genes initiates at HSP2, suggesting a methylation-mediated effect
that is distinct from transcription initiation. Instead, mtDNA methylation may interfere with
proper termination of transcription of the rRNA genes initiating at HSP1, resulting in increased
readthrough from HSP1 to the next open reading frame, ND1. A schematic representation of this
proposed effect is depicted in Figure 2-16, and is discussed in more detail in the next section.
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The function of 5hmC in the nuclear genome is not yet clear. It has been proposed that
5hmC is an intermediate metabolite in either active demethylation of the genome by repair
enzymes (101, 102), or passive demethylation as a result of lack of recognition by enzymes
involved in maintenance methylation (101, 103). Evidence for the former hypothesis is stronger,
as a recent study described a TET1-mediated oxidation-deamination mechanism for active DNA
demethylation in the brain (47). It has also been proposed that 5hmC alters local chromatin
structure because 5hmC is not recognized by 5mC-binding proteins (101). If mtDNA
methylation or binding by 5mC-specific binding proteins serves to open the configuration of
mtDNA as discussed above, then perhaps 5hmC modifications induce a more compact mtDNA
configuration, resembling a “heterochromatic” state, and repressing mitochondrial transcription.
Studies using ChIP-seq to map the positions of the TET1 enzyme bound to nuclear DNA
demonstrated that TET1 was bound to CpG-rich promoters (101), contrasting the trends seen for
nuclear methylation, where 5mC is normally absent at CpG-rich promoters. Furthermore, it has
been shown that DNMT1 does not bind to its target cytosine when positioned opposite from a
5hmC residue in hemi-hydroxymethylated DNA (103). Together, these findings suggest that
5hmC may serve to prevent inappropriate methylation and silencing of CpG-rich genes. Thus,
the roles for 5mC and 5hmC in mitochondria could be reversed from their functions in the
nucleus. Nonetheless, if 5mC represents methylation and 5hmC represents demethylation of
mtDNA, then the levels of these marks in mitochondria are likely in a delicate balance, affected
themselves by enzymatic function, and with downstream consequences including changes in
mitochondrial gene expression.
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b. Proposed role for mtDNMT1 in mitochondria
Although DNMT1 is generally considered to be the maintenance DNA methyltransferase,
it is able to methylate completely unmethylated DNA in vitro with an efficiency that exceeds that
of the de novo methyltransferases, DNMT3a and DNMT3b (59). Thus, DNMT1 appears to be
capable of both initiating and maintaining cytosine methylation in the nucleus, and the lack of de
novo methyltransferases in mitochondria implies that mtDNMT1 is involved in both processes in
this organelle. The presence of modified cytosines in the D-loop control region of mtDNA,
which houses the H-strand origin of replication and the promoters driving transcription initiation
of both heavy and light strands, supports a role for mtDNMT1 in the regulation of mitochondrial
gene expression.
We observed a significant increase in ND1 expression, regardless of whether we looked
at an average of both heavy and light strand messages (Figure 2-13), or the heavy strand only
(Figure 2-14). We hypothesize that either mtDNMT1 itself or methylation by mtDNMT1 may be
interfering with proper termination of transcription from HSP1 (Figure 2-16). A binding site for
mitochondrial termination factor 1 (mTERF1) is located between the end of the 16S rRNA gene
and the translation start of ND1 (Figure 1-2) (1). mTERF1 binds to both HSP1 and the
terminator binding site, forming a transcription loop that maintains high-level production of
rRNA. Transcripts initiating at HSP2 produce polycistronic messages encoding the entire heavy
strand (1). Our data raise the possibility that mtDNMT1, either through modification of CpG
dinucleotides or by direct protein-protein interaction, interferes with mTERF-dependent
transcription termination, allowing read-through from HSP1 to the next transcriptional unit
(ND1) without impacting polycistronic mRNA synthesis from HSP2 (Figure 2-16).
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Figure 2-16: Proposed mechanism for up-regulation of ND1 expression. Normally, the
transcription terminator, mTERF1 binds simultaneously to HSP1 and its Term site (yellow bar),
forming a rDNA loop to yield high level transcription of the rRNA genes. When mtDNMT1 is
up-regulated, we observe an increase in transcription of ND1, the first protein-coding gene on the
H strand, immediately downstream of the rRNA genes and Term site. We hypothesize that
either: 1) methylation of a CpG dinucleotide within the Term site, or 2) direct binding of
mtDNMT1 at the Term site, serves to disrupt proper termination of transcription from HSP1.
Failure to terminate H strand transcription at the Term site would result in readthrough of the
transcriptional machinery to the next coding unit (ND1), causing increased expression of ND1,
and possibly other ORFs downstream of ND1.
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c. Are the observed effects on mitochondrial transcription gene-specific or strandspecific?
Results from the first RT-qPCR experiments, which measured changes in mitochondrial
gene expression in isogenic WT and p53-/- MEFs using random hexamer-primed cDNA (Figure
2-13), appeared to suggest that the effects of overexpression of mtDNMT1 may be strandspecific, as we observed an increase in ND1 transcription on the heavy strand with a decrease in
ND6 transcription on the light strand. However, the absence of change in ATP6 or COX1
expression, both on the heavy strand, implied that the effect of mtDNMT1 overexpression on
mitochondrial transcription was more complicated than anticipated, and led us to focus our
attention on transcription of one mtDNA strand at a time.
RT-qPCR measuring changes in mitochondrial gene expression in WT and p53-/- MEFs,
this time from strand-specific primed cDNA (Figure 2-14), also suggested a gene-specific
phenomenon was at play. The increase in ND1 expression was reiterated using this modified
strategy, so this effect is consistent between the two experiments. However, an increase in COX1
expression (heavy strand) was also revealed using strand-specific-primed cDNA, an effect that
we predict may have been hidden using random-hexamer-primed cDNA and looking at an
average across both strands.
One major difference in the results obtained from the two different cDNA priming
strategies was in the expression of ND6: using random-hexamer-primed cDNA, we observed a
statistically significant decrease upon upregulation of mtDNMT1 (Figure 2-13), but this
difference disappeared using strand-specific-primed cDNA (Figure 2-14). This apparent “loss”
of an effect is likely a technical artifact, resulting from the method used to generate cDNA and

85

differences in priming efficiencies between the ATP6asn and ATP6sn primers used to synthesize
the H- and L-strands, respectively.
Other changes in mitochondrial gene expression were also observed upon mtDNMT1
overexpression using strand-specific-primed cDNA (Figure 2-14): a decrease in 16S rRNA
(heavy strand), which is consistent with other reports in the literature of a p53-dependent effect
on mitochondrial transcription (86, 104), and increases in NC1 and NC2 (light strand).
Consistent changes in expression of genes on each strand would afford greater confidence in
concluding that mtDNMT1 affects mitochondrial transcription in a strand-dependent manner.
However, the variability of effects from gene to gene along the same strand suggest that
overexpression of mtDNMT1 has a gene-specific effect on mitochondrial transcription.

d. Are the observed effects on mitochondrial transcription p53-dependent or
mtDNMT1-dependent?
We hypothesize that the observed differential effects on mitochondrial transcription are
mtDNMT1- or methylation-dependent. However, we cannot ignore the confounding effects due
to altered p53 status, which is an obvious limitation of these experiments. The isogenic WT amd
p53-/- MEF cell lines were used to induce changes in mtDNMT1 expression because they were
readily available, but this is not a clean system. Therefore, at this time, we cannot conclude that
p53 status is not contributing to these transcriptional effects. Other labs have reported that p53
influences mtDNA copy number, showing that cells lacking p53 exhibited a significant reduction
in mtDNA content compared to WT cells (105, 106). If this is true, then we would expect a
reduction in mtDNA content to be reflected by a generalized decrease in mitochondrial
transcription. In our mitochondrial transcription experiments, we observe a decrease in 16S
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rRNA; perhaps this effect can be explained by reduction in mtDNA copy number as a result of
the loss of p53. However, the consistent increase in ND1 expression on the heavy strand, as well
as increases in NC1 and NC2 on the light strand, does not conform to that theory. Such genespecific effects are more likely a characteristic of gene-specific changes in mtDNA methylation
profiles, or occupancy of specific sites along mtDNA by mtDNMT1. We propose to further
investigate the effects of mtDNMT1 alone on mitochondrial gene expression by either overexpression or selective depletion of mtDNMT1. Some of these studies are described in more
detail in Chapter 5.

Conservation of DNMT1 MTSs across mammalian species and thoughts on import and
proteolytic processing of mtDNMT1
Our studies report a mitochondrial isoform of DNMT1, which is the only member of the
catalytically active mammalian DNA methyltransferase family found in this organelle. The
conservation of an ORF encoding a mitochondrial targeting sequence upstream of the commonly
accepted translational start codon across multiple mammalian species suggests an important role
for this enzyme in mitochondrial function.
Like the majority of other nuclear-encoded mitochondrial proteins, mtDNMT1 is directed
to the organelle by way of a cleavable, N-terminal targeting sequence. Such presequences
typically direct import of their mitochondrial precursor proteins to the mitochondrial matrix,
employing translocase of the outer mitochondrial membrane (TOM), translocase of the inner
mitochondrial membrane (TIM23) and presequence translocase-associated motor (PAM)
machinery (6, 7). Upon import into the matrix, the targeting presequence is cleaved by the
mitochondrial processing peptidase (MPP), to generate the final functional protein. Our data
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suggest that a similar import mechanism is used for mtDNMT1, as a protein of the expected size
for GFP after cleavage of the DNMT1-MTS appeared in the mitochondrial fraction of cells
transfected with our MTS-GFP constructs. In these experiments, the heterologous protein, GFP
was used as both a fluorescent and an immunoreactive marker, allowing us to track the
subcellular localization of the presumed MTS. These experiments prompted us to devise a model
for mtDNMT1 import and subsequent proteolytic processing within the mitochondrial
compartment (Figure 2-17).
Immunoblots of subcellular fractions from both human and mouse cell lines show that
full-length DNMT1 (185kDa) is easily detected using an antibody directed against a far Nterminal epitope (aa1-10, Abcam), along with a smaller immunoreactive protein species
approximately 60kDa in size (Figure 2-10). Interestingly, upon genetic deletion of p53, a
dramatic increase in expression of only full-length mtDNMT1 is observed; expression of the
60kDa band remains the same between WT and p53-/- MEFs (Figure 2-12B). This suggests that,
if this smaller protein species is in fact a proteolytic cleavage product of the full-length enzyme,
it is not subject to the same p53-dependent regulation as the full-length enzyme. Alternatively,
the lack of up-regulation of the 60kDa species could mean that the mitochondrial processing
peptidase (MPP) is saturated and cannot maintain proteolytic processing of higher levels of
mtDNMT1. It is also possible that this immunoreactive protein represents non-specific binding,
and is simply an artifact of the antibody used. Because this 60kDa protein is detected with an Nterminal antibody, it would represent an N-terminal fragment, lacking the catalytic domain and
enzymatic active site, and thus would likely not be active on mtDNA. Such a fragment would
still contain the MTS for translocation to the mitochondrial compartment, and DNA binding
domains, which may allow this truncated protein to compete with the catalytically-active form of
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Figure 2-17: Model for translocation, import and proteolytic processing of mtDNMT1. This
model is based on the most common route of import for nuclear-encoded mitochondrial
precursor proteins containing an N-terminal mitochondrial targeting sequence (MTS). The red
arrow indicates the flow of direction for import through the translocase machinery. The MTS for
mtDNMT1 would first be recognized by receptors on the mitochondrial outer membrane (OM),
which then direct its passage through the main entry gate for mitochondria, the translocase of the
outer membrane (TOM) complex. At this stage, precursor proteins follow different sorting
pathways, based on their ultimate function within the organelle. Since mtDNMT1 is expected to
bind and methylate mtDNA, it would be directed to the matrix, which would involve traversing
the inner membrane (IM) via the translocase of the inner membrane (TIM) machinery. The TIM
complex is assisted by the presequence associated motor (PAM), and other specific chaperone
proteins, to fully import the precursor protein into the mitochondrial matrix. Once inside the
matrix, the precursor protein undergoes cleavage of its N-terminal MTS, and as we suspect for
mtDNMT1, additional proteolytic processing events to generate the final functional form of
mtDNMT1.
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mtDNMT1 for binding to mtDNA, thereby imposing control over which sites become
methylated.

Regulation of mtDNMT1 by factors controlling mitochondrial function
Conservation of not only the MTSs across species, but also the configuration of
transcription factor binding sites within the MTSs across species (Tables 2-3, 2-4 and 2-5), is
suggestive that the mtDNMT1 isoform has some evolutionary significance with regard to proper
functioning of the organelle. It has been well established that NRF1 and PGC1α function as
transcriptional coactivators that respond to conditions of oxidative stress by up-regulating
expression of nuclear-encoded mitochondrial proteins, and stimulating mitochondrial biogenesis
(1, 3). Our observations that mtDNMT1 is up-regulated in a manner similar to many other
nuclear-encoded mitochondrial proteins (Figure 2-11) is evidence that mtDNMT1 is controlled
by factors directly involved in mitochondrial function, and implicated mtDNA methylation in the
mitochondrial response to cellular stress.
p53 is best known as the most frequently mutated gene in cancer, but it has also been
shown to be intimately linked to mitochondrial function (86, 88, 104-106). Studies have reported
that p53 is involved in regulating the balance between the utilization of respiratory and glycolytic
pathways in the mitochondria by controlling expression of the subunit proteins forming the COX
complex (88). Thus, regulation of the mtDNMT1 isoform by p53 (Figure 2-12) is suggestive that
changes in expression or activity of mtDNMT1 may have downstream consequences affecting
overall functioning of the organelle. Collectively, our studies on the regulation of mtDNMT1
demonstrate that this isoform is controlled by factors intimately linked with mitochondrial
function, and lend further support to our hypothesis that mtDNMT1 is functionally relevant.
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Is there a connection between the endosymbiotic theory and conservation of the catalytic
domain of DNMTs across eukaryotes and prokaryotes?
Common to all of the DNMTs is the structure and amino acid composition of the
catalytic domain (35, 59, 71). This C-terminal domain houses the conserved motifs characteristic
of all mammalian and even prokaryotic DNA-(cytosine-5)-methyltransferases. This homology
with bacterial DNMTs is interesting, particularly in light of the endosymbiotic theory, which
proposes that mitochondria are remnants of prokaryotes themselves. The endosymbiotic theory
proposes that mitochondria originated as free-living bacteria that were engulfed, and eventually
propagated, by eukaryotic cells. This symbiotic union was tolerated because the acquisition of
mitochondria by a eukaryotic cell provided some advantage, for example, more efficient energy
production, and over time, most of the genes encoded in this symbiotic prokaryote were
transferred to the nucleus. As a result, the symbiotic prokaryote or mitochondrion precursor
became dependent on the transfer of nuclear proteins and enzymes to assist in complete
functioning of the organelle. It is both tempting and reasonable to speculate that the mtDNMT1
isoform is among the proteins that originated in a bacterial symbiont, was transferred to the host
nucleus, where it acquired additional sequence and structure including a MTS, and is now
targeted back into mitochondria to maintain methylation of mtDNA.
As discussed in Chapter 1, the molecular structure of DNMT1 is thought to have arisen
through the fusion of three separate genes: one gene that encoded the catalytic domain and shares
strong homology with bacterial methyltransferases, and two genes that together form the
regulatory domain (71). It is possible that what is now regarded as the C-terminal catalytic
domain was at one time the full active form of DNA methyltransferase within the symbiotic
prokaryote. Hypothetically, upon invasion of a host organism, the prokaryotic origin of DNMT1
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was amended for a specific purpose within the host nucleus by adding a nuclear localization
signal, DNA binding domains and other domains for efficient functioning in the nucleus. Over
time, it became apparent that the symbiotic prokaryote also required a functional DNA
methyltransferase, thus a mitochondrial targeting sequence was added to allow proper
translocation of the modified precursor DNMT1 back into what is now a subcellular organelle:
the mitochondrion.
In keeping with this idea, bacterial DNA is thought to be methylated as a protective
measure, to prevent its restriction by endonucleases. If mitochondria are truly remnants of
prokaryotes, then perhaps methylation of mtDNA has evolved along with the organelle, as a
means of protecting it from intra-mitochondrial endonuclease cleavage.
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Chapter 3: Generation of a TAP-tagged DNA methyltransferase 1 (DNMT1) cell line

INTRODUCTION
I.

Objectives
Central to understanding the function of DNMT1 in the mitochondrial compartment, was

the need for a means of efficiently isolating the enzyme under a variety of experimental
conditions, including its native context. We needed a straightforward way to ask whether
mtDNMT1 binds and methylates mtDNA, and which accessory proteins are required for its
function in the mitochondria.

II.

The Tandem Affinity Purification (TAP) tag
An efficient method for isolating native protein complexes was initially developed in

yeast (107, 108) and since, has been applied successfully to a number of other organisms,
including mammalian cells. The method is called tandem affinity purification (TAP), and
involves fusion of the TAP-tag in-frame with a gene of interest, allowing expression of a hybrid
fusion protein. The TAP-tag contains an IgG-binding domain of the Staphylococcus aureus
protein A (ProtA) and a calmodulin-binding peptide (CBP) domain, separated by a tobacco etch
viral (TEV) protease cleavage site (Figure 3-1A). The combination of ProtA and CBP tags
allows for two high-affinity purification steps, to achieve greater purity than either step alone
(109, 110). Additionally, the entire procedure is carried out under mild, non-denaturing
conditions so that the purified protein should retain functionality. This was critical for our
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Figure 3-1: Molecular structure of the TAP-tag and rAAV Helper Free system used for
gene targeting. (A) The tandem affinity purification (TAP)-tag consists of a Protein A (ProtA)
domain and a calmodulin-binding peptide (CBP) domain, separated by a tobacco etch viral
(TEV) protease cleavage site. The TAP-tag was fused to the C-terminus of DNMT1, just
upstream of the endogenous stop codon for DNMT1. (B) The rAAV Helper Free system
(Stratagene) consists of the pAAV-MCS plasmid for direct insertion of your target gene into the
multiple cloning site (MCS). The pAAV-MCS vector is not infectious alone, however, when cotransfected with the pAAV-RC and pHelper plasmids, it acquires the genes and accessory
proteins necessary for efficient packaging and replication of the recombinant adeno-associated
virus.
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analyses, because we hoped to determine whether the mtDNMT1 isoform possessed catalytic
activity and might be responsible for methylating mtDNA.
The TAP-tag purification protocol is depicted in Figure 3-2. Briefly, the ProtA domain of
the tagged protein binds tightly to IgG sepharose beads. Since ProtA bound by matrix IgG can
only be released at low pH under denaturing conditions, a specific tobacco etch viral (TEV)
protease cleavage site was conveniently placed between the two affinity tags (109, 110).
Incubation with TEV protease cleaves the tag, allowing elution of the target protein under native
conditions. The eluate of this first affinity purification is then incubated with calmodulin
sepharose beads in the presence of calcium to allow a tight calmodulin-CBP interaction. A series
of washes removes contaminants, including TEV protease, and the bound material is released
through the addition of EGTA, which chelates the calcium required for the calmodulin-CBP
interaction.
Prior to development of the TAP-tag and its associated purification method,
comprehensive studies examining protein assemblies were limited to in vitro and ex vivo
systems, which often rely on expression of a target protein at levels far from physiologically
relevant. TAP-tag purification paired with mass spectrometry (TAP-MS) is an extremely
powerful method for determining the identity of unknown proteins in complex with a purified
protein of interest, all expressed at natural levels. Several large-scale studies employing the TAPtag methodology provided insight into how the yeast proteome is organized (107, 111, 112).
Proteins of interest were endogenously tagged at their 3’ ends with the TAP-tag, purified from
total cellular lysates by the TAP-tag method, and resolved on denaturing SDS-PAGE gels.
Protein bands were digested with trypsin and analyzed by matrix-assisted laser
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Figure 3-2: Schematic diagram of TAP-tag purification. Purification of a TAP-tagged protein
is achieved in four simple steps: 1) Binding of the tagged protein to IgG sepharose, 2) Release of
the bound protein by TEV protease cleavage, 3) Binding of the now CBP-tagged protein to
calmodulin-coated beads in the presence of high [Ca2+], and 4) Elution of the bound protein
with a buffer containing a divalent cation chelating agent, such as EGTA.
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desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS); their identities were
predicted by database searches and algorithms (107).
These experiments generated libraries of over 1,500 yeast strains, and purified nearly
2,000 TAP-fusion proteins, which are estimated to represent approximately 60% of the entire
yeast proteome, spanning all functional classes and subcellular localizations of proteins (107,
111). Of the TAP-fusion proteins analyzed, the majority (78-88%) were purified in association
with at least one protein binding partner, demonstrating the utility and efficiency of this approach
for purifying protein complexes (107, 111). Protein complexes were observed ranging in size
from 2-83 components, which illustrates the ability of the TAP approach to purify even large,
multi-subunit protein complexes (107).
The TAP-MS method was shown to be highly reproducible, with a 70% probability of
detecting the same protein in duplicate preparations (107, 111). Sensitivity of the TAP-MS
approach is also high, with limits of detection and identification of proteins present as low as 15
copies per cell (107). In only a small percentage (18%) of attempts did TAP-tagging the Cterminus of a protein generate a non-viable yeast strain, suggesting that insertion of the TAP-tag
impaired protein function (107).
From the data collected, researchers were able to assign functional roles to whole
complexes, based on the known functions of its individual protein components. There was a wide
distribution of predicted cellular roles for the purified complexes, including roles in the cell
cycle, transcription/DNA maintenance/chromatin structure, protein/RNA transport, and energy
metabolism, among others (107).
Perhaps the most valuable information obtained from these systematic analyses was in
the identification of novel protein-protein interactions. These studies were able to propose
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cellular roles for proteins that had no known function, and new roles for known proteins.
Together, the data paints a clearer picture of how eukaryotic proteins exist in time and space, and
how they are organized into higher-order functional networks. Since the advent of the TAP-MS
approach in yeast, numerous other groups have used this technique to endogenously tag various
epitopes within human somatic cells, including phosphatase and tensin homolog (PTEN), signal
transducer and activator of transcription 3 (STAT3) and p53, among others (113, 114).

III.

Gene targeting in somatic cells
Among the many considerations regarding an optimal method for delivery of the TAP-tag

targeting vector to HCT116 human colon carcinoma cells was that overexpression of DNMT1TAP was not preferable, particularly because our goals included looking at activity and
interactions of the protein, and overexpression is known to lead to the formation of nonspecific
interactions and/or false-positive activity readings (108, 109). Dr. Bert Vogelstein and colleagues
(115) described an efficient method for gene targeting in somatic cells through homologous
recombination. The protocol was adapted from those used successfully in yeast (107, 108), and
employed recombinant adeno-associated viruses (rAAV) to achieve 10-100 times higher
frequencies of recombination than those obtained with more conventional plasmid vectors (115).
The rAAV technology is now marketed and available for purchase through Stratagene, termed
the “AAV Helper-Free System”. The kit provides the pAAV-MCS vector (Figure 3-1B), into
which the targeted insertion/deletion construct is cloned, as well as the pAAV-RC and pHelper
plasmids, which encode the rep and cap genes and accessory adenovirus proteins required for
efficient rAAV packaging and replication (115). The simplicity of this approach made
construction of the TAP-tagged DNMT1 targeting construct a straightforward exercise in PCR
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and cloning, and resulted in a valuable tool that will be useful in a variety of downstream
applications.

IV.

Destabilization of DNMT1 mRNA through interaction with AUF1
The C-terminus of DNMT1 was selected for targeted insertion because we wanted the

DNMT1-TAP fusion protein to be expressed off of the native DNMT1 promoter, and under the
same regulation as the non-tagged endogenous DNMT1 allele. Additionally, the mitochondrial
targeting sequence (MTS) for DNMT1 is located within the 5’ flanking sequence of the gene (far
N-terminus), and remains to be fully characterized, making the C-terminus a more desirable
option for tagging. However, among the potential pitfalls of targeting the C-terminus of DNMT1
is that it may interfere with normal regulation of the DNMT1-TAP fusion protein, as DNMT1
has been shown to contain a conserved AU-rich element in the 3’UTR, which mediates stability
of the DNMT1 mRNA (92, 116, 117).
Many human genes, including c-myc, c-fos, and several cytokines contain AU-rich
elements (AREs) that serve as regulatory regions, modulating their mRNA levels posttranscriptionally in response to changing cellular conditions (116, 117). Interaction of these
regions with ARE binding factors, such as AU-rich element/poly(U)-binding/degradation factor
1 (AUF1) has been shown to accelerate mRNA decay (117). Szyf and colleagues (92, 116)
identified a similar conserved ARE within the 3’UTR of DNMT1, which came to our attention as
we designed the C-terminal DNMT1-TAP targeting construct. Using RNA immunoprecipitation
with an AUF1 antibody, followed by RT-qPCR, Torrisani, et al. (92) showed that when this
region was bound by AUF1, the DNMT1 mRNA underwent rapid decay. Overexpression of
AUF1 resulted in a decrease in the DNMT1 mRNA level; alternatively, knockdown of AUF1 led
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to increased DNMT1 protein expression (92). The exosome complex was found to be involved in
this process, so they concluded that the mechanism underlying AUF1-mediated regulation of
DNMT1 is destabilization of the DNMT1 mRNA by targeting it to the exosome (92).

MATERIALS AND METHODS
Materials
HCT116 neoS parental cells and HEK293 cells were obtained from American Type
Culture Collection (ATCC, Manassas, VA). DNA oligo primers (25nmoles) were designed and
purchased from Integrated DNA Technologies (IDT, Coralville, IA). All tissue culture was
performed in a sterile, laminar-flow tissue culture hood in a designated room, separate from the
rest of the laboratory. The pZome-1C vector, containing the tandem affinity purification (TAP)
tag was obtained from Dr. Bertrand Seraphin, European Molecular Biology Lab. The pNeDaKONeo vector, housing the NeoR cassette used for selection of successfully-transfected clones was
obtained from Dr. Bert Vogelstein, Johns Hopkins University. The pMC1-Cre plasmid was
obtained from Dr. Jolene Windle, VCU, and purified by Cortney Heyer in Dr. Moran’s
laboratory. 2x iProof GC-rich Mastermix (BioRad, cat # 172-5320) was used for all endpoint
PCR, unless otherwise stated. A BioRad Peltier Thermal Cycler (DNA Engine, model PTC-200)
was used for all endpoint PCR reactions with cycling conditions described for each primer set
separately. A 10µL aliquot of the 1kb+ DNA ladder (Invitrogen, cat # 10787-018) was used to
determine the size of all electrophoresed DNA products. The Promega Wizard SV gel and PCR
clean-up kit (cat # A9282) was used to purify all PCR products excised from agarose gels; the
“DNA Purification by Centrifugation” protocol was followed as described in the manufacturer’s
instructions. Quantitect SYBR Green Mastermix (cat# 204145) was purchased from Qiagen and
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used for all qPCR analysis. BioRad DNA Engine Peltier thermal cyclers, fitted with Chromo 4
Real-Time Fluorescence Detector attachments were used for all studies involving qPCR. Realtime qPCR data was analyzed with Opticon Monitor 3 Software. All restriction endonucleases
were purchased from New England Biolabs (Ipswich, MA) unless otherwise stated. Antibodies
were purchased from Abcam (Cambridge, MA), Sigma (St. Louis, MO), Upstate Biotechnology
(Billerica, MA) and Open Biosystems (Rockford, IL), and will be discussed individually below.
Radioactivity in Southern blots and DNMT1 enzymatic assays was measured using a Beckman
Coulter LS 6500 Multi-purpose liquid scintillation counter with programs specific to each
isotope.

Methods
Cell Culture
HCT116neoS cells and HCT116-TAP cells were grown at 37°C in 5% CO2 inRPMI 1640
(Gibco/Invitrogen) medium, supplemented with 10% FBS, 100U/mL Penicillin and 100mg/mL
Streptomycin. HEK293 cells were grown at 37°C in 10% CO2 in DMEM (Gibco/Invitrogen)
medium, supplemented with 10% FBS, 100U/mL Penicillin and 100mg/mL Streptomycin. Cell
cultures were fed every other day, and stock cultures were maintained at subconfluent cell
densities.
For experimental consistency and because DNMT1 is cell-cycle regulated (78, 92), all
cells were treated the same way in the days leading up to an experiment. Cells were fed 48 hrs
prior to harvest, trypsinized and seeded 24 hrs prior to harvest to ensure that the majority of cells
were still in S-phase, and expressing the maximal level of DNMT1.
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Generation of the DNMT1-TAP-tag targeting construct
Amplification and gel purification of homology arms
Approximately 950bp of sequence homologous to coding exons 39 and 40 and intron 39
from human DNMT1 comprised the left homology arm (LHA), and approximately 900bp of
sequence homologous to the 3’ UTR (Exon 40) and the 3’ flanking sequence from the human
DNMT1 gene comprised the right homology arm (RHA). These stretches of 900-950bp matching
the endogenous C-terminus of DNMT1 provide sufficient sequence (113) to allow for
homologous recombination of the targeting vector with the genomic DNMT1 locus, thereby
inserting the TAP-tagged DNMT1 sequence into the genome.
Both the LHA and RHA were amplified against 20ng genomic DNA from HCT116 cells
using primers P1sn and P2asn for LHA or primers P3sn and P4asn for RHA (Table 3-1) in a
25µL reaction containing 12.5µL of 2x iProof GC-rich Mastermix, 0.6µM of each primer, and
3% DMSO. The PCR program consisted of initial denaturation at 94°C for 30sec, and 35 cycles
each including: denaturation at 94°C for 30sec, annealing at primer set-specific temperatures for
30sec, extension at 72°C for 1min, followed by final extension at 72°C for 5min and a hold at
4°C.
Both P1sn and P4asn primers were designed to include NotI restriction sites (Figure 3-3),
such that these sites would be located at the far 5’ and 3’ ends of the final targeting construct, for
digestion and ligation into the pAAV-MCS vector (Figure 3-1). The P2asn primer contained
24bp of sequence complementary to the TAP-tag, and 21bp of sequence complementary to the 3’
end of the LHA, excluding the endogenous “stop” codon for DNMT1. The P3sn primer
contained 23bp of sequence at the 3’ end of the NeoR cassette (labeled as Linker “B” in Figure 3-
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Table 3-1: TAP-tagging DNMT1 primers

P1sn
P2asn
P3sn
P4asn
TAPsn
TAP-LinkerA-asn
P5a
TAPrev
P6b

TAP-tagging DNMT1 Primers
5'-ATACATACGCGGCCGCCCCACGTGTCTTTGTCTCAAGTCTTTC-3'
5'-CCATCTTCTCTTTTCCATGGATCCGTCCTTAGCAGCTTCCTCCTC-3'
5'-CGCCCTATAGTGAGTCGTATTACTTCTGCCCTCCCGTCACCCCTGTTT-3'
5'-ATACATACGCGGCCGCAGGAGGCAGAGGCTGCATTGAACG-3'
5'-GGACGGATCCATGGAAAAGAGAAGATGG-3'
5'-GCTCCAGCTTTTGTTCCCTTTAGCTAATTAGCGTCTACTTTCGGCGC-3'
5'-AGCGAAACGTGTCTAGGTGGCC-3'
5'-TAGCGCTTTGGCTTGGGTCATCTT-3'
5'-TCCAGTGGCCAAAGGACACACAGAAG-3'

LHA-TAPseq
Neo sn

Sequencing
5-CGGGCGTGTTCCCCAGAGTGAC-3'
5'-TGGGCTCAGAGGCTGGGAAGGGGTG-3'

Primer Set

Forward

Reverse

SB LHA2
SB RHA2

Amplification of Southern Blot Probes
5'-CCGTATGCTGTCACAGTGCCATTT-3'
5'-GCCTATTTAGAAACGCCTTTCCTCCC-3'

5'-TTAAGCCAACCCGACACCTGAGAA-3'
5'-GATCAAGGTGCCTTGGAATCCAGAA-3'

WT
TAP
Internal DNMT1
Human β-actin

Quantitative PCR
5'-TGCTAAGGACTAGTTCTGCCC-3'
5'-TGCTAAGGACGGATCCATG-3'
5'-TCCGAGATGCCGGCGCGTACC-3'
5'-CACCACACCTTCTACAATGAG-3'

5'-CCTCACACAACAGCTTCATGTCAGC-3'
5'-TTGTTGTCCACGGCTTCATC-3'
5'-CTCTTTCCAAATCTTGAGCCGCC-3'
5'-GGTCTCAAACATGATCTGGGTC-3'

hFOS
Ex37-38

RNA Immunoprecipitation
5'-GAGAGCTGGTAGTTAGTAGCATGTTGA-3'
5'-TTCTTCAGCACAACCGTCACCAAC-3'

5'-AATTCCAATAATGAACCCAATAGATTAGTTA-3'
5'-TTGTCCAGGATGTTGCCGAAGA-3'
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3, which was required for subsequent Fusion PCR reactions) and 25bp of sequence spanning the
end of Exon 40 into the 3’ UTR for DNMT1.
PCR products for the LHA and RHA amplication reactions were electrophoresed on a 1%
TAE-EtBr agarose gel alongside the 1kb+ DNA standard ladder, and visualized by UV
transillumination. PCR products of the correct size (~950bp for LHA; ~900bp for RHA) were
excised from the gel using a sterile razor blade and purified using the Promega Wizard SV gel
and PCR clean-up kit. Purified PCR products were quantitated on the NanoDrop
spectrophotometer, and stored at -20°C.
Amplification of the TAP-tag from the pZome-1C vector
The TAP-tag is comprised of sequence encoding a Protein A domain (ProtA), linked in
tandem to sequence encoding a calmodulin binding peptide (CBP), and between them lies a
cleavage site for tobacco etch viral (TEV) protease (Figure 3-1). The TAP-tag was amplified
using 50pg of the pZome-1C plasmid with primers TAPsn and TAP-LinkerA-asn (Table 3-1) in
a 25µL reaction containing 12.5µL of 2x iProof GC-rich Mastermix, 0.6µM of each primer, and
3% DMSO. The PCR program consisted of initial denaturation at 94°C for 30sec, and 35 cycles
each including: denaturation at 94°C for 30sec, annealing at 50°C for 30sec, extension at 72°C
for 30sec, followed by final extension at 72°C for 5min and a hold at 4°C. The TAPsn primer
contained 24bp of sequence complementary to the P2asn primer, which was required for
subsequent Fusion PCR reactions. The TAP-LinkerA-asn primer contained 23bp of sequence
complementary to the 5’ end of the NeoR cassette, and 24bp of sequence complementary to the
“Linker A” region, located at the 3’ end of the TAP-tag.
PCR products for the TAP-tag amplication reactions were electrophoresed on a 1% TAEEtBr gel alongside 10µL of 1kb+ DNA standard ladder, and visualized by UV transillumination
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Figure 3-3: Fusion PCR strategy to generate the TAP-tagged DNMT1 targeting construct.
(A) Left and right homology arms (LHA and RHA, respectively) were amplified from the
genomic locus of DNMT1 using total gDNA from HCT116 cells as a template. Primers are
denoted by arrows; primer sequences can be found in Table 3-1. (b) The TAP-tag was amplified
using the pZome-1C plasmid as a template. (C) The NeoR selection cassette was excised from
the pNeDaKO-Neo vector by restriction digest with the PvuI endonuclease. (D) The LHA was
fused with the TAP-tag by PCR using the TAPsn primer, paired with the TAP-LinkA-asn primer
to generate a ~1500bp fragment representing the Fusion 1 product. (E) The final DNMT1-TAP
targeting construct was created by 3-way fusion PCR, generating a 4.5kb fragment for insertion
into the pAAV-MCS vector. A NotI restriction digest was performed to verify whether clones
contained the full insert in the correct orientation.
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(Figure 3-3). PCR products of the correct size (~550) were purified, quantitated on the
NanoDrop spectrophotometer, and digested with SacI restriction enzyme (NEB, cat # R0156S) to
verify the identity of the PCR product. SacI digestion was performed in a 25µL reaction,
containing 250ng purified TAP-tag DNA template, 20U (1µL) SacI enzyme, and 2µL 10x NEB
Buffer 1. Digest products were electophoresed on a 1% TAE-EtBr agarose gel alongside the
1kb+ DNA ladder and visualized by UV transillumination. Two bands of the expected sizes were
observed, indicating that we had purified the correct TAP-tag PCR product.
Restriction digest to excise the NeoR cassette from the pNeDaKO-Neo vector
The pNeDaKO-Neo vector was digested with PvuI restriction endonuclease (NEB, cat #
R0150S) in a 20µL reaction containing the following: 6.5µg pNeDaKO-Neo plasmid, 10U (1µL)
PvuI enzyme, 2µL 10x NEB Buffer 3, 0.2µL 10x BSA. The reaction was incubated at 37°C for
1hr. Digestion products were electrophoresed on a 1% TAE-EtBr agarose gel alongside the 1kb+
DNA standard ladder, and visualized by UV transillumination. The expected 3kb band was
purified.
Fusion1 PCR to link the LHA with the TAP-tag
Equimolar amounts of the purified LHA and TAP-tag templates were combined in a
25µL reaction containing 12.5µL 2x iProof GC-rich Mastermix, 0.6µM P1sn primer, and 0.6µM
TAP-LinkA-asn primer. The PCR cycling program consisted of initial denaturation at 94°C for
30sec, followed by 35 cycles of the following: denaturation at 94°C for 30sec, annealing at 58°C
for 30sec, and extension at 72°C for 1min, followed by final extension at 72°C for 5min, and a
hold at 4°C. PCR products were electrophoresed on a 1% TAE-EtBr agarose gel alongside the
1kb+ DNA standard ladder , and visualized by UV transillumination. Faint bands of the expected
size of 1500bp (950bp LHA + 550bp TAP) were observed in both lanes (Figure 3-3D).
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Adenylation of the LHA-TAP Fusion 1 PCR product was achieved by combining a
maximal volume of the PCR product with 1U (0.2µL) Taq Polymerase and 1µL dATP in a 25µL
reaction, and incubating at 72°C for 15min. Adenylated products were electrophoresed on a 1%
TAE-EtBr agarose gel alongside the 1kb+ DNA standard ladder and visualized by UV
transillumination. The LHA-TAP Fusion PCR product + A’s migrated at the expected size of
1500bp, thus bands of the appropriate size were excised from the gel and purified using the
Promega Wizard SV gel and PCR clean-up kit.
3-way Fusion PCR to create the final targeting construct
A total of 350ng of the purified LHA-TAP Fusion 1 PCR product, 350ng of the purified
RHA PCR product, and 400ng of the purified NeoR cassette, representing the three DNA
templates to be fused in this PCR reaction (Figure 3-3E), were combined into a 400µL
mastermix, containing the following: 200µL of 2x iProof GC-rich Mastermix, 0.6µM P1sn
primer, and 0.6µM P4asn. The large 400µL reaction was mixed thoroughly by vortexing and
quickspun to collect all contents at the bottom of the tube, before aliquoting 50µL into the eight
individual 0.2mL wells of a TempAssure 8-tube PCR strip (USA Scientific, cat # 1402-2700).
The PCR cycling program consisted of initial denaturation at 94°C for 2min, followed by 20
cycles, each including: denaturation at 94°C for 30sec, annealing at 56°C for 30sec, extension at
68°C for 4min, followed by final extension at 68°C for 5min and a hold at 4°C.
NotI digestion of 3-way Fusion PCR product and pAAV-MCS vector
The eight PCR tubes containing 3-way fusion products were pooled into four 1.5mL
microcentrifuge tubes (each containing 100µL) for enzymatic digestion with NotI restriction
endonuclease. For each of four reactions, the following was combined in a 200µL reaction:
100µL 3-way Fusion PCR products, 60U (1.2µL) NotI restriction enzyme, 20µL 10x NEB
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Buffer 3, and 8µL 10x BSA. The reactions were pulse-vortexed to mix and quick-spun to ensure
all contents were at the bottom of the tubes, before incubating at 37°C for 3hrs. All four digested
samples were pooled into two 1.5mL microcentrifuge tubes for Phenol/Chloroform extraction
and EtOH precipitation, performed as described in Chapter 2 for MeDIP. Each DNA pellet was
resuspended in 20µL of TE, and mixed thoroughly to ensure the DNA pellet was fully
solubilized. All 40µL of precipitated DNA was loaded onto a 0.8% TAE-EtBr agarose gel,
electrophoresed and visualized by UV transillumination. Bands of the expected size (~4.5kb)
appeared in both sample lanes (Figure 3-3), and were excised and purified. Purified DNA
products were quantitated on a NanoDrop spectrophotometer, and stored at -20°C.
To linearize the pAAV-MCS plasmid and prepare it for insertion of the TAP-tagged
DNMT1 construct, 2µg of the circular pAAV-MCS plasmid was combined with 75U (1.5µL)
NotI restriction endonuclease (NEB, cat # R0189M), 2µL 10x NEB Buffer 3, and 0.2µL BSA in
a 20µL reaction. The reaction was incubated at 37°C for 2hrs, before 20U (2µL) of calf intestinal
phosphatase was added, and incubated for an additional 15min to dephosphorylate the vector.
Restriction digest products were electrophoresed on a 1% TAE-EtBr agarose gel alongside the
1kb+ DNA ladder, and visualized by UV transillumination. A band of the expected 3kb size was
observed, excised from the gel, and purified using the Promega Wizard SV kit according to
manufacturer’s instructions.
Cloning of the DNMT1-TAP targeting construct into pAAV-MCS
To ligate the purified, NotI-digested 3-way Fusion PCR product into the NotI-digested
pAAV-MCS vector for cloning, the following was combined in a 20µL ligation reaction: 70ng
(12.5µL) of NotI-digested 3-way Fusion PCR product, 11ng (0.5µL) of the linearized pAAVMCS plasmid, 2µL of 10x T4 DNA Ligase Buffer and 1µL of T4 DNA Ligase (Invitrogen, cat #
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15224-017). A no-insert negative control ligation reaction was also set up using 12.5µL of H2O
instead of insert. Both reactions were pulse-vortexed to mix, and quickspun to collect all contents
at the bottom of the tube. Ligation reactions were incubated at room temperature for 30min, then
placed on ice for 5min. Half of each ligation reaction (10µL) was used in a transformation
reaction, the other half (10µL) was stored at 4°C as a back-up.
Transformation of the ligated pAAV-MCS-DNMT1-TAP vector was achieved using
OneShot TOP10 Chemically-competent E.coli cells (Invitrogen, cat # C404010). Two vials of
TOP10 cells were removed from storage at -80°C and thawed on ice. SOC Medium, supplied
with the TOPO TA cloning kit (Invitrogen, cat # K4500-01) was removed from storage at -20°C
and warmed in a water bath set to 42°C until use. The pUC19 positive control plasmid for
transformation was also removed from storage at -20°C and thawed on ice. 10µL of the pAAVMCS-DNMT1-TAP ligation reaction was added to 1 vial (~50µL) of TOP10 cells, and the tube
was tapped gently to mix its contents. To half of the other vial of TOP10 cells, 10µL of the noinsert negative control ligation reaction was added, and the tube was tapped gently to mix.
Lastly, to the remaining half vial of TOP10 cells, 1µL of the pUC19 positive control vector was
added, and the tube was tapped gently to mix. All transformation reactions were incubated on ice
for 30min, then heat-shocked for 45sec in a 42°C water bath. The transformations were placed
on ice for 2-5min, and then 250µL of pre-warmed SOC Medium was added directly to each vial.
The vials were placed in a heated horizontal shaker, shaking at 225rpm at 37°C for 1hr.
To prepare LB agarose plates for plating the transformation reactions, LB agarose (10g
Bacto-tryptone, 5g yeast extract, 10g NaCl, and 15g agar in 1L ddH2O) was melted and allowed
to cool almost to room temperature. To 48mL of LB agar, 40µg/mL of Zeomycin and 60µg/mL
of Carbenicillin was added and swirled to mix. Approximately 12mL of LB agar plus Zeomycin
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(Zeo) and Carbenicillin (Carb) selection agents was poured into each bacterial petri dish and
allowed to solidify. 125µL of each tranformation reaction was added dropwise to each Carb-Zeo
plate, and spread with a sterile glass rod until fully absorbed by the agar. Inoculated plates were
incubated at 37°C in bacterial incubator overnight. 10 colonies were picked from each ligation
plate (20 colonies total) for further analysis. Liquid cultures of each colony were made by
inoculating 5mL of LB + Carb + Zeo liquid broth. Cultures were placed in 14mL round bottom
conical tubes (BD Falcon, cat # 352059) with the caps loose to allow sufficient oxygen
exchange, and incubated in a heated horizontal shaker at 37°C, shaking at 225rpm overnight.
Purification and verification of DNA from pAAV-MCS-DNMT1-TAP clones
DNA was purified from liquid cultures of pAAV-MCS-DNMT1-TAP transformed
colonies using the Promega Wizard Plus SV Miniprep DNA Purification System (cat # A1460)
following the centrifugation protocol according to manufacturer’s instructions. Two elution
steps, 50µL each, were used to collect the purified DNA from the spin columns. Samples were
quantitated on the NanoDrop spectrophotometer, and stored at -20°C until further analysis.
DNA samples were thawed, pulse-vortexed to mix, and quickspun to collect all contents
at the bottom of each tube. A restriction digestion with NotI endonuclease was set up to verify
the identity of each DNA sample. For each 20µL digest, the following was combined: 250ng of
Miniprepped DNA product, 15U (0.3µL) of NotI enzyme, 2µL of 10x NEB Buffer 3, and 0.2µL
of 10x BSA. Tubes were tapped and quickspun to be sure that all reaction contents were wellmixed and at the bottom of each tube, and reactions were incubated at 37°C for ~2.5hrs.
Digested products were electrophoresed on a 0.8% TAE-EtBr agarose gel and visualized by UV
transillumination (Figure 3-3E). Two of the 20 colonies were shown to contain the expected
restriction digest products: a 4.5kb band, representing the excised DNMT1-TAP insert, and a 3kb
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band, which represents the linearized pAAV-MCS vector. A third colony was questionable, as it
produced bands of 3kb and 4kb; the latter product was slightly smaller than expected for the full
insert. A second restriction digest was performed to ensure that the clones contained the right
sequence. FspI restriction endonuclease (NEB, cat # R0135S) was chosen for this second digest.
FspI cut three times within the pAAV-MCS-DNMT1-TAP targeting vector sequence: once
within the vector, once within the TAP-tag sequence, and once within the NeoR cassette,
generating three separate fragments. Minprepped DNA (250ng) from the three colonies of
interest were added to 20µL digestion reactions, combined with 1.5U (0.3µL) FspI enzyme, and
2µL of 10x NEB Buffer 4. Tubes were tapped and quickspun to be sure that all reaction contents
were well-mixed and at the bottom of each tube, and reactions were incubated at 37°C for
~1.5hrs. Digested products were electrophoresed on a 0.8% TAE-EtBr agarose gel and
visualized by UV transillumination. Two of the three clones (1b and 2c) produced bands of the
expected sizes: 1.1kb, 2.5kb and 3.5kb, indicating that they did indeed contain the correct
targeting construct (Figure 3-3). DNA from these two samples was prepared for sequencing by
the VCU Nucleic Acids Research Facility, according to their specifications.

Construction of a positive control plasmid for screening recombinant DNMT1-TAP clones
by PCR
In order to screen the resultant HCT116 TAP-tagged DNMT1 clones for proper
integration of the targeting construct, we first needed to create a positive control plasmid
containing the endogenous DNMT1 sequence extending outside of the insertion site, fused to one
of the artificial knock-in elements (i.e. the TAP-tag). This would allow us to PCR amplify and
sequence across the sites of integration of the DNMT1-TAP targeting construct to directionally
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verify its proper insertion into the genomic locus of DNMT1 in each of our G418-resistant
clones.
The genomic sequence for DNMT1 surrounding the insertion site of the DNMT1-TAP
targeting construct, from Exon 38 through the 3’UTR, was analyzed by Repeat Masker
(www.repeatmasker.org) to highlight stretches of sequence that were unique to human DNMT1,
so that stretches of highly repetitive sequence could be avoided during primer design. Using this
information, new primers were designed to fall only within the regions specific to DNMT1. The
P5a primer (Table 3-1) was designed against sequence located >100bp upstream of the LHA. A
series of enrichment PCR reactions were run such that the product purified from one PCR
reaction was used as the template in the next PCR reaction, all using the same set of primers (P5a
and P2asn). An aliquot (100µL) of an enrichment PCR reaction, containing: 50µL of 2x iProof
GC-rich mastermix, 0.6µM primer P5a, 0.6µM primer P2asn, and 30ng (10µL) purified
Extended LHA PCR product, was assembled, mixed thoroughly and divided into four 25µL
reactions. The PCR cycling program consisted of initial denaturation at 94°C for 2min, followed
by 35 cycles, each including: denaturation at 94°C for 30sec, annealing at 56-59°C for 30sec,
extension at 72°C for 1min, followed by final extension at 72°C for 5min and a hold at 4°C. PCR
products were resolved by gel electrophoresis on a 1% TAE-EtBr agarose gel, and visualized by
UV transillumination. All four sample lanes showed bright bands at the expected 1.2kb size,
representing the ExtLHA positive control products. These bands were excised from the gel using
a clean razor blade, purified using the QIAquick Gel Extraction kit (Qiagen, cat # 28706) and
quantitated on the NanoDrop spectrophotometer.
This new ExtLHA product next needed to be fused with the TAP-tag, exactly as before
for the LHA-TAP Fusion 1 PCR reaction. Equimolar amounts of the ExtLHA template and the
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purified TAP-tag template, were combined in a 100µL PCR reaction, containing 50µL of 2x
iProof GC-rich mastermix, 0.6µM P5a primer, and 0.6µM TAP-LinkA-asn primer. These
reagents were mixed well and aliquoted into four separate PCR tubes. The PCR cycling
conditions consisted of initial denaturation at 94°C for 2min, followed by 35 cycles, each
including: denaturation at 94°C for 30sec, annealing at 56-59°C for 30sec, extension at 72°C for
1min, followed by final extension at 72°C for 5min and a hold at 4°C. PCR products were
resolved by electrophoresis on a 1% TAE-EtBr agarose gel and visualized by UV
transillumination. All four samples lanes showed bright bands of the expected 1.75kb size. These
fragments were excised from the gel and purified using the QIAquick Gel Extraction kit
(Qiagen).
Because the iProof GC-rich enzyme (BioRad) generates blunt-ended PCR products, the
purified 1.75kb ExtLHA-TAP fragment was adenylated at both ends by combining the following
into a 25µL reaction: 20.55µL purified ExtLHA-TAP PCR product, 1U (0.2µL) Taq polymerase
(Invitrogen, cat # 10342-053), 200nM dATP, 5µL of 10x PCR Buffer, and 1.5mM MgCl2. The
reaction was incubated at 72°C for 15min, then put into a ligation reaction for cloning using the
TOPO TA Cloning Kit for Sequencing (Invitrogen, cat # K4575-01), according to the
manufacturer’s instructions. Ligation, transformation and cloning of the positive control
ExtLHA-TAP fusion insert was performed as described previously for the pAAV-MCSDNMT1-TAP targeting vector. DNA was purified from 10 colonies surviving Carb selection and
verified by restriction digest using PstI enzyme (NEB, cat # R0140S), in a 20µL digestion
reaction containing: 2.0µL of 10x NEB Buffer 3, 2.0µ 10X BSA, ~300ng (2.0µL) purified
ExtLHA-TAP positive control plasmid DNA, 20U (1.0µL) PstI enzyme. The reaction was pulsevortexed to mix well and quick-spun to collect all contents at the bottom of the tube before

113

incubating at 37°C for 1hr. Digested products were electrophoresed on a 1% TAE-EtBr agarose
gel and visualized by UV transillumination. For all 10 colonies, bands were observed at sizes
suggesting that the insert is backwards in its orientation. While this does not matter for screening
purposes, because the primers used for PCR screening will recognize the insert regardless of its
orientation, this detail will need to be kept in mind for future experiments, or when considering
other possible uses for this positive control plasmid.

Packaging of the pAAV-MCS-DNMT1-TAP viral vector in HEK293 cells
Because the pAAV-MCS vector containing the DNMT1-TAP targeting construct lacks
the cis-acting elements required for replication and packaging of the adeno-associated virus, cotransfection with the pAAV-RC and pHelper plasmids (Strategene AAV Helper-Free System)
provided these elements in trans (Figure 3-1B). The Lipofectamine 2000 reagent (Invitrogen, cat
# 11668-027) was used to supply the AAV plasmids to human embryonic kidney (HEK293) cells
(ATCC) for packaging of the virus. Two separate transfection reactions were prepared under a
sterile, laminar-flow tissue culture hood: one each for clone 1b and 2c, which contain verified
pAAV-MCS-DNMT1-TAP constructs. In each transfection reaction, 2.5µg of purified DNA
from one of the verified pAAV-MCS clones was combined with 2.5µg of pAAV-RC and 2.5µg
of pHelper plasmids. These DNA mixtures were dissolved in 1x Opti-MEM (Invitrogen/Gibco,
cat # 31985-070) to a final volume of 750µL. In two separate tubes, 54µL of Lipofectamine 2000
was dissolved into 696µL of 1x Opti-MEM, to a total volume of 750µL, and allowed to incubate
at room temperature under the hood for 5min. After the 5min incubation, the diluted DNA was
combined with the diluted Lipofectamine in a sterile 1.5mL microcentrifuge tube, and incubated
at room temperature under the hood for 15min. This incubation period is critical for the
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formation of cationic lipid complexes with the viral DNA, for more efficient delivery and
expression in the packaging cells.
Two T-75 flasks of HEK293 cells, grown to 50-60% confluence, were prepared for
transfection by aspirating-off all old media and washing once with 10mL Hank’s Balanced Salt
Solution (HBSS) (Invitrogen/Gibco, cat # 14170-112). 10mL of fresh media was replaced, and
the DNA-Lipofectamine mixtures were added to the cell medium dropwise, swirling the flask to
mix. The cells were incubated at 37°C with 10% CO2 for 3-4hrs. After the incubation period, the
media-DNA-Lipofectamine solution was aspirated-off by vacuum, and 10mL of fresh
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS and 1%
Penicillin/Streptomycin (PenStrep) was added. Transfected HEK293 cells were incubated at
37°C with 10% CO2 for 48hrs to allow packaging of the virus.
After 48hrs, the virus was harvested. Media was aspirated-off, and cells were rinsed once
with 1x Phosphate Buffered Saline (PBS), pH 7.4 (Invitrogen/Gibco, cat # 10010-049). The
AAV-transfected HEK293 cells were scraped to detach them from the bottom of the tissue
culture flask, using a sterile cell scraper (Greiner BioOne, cat # 541070), dipped first into 1x
PBS, pH 7.4. The scraped cells were collected and transferred into a 14mL round-bottom conical
tube (BD Falcon, cat # 35029) already containing 1mL of 1x PBS, pH 7.4. The flask was rinsed
once with 1mL of 1x PBS, pH 7.4, and this wash was collected and transferred to the same
conical tube. Three cycles of freeze-thaw were performed to lyse the cells: 10min in a dry ice70% ethanol bath, followed by 10min in a 37°C water bath. Tubes were tapped to mix their
contents after each thaw cycle. After lysis, the lysate was transferred to 2mL microcentrifuge
tubes for clarifying. Lysates were clarified by spinning at 12,000rpm in a tabletop microfuge for
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10min at 4°C. The supernatant was removed and aliquoted into five pre-labeled 1.5mL
microcentrifuge tubes (330µL each), and aliquots were stored at -80°C.

Gene targeting in HCT116 parental cells
Generation of the HCT116-TAP cell line was achieved as depicted in Figure 3-4. Two T75 flasks containing G418-sensitive wild-type HCT116 cells, grown to 60-80% confluence in
RPMI 1640 supplemented with 10% FBS, 100U/mL Penicillin and 100mg/mL Streptomycin,
were used for gene targeting. Medium was aspirated and cells were washed once with 10mL
HBSS, and 4mL of pre-warmed growth medium was added to the flask. One aliquot (330µL) of
thawed viral lysate from either verified clone (1b or 2c) was added dropwise to the cell medium
in each of two T-75 flasks, swirling the flasks to mix. The virus was allowed to infect cells for 23hrs at 37°C, 5% CO2. After transduction, 8mL of pre-warmed growth medium was added to
each flask, and cells were incubated at 37°C, 5% CO2, for 48hrs before selection.

Selection, screening and verification of original HCT116-TAP cell lines
Plating and selection of recombinants by G418 resistance
Virus-infected HCT116 cells were harvested from both T-75 flasks by trypsinization, and
the cell pellets were resuspended in 5mL of fresh growth media. 202mL of selection medium
consisting of RPMI 1640, supplemented with 10% FBS, 100U/mL Penicillin, 100mg/mL
Streptomycin and a final concentration of 400µg/mL of G418/Geneticin (Gibco/Invitrogen, cat #
11811-031) was prepared and 5mL of resuspended cells was added. Using a multi-channel
pipettor fitted with a 300µL head, approximately 200µL of targeted cells in selection medium
were seeded into ten 96-well plates (BD Falcon, cat # 353916). Remaining cells (~5mL) were
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Figure 3-4: Generation of the HCT116 TAP-tagged DNMT1 cell line. The final DNMT1TAP targeting vector was inserted into the DNMT genomic locus by homologous recombination.
Neo-sensitive HCT116 parental cells were used for targeting. The original hDNMT1-TAP cell
lines were selected by Neo-resistance and screened by PCR to verify proper integration of the
TAP-tag. Positive recombinants were transfected with Cre-recombinase to excise the the loxPfloxed NeoR cassette, resulting in the final HCT116-TAP Cre cell lines.
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added to a T-25 flask, to be maintained as a back-up culture. The 96-well plates were stacked
and incubated at 37°C in 5% CO2 for approximately two weeks.
After two weeks of incubation time, the targeted HCT116-TAP cells were screened for
growth of positively-recombined colonies. The stacks of 96-well plates were removed from the
incubator and left to sit at room temperature for approximately 30min to allow the media to
change color. Yellowing of the growth medium in wells containing growing colonies was an
easy way to identify which wells were to be marked for further analysis. After approximately
30min, the plates were held up to the light and all wells with an obvious color change were
marked with a “/” to indicate apparent growth in that well. Old growth medium was aspirated off
from all wells, and 100µL of 1x Trypsin-EDTA was added to each marked well only. Once
trypsin had been added to all appropriate wells, the lid of the plate was replaced, and the plate
was shaken by hand gently to aid detachment of the cells from the plate. Using a multi-channel
pipettor, 150µL of fresh RPMI 1640 growth medium, supplemented with 10% FBS, 100U/mL
Penicillin, 100mg/mL Streptomycin and 400µg/mL G418 was added to each well of two new 96well plates. These plates were labeled and set-up identically, such that each well on one plate
corresponded to a well in the same position on the other plate. An aliquot (50µL) of each
trypsinized clone was transferred into the same corresponding wells on two identical 96-well
plates. One plate was labeled to be harvested for purification of gDNA, the other plate was
labeled to be frozen as a back-up.
PCR screening to verify correct integration of the TAP-tag
To one set of duplicate 96-well plates, 50µL of freezing medium (FBS and 10% dimethyl
sulfoxide (DMSO)) was added to each well. Plates were sealed individually with parafilm
(Thomas Scientific, cat # 7315D45) to prevent evaporation, and stored at -80°C as a back-up.
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The other set of duplicate 96-well plates was emptied of all growth medium, wrapped in
parafilm and frozen at -80°C for storage until DNA purification. Total genomic DNA (gDNA)
was isolated from 24 of the positively-recombined, G418-resistant HCT116-TAP clones from
only one plate first, using the Gentra Puregene Cell kit (Qiagen, cat # 158388). The
recommended protocol for DNA purification from cultured cells was followed as described in
the manufacturer’s instructions, however, because the number of cells plated in the 96-well
format is so low, the volumes used for each reagent were scaled-down proportionately. DNA
purification was performed using the following volumes: 60µL of Cell Lysis Solution, 2µg of
RNase A, 20µL of Protein Precipitation Solution, 60µL of Isopropanol, 60µL of 70% ethanol,
and 10µL DNA Hydration Solution. DNA dissolved in DNA Hydration Solution was incubated
at room temperature with gentle end-over-end rotation overnight. After solubilizing overnight,
sample tubes were quickspun to collect all contents at the bottom of each tube, and quantitated
on the NanoDrop spectrophotometer. The amount of DNA recovered was below the limit of
detection for the NanoDrop spectrophotometer. Nonetheless, we performed a “practice PCR
screen” using the DNA purified from four individual G418-resistant clones (A1, A2, B1, and B2)
and the P1sn-P2asn primer set, which consistently gave robust PCR products under its optimal
conditions. Both a no-template negative control and a positive control reaction using HCT116
gDNA were included. The amplification products from this “practice PCR” were resolved on a
1% TAE-EtBr agarose gel, and showed bands of the expected 950bp size in all sample lanes,
except the negative control. Thus, although we could not get an accurate quantitation of the
amount of DNA purified from the 96-well plate, the results of this practice run gave us
confidence that we had enough to proceed with screening by PCR, and that the purified DNA
was of sufficient quality to yield robust PCR products.
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For each row of positive recombinant DNMT1-TAP clones (A1-12, and B1-12), a large
PCR mastermix in a total volume of 300µL was prepared by combining 150µL 2x iProof GCrich mastermix, 0.6µM primer P5a, 0.6µM primer TAPrev (Figure 3-5 and Table 3-1) and 2µL
template DNA from each DNMT1-TAP clone. The tubes of PCR mastermix were pulse-vortexed
and quickspun to ensure all contents were mixed thoroughly and collected at the bottom of the
tubes. 24µL of PCR mastermix was aliquoted into each of 12 wells contained on 0.2mL clear 8tube PCR strips. 2.0µL of DNA purified from each positive recombinant DNMT1-TAP clone
was added individually to each of the 12 wells, and the complete reaction was stirred gently with
the pipet tip to mix. The PCR cycling program consisted of initial denaturation at 94°C for 2min,
followed by 35 cycles, each including: denaturation at 94°C for 30sec, annealing at 59°C for
30sec, extension at 72°C for 1min, followed by final extension at 72°C for 5min and a hold at
4°C. PCR products were resolved by gel electrophoresis on a 1% TAE-EtBr agarose gel, and
visualized by UV transillumination (Figure 3-6A and 3-B LHA).

Cre recombinase-mediated excision of NeoR cassette
The pMC1-Cre recombinase plasmid (obtained from Dr. Jolene Windle, VCU) was used
to excise the bulky NeoR cassette from the targeted DNMT1-TAP allele. Adapting protocols
from both Cortney Heyer in Dr. Moran’s laboratory, and the manufacturer’s instructions for the
Lipofectamine 2000 reagent, we developed a transfection protocol that worked best for our
purpose. Briefly, we used a 6-well plate format, with 2mL total plating volume, and transfected
4.0µg of the pMC1-Cre plasmid using 10µL of Lipofectamine reagent.
The morning of transfection, the growth medium on cells to be transfected was changed
to fresh RPMI 1640, supplemented with 10% FBS only (in the absence of PenStrep, and
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Figure 3-5: PCR screening and RT-qPCR strategies. (A) A sense primer placed across the
LHA-TAP fusion junction and an antisense primer placed within the TAP-tag were used to
screen G418-resistant clones for proper insertion of the TAP tag into the genomic DNMT1 locus.
(B) Abundance of the WT DNMT1 allele was measured using a sense primer crossing the native
termination codon for DNMT1, and an antisense primer within the 3’UTR of Exon 40.
Abundance of the DNMT1-TAP allele was measured with the TAPsn primer, paired with an
antisense primer placed within the TAP-tag.
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Figure 3-6: Screening of clones by PCR identifies positive recombinants. (A) Neo-resistant
clones were screened first by PCR to verify proper integration of the TAP-tag. Clones A4, B3
and B7 all showed a positive result. These original clones were transfected with Cre recombinase
and subcloned to ensure that all subsequent analysis was performed on homogeneous cell lines.
(B) Cre Subclones and their parental lines were again screened by PCR, this time with primers
directed against both the LHA and the RHA. Two TAP Cre subclones (CreA42 and CreB33)
screened correctly from both sides of the insertion site. The Orig B7 clone turned out to be a
mixed population of cells, and was subsequently discarded from further analysis.
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400µg/mL G418). The cells were allowed to incubate in this medium for approximately 3hrs
prior to transfection. Under the tissue culture hood, two sterile 1.5mL microcentrifuge tubes
were labeled for each clone to be transfected. One tube was prepared with 4.0µg of the purified
pMC1-Cre DNA, and brought to a total volume of 250µL with OptiMEM solution. The other
tube was prepared by adding 10µL Lipofectamine and 240µL OptiMEM, for a 250µL total
volume. The mixtures in each tube were allowed to incubate separately at room temperature
under the hood for 5min before combining tubes, to a total of 500µL transfection reaction per
clone. The DNA-Lipofectamine mixtures were incubated together for 20min at room temperature
under the tissue culture hood. After 20min, the entire 500µL transfection reaction was added
dropwise to each well of a 6-well plate, the lid on the plate was replaced, and the plate was
swirled gently to mix. Transfected cells were incubated at 37°C overnight before subcloning.

Selection, screening and verification of final HCT116-TAP Cre cell lines
Subcloning of HCT116-TAP Cre clones
Subcloning of positively-recombined cells was performed to ensure that all final cell lines
were true homogeneous clones, resulting from only a single progenitor cell, and representing
only a single recombination event. Clones arising from mixed populations of cells – some
correctly-targeted, some random integrants – would complicate our downstream analyses. Dr.
Taylor assisted with the development of this subcloning strategy, to increase the ease of
screening for single progenitor cells and to save time.
Cre-transfected HCT116-TAP (HCT116-TAPCre) cells were harvested by trypsinization,
and pelleted by centrifugation. Under the tissue culture hood, a 20µL drop of fresh RPMI 1640
growth medium supplemented with 10% FBS was added to each well of two destination 24-well
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tissue culture plates. An estimated cell number for the plated HCT116-TAPCre cells was used to
calculate the series of dilutions necessary to achieve a seeding density of 0.25cells/well for each
clone. Serial dilutions were performed in sterile 50mL or 15mL conical tubes using fresh RPMI
1640 growth medium, each time, pipetting up and down several times to achieve a single cell
suspension and to mix thoroughly. The appropriate volume of cell resuspension calculated for
each clone was then added to the drop of medium already in each well of the two 24-well plates.
The lids were replaced on all plates, and plates were incubated at 37°C for approximately 2hrs, to
allow the seeded cells to adhere to the plate. After 2hrs, the plates were examined under a light
microscope for the presence of only one cell per well. Wells containing what appeared to be only
one cell were marked, and an additional 0.5mL of RPMI 1640 growth medium supplemented
with 10% FBS was added to the marked wells. These colonies were screened again by light
microscopy after 24 and 48hrs, looking for colonies no bigger than the expected size for cells
with a doubling time of approximately 24hrs. Subcloned colonies were propagated by feeding
0.5mL fresh growth medium once per week until they contained enough cells to be split between
duplicate plates for selection.
Once the DNMT1-TAP Cre subclones had achieved a colony size of ~100,000 cells, or
approximately 50% confluency, they were harvested by trypsinization and transferred to
corresponding wells on two duplicate 24-well plates. Cells were allowed to incubate for 24hrs in
normal RPMI 1640 growth medium supplemented with 10% FBS before 400µg/mL G418
selection medium was added to one of the duplicate 24-well plates, as described previously. This
time, however, we were looking for cells that had become sensitive to G418 selection, as this
indicates the proper excision of the NeoR cassette. After 10 days under selection, the G418treated plates were removed from the incubator and allowed to sit at room temperature for
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approximately 30min. Media is wells containing growing cells remained yellow, while those
without growth (neoS) remained a richer red color. The sensitivity to G418 selection was
confirmed for each marked well by light microscopy. Corresponding wells on the G418-negative
plate were then marked, and these clones were seeded into larger T-25 flasks and propagated for
further characterization.
PCR screening for correct excision of NeoR cassette
To verify proper integration of the RHA into the DNMT1 genomic locus, and to verify
excision of the NeoR cassette after transfection with Cre recombinase, a PCR screen was again
employed (Figure 3-5A). This time, a forward primer placed within the TAP-tag (TAPsn, Table
3-1) was paired with an antisense primer located ~100bp downstream of the RHA (primer P6b).
Total gDNA from non-tagged HCT116neoS cells and each TAP clone of interest (both original
cell lines with the NeoR cassette and Cre subclones without the NeoR cassette) was isolated using
the Qiagen DNeasy kit, according to manufacturer’s instructions. 50ng of gDNA from each cell
line was added to a 25µL PCR reaction, containing 22µL of Platinum PCR SuperMix High
Fidelity (Invitrogen, cat # 12532-016), 0.6µM of primer TAPsn, and 0.6µM of primer P6b. PCR
cycling conditions consisted of initial denaturation at 94°C for 2min, followed by 35 cycles, each
including: denaturation at 94°C for 30sec, annealing at 60°C for 30sec, extension at 68°C for
4min, followed by final extension at 68°C for 10min and a hold at 4°C. PCR products were
resolved by gel electrophoresis on a 1% TAE-EtBr agarose gel, and visualized by UV
transillumination (Figure 3-6B RHA).
Southern Blot
DNA probes were designed against all four regions critical to the TAP-tagged DNMT1
cell line: the LHA, the TAP-tag, the NeoR cassette, and the RHA. LHA, TAP and RHA probes
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were amplified by PCR using primers as described in Table 3-1 (SB LHAsn2-SB LHAasn2,
qPCR TAPsn- qPCR TAPasn, SB RHAsn2-SB RHAasn2). PCR products from each
amplification reaction were resolved on 1% TAE-EtBr agarose gels, and visualized by UV
transillumination. Bands representing PCR products of the expected size for each probe were
excised with a clean razor blade and purified using the Qiagen QIAquick Gel Extraction kit,
according to manufacturer’s instructions. The concentrations for purified DNA probes were
determined using the NanoDrop spectrophotometer. An aliquot of the NeoR cassette, excised
from the pNeDaKO-Neo vector and purified for use in fusion PCR reactions to create the
DNMT1-TAP targeting vector, was used as the Neo probe.
Total gDNA was prepared from non-tagged HCT116neoS cells, as well as each DNMT1TAP clone of interest using the Qiagen DNEasy Blood and Tissue kit (cat # 69506) according to
manufacturer’s instructions. The optional RNaseA treatment was performed, as recommended
for RNA-free DNA preparations. Approximately 1µg of purified gDNA was resolved on a 1%
TAE-EtBr agarose gel, and visualized by UV transillumination, next to both the 1kb+ DNA
ladder, and λ-HindIII fragments. This visual check ensured that the gDNA had no visual
degradation, and was of sufficient quality to be used as input for the Southern Blot digests. Once
the quality of the purified gDNA was confirmed, 25µg of gDNA from each of the 21 clones of
interest was digested with 25U BamHI restriction endonuclease (NEB, cat # R0136L) in 1x NEB
Buffer #3 with 100µg/mL BSA. Tubes were pulse-vortexed and quickspun to ensure that all
reaction contents were well-mixed and collected at the bottom of the tube. Each enzyme reaction
was incubated at 37°C for approximately 1.5hrs, an additional 60U (3.0µL) of BamHI enzyme
was added and incubations continued at 37°C overnight, to ensure complete digestion.
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Approximately 1µg (8µL) of each digest was resolved on a 0.8% TAE-EtBr agarose gel,
and visualized by UV transillumination, alongside the 1kb+ DNA ladder, λ-HindIII fragments,
and 1µg of uncut gDNA to verify digestion. Although BamHI is not a frequent cutter of total
gDNA, a substantial difference was observed in the smearing pattern of cut versus uncut DNA,
giving us confidence that the digestion was sufficient to proceed. The remaining BamHI-digested
gDNA samples for each clone were extracted with Phenol/Chloroform, precipitated and DNA
pellets were resuspended in 20µL of 10x NEB Buffer 4, in preparation for the second restriction
digest with PpuMI restriction endonuclease (NEB, cat # R0506L). The remaining 24µg of gDNA
from each DNMT1-TAP Cre clone was digested with 25U (5.0µL) PpuMI enzyme in a total
volume of 200µL. Reactions were incubated at 37°C for approximately 2hrs, an additional 15U
(3.0µL) PpuMI enzyme was added and incubation was continued at 37°C overnight, to drive the
reaction to completion.
Digestion was verified by resolving 1µg (8µL) of each digest on a 0.8% TAE-EtBr
agarose gel, and visualizing by UV transillumination, alongside the 1kb+ DNA ladder, λ-HindIII
fragments, and 1µg of uncut gDNA. This digest also looks as expected, with DNA smearing
evident the full length of each lane, with an equal intensity of DNA staining per lane, suggesting
that the DNA has been fully digested, and that an equal amount of DNA was recovered from
each sample after the first phenol/chloroform extraction. BamHI/PpuMI-digested gDNA samples
for each clone were subjected to Phenol/Chloroform extraction and precipitation as previously
described. DNA pellets were resuspended in 40µL TE buffer.
BamHI/PpuMI DNA fragments were resolved on a 0.8% TBE-EtBr agarose gel,
interspersed with lanes loaded with the1kb+ DNA ladder. The gel was electrophoresed at 40V
for 14.5hrs, and visualized by UV transillumination to ensure that sufficient resolution was
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achieved. The positions of each of the 1kb+ DNA ladder fragments were marked on the gel using
a 21G needle and India Ink, while holding the gel over a UV light box.
The transfer sandwich was assembled by placing the gel in the bottom of an 8x8” square
glass dish, and trimming the edges to remove the meniscus. Trimming the edges ensures that full
contact is achieved between the gel and the BioTrans(+) nylon transfer membrane (MP, cat #
810205), however, the wells were left intact to mark their position on the membrane after
transfer. The gel was covered with approximately 100mL of 0.25N HCl, and the dish was rocked
at room temperature for 20min to fully depurinate the DNA contained within the gel. The gel
was rinsed once with Milli-Q distilled H2O, and incubated twice with denaturing solution (1.5M
NaCl, 0.5M NaOH) and neutralization solution (1.5M NaCl, 1M Tris, pH 7.4) for 20min, rinsing
the gel with Milli-Q distilled H2O in-between. The bottom of a large 13x9” rectangular glass
dish was pre-wet with 10x SSC (1.5M NaCl, 150mM sodium citrate, pH 7.4), then three layers
of pre-cut 3MM Chromatography paper (Whatman, cat # 3030-917) were added, one piece at a
time, and bubbles were removed with a hand-held flat rolling pin. The gel was removed from
Neutralization solution and flipped face-down, directly on top of the 3MM papers. Placing the
gel face-down will maintain the orientation of the wells from left to right on the transfer
membrane. Parafilm was used to line the edges of the gel to prevent unwanted contact between
the Whatman 3MM papers around the gel, and force the transfer buffer to soak through the gel
only. The nylon transfer membrane was cut to size, and pre-soaked in 10x SSC. The membrane
was placed carefully on the gel, making sure to line it up correctly before laying it down. This
step is critical because the position of the membrane cannot be adjusted once it has touched the
gel; the transfer begins immediately. An additional three sheets of Whatman 3MM paper were
cut to size and also pre-soaked in 10x SSC. These were added on top of the transfer stack one at
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a time and rolled to remove any bubbles, being careful not to shift the membrane below. On top
of the pre-soaked 3MM papers, a 1-inch stack of bi-fold brown paper towels was placed, and the
transfer stack was topped with a slightly smaller glass dish, and two half-full reagent bottles were
placed inside the top dish to weight it down. The membrane was left on the benchtop overnight
to allow transfer to occur by capillary action.
After transfer, the transfer sandwich was carefully disassembled, and the flattened,
dehydrated gel was placed in a glass dish with H2O and EtBr and rocked for approximately
15min to re-hydrate and stain any residual DNA within the gel. A post-transfer picture was taken
of the gel using UV transillumination to visualize DNA staining. The nylon membrane was
placed to dry on a piece of saran wrap, and Auto-crosslinked to fix the DNA to the membrane.
The crosslinked membrane was placed in the bottom of a square plastic Tupperware container,
covered with saran wrap and fitted with the container lid to prevent evaporation. 50mL of
Denhardt’s Complete hybridization solution (50% formamide, 5x SSC, 10% Dextran sulfate,
0.5% SDS, 1x Denhardt’s solution (Kim Stratton’s recipe) and 0.5mL salmon sperm DNA), prewarmed to 42°C, was added to the Tupperware container to cover the membrane. The membrane
was incubated in this “prehybridization” solution at 42°C for approximately 4hrs.
During the prehybridization period, 25ng of each of the four DNA probes (LHA, TAP,
Neo, RHA) was labeled using the Random Primers DNA Labeling System (Invitrogen, cat #
18187013), according to the manufacturer’s standard labeling protocol. 32P-dATP and 32P-dCTP
deoxynucleotides were purchased from Perkin Elmer (cat # BLU512H250UC, and
BLU513H250UC, respectively), and used in combination with cold dGTP and dTTP, supplied
with the Random Primers kit. Labeled probes were purified over illustra ProbeQuant spin
columns (GE Healthcare, cat # 28-9034-08) according to manufacturer’s instructions. A 1µL
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sample of each probe was counted to check the level of incorporated

32

P-labeled nucleotides by

liquid scintillation counting. Counts of 108-109 per 1µg of DNA were desired. 10mg/mL of
UltraPure salmon sperm DNA (Invitrogen, cat # 15632011) was added to each purified, labeled
probe. This DNA solution was boiled for 5min, and quenched on ice, before adding to the prehybridization solution, and incubated at 42°C overnight.
After overnight hybridization with the

32

P-labeled probes, the membrane was washed as

follows: two times with 5x SSC + 0.1% SDS at room temperature, once with 5x SSC + 0.1%
SDS at 50°C, and twice with 2x SSC + 0.1% SDS at 50°C. The membrane was checked for wash
efficiency with a Geiger counter, looking for distinguishable spots of “hot” and “cold”. Washing
was continued in 1-2x SSC + 0.1% SDS at 50°C until such “hot” and “cold” areas could be
detected. The blot was developed by autoradiography using Genemate Blue Lite film (ISC
BioExpress, cat # F-9024-8X10), an X-ray film cassette and a Konica SRX-101A developer,
taking exposures of various lengths (6-72hr) until the best exposure was obtained for each probe.
Sequencing
Total gDNA from the TAP CreB33 subclone was used as a template in a series of PCR
reactions to generate discrete products for sequencing. A set of three nested sense primers (LHATAPseq, Neo sn, P3sn) were used to sequence across the LHA-TAP fusion, the excised NeoR
cassette and the RHA, respectively. One antisense primer (P6b), placed outside the site of
integration of the DNMT1-TAP targeting vector, was used to sequence across the RHA, crossing
into the 3’ DNMT1 genomic locus. All primer sequences are listed in Table 3-1.
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DNMT1 and DNMT1-TAP Expression Analyses
Cellular lysate preparation
Tissue culture dishes containing cells plated 24hrs prior to harvest were removed from
the incubator and placed on ice. Media was aspirated off, and dishes were washed twice with
cold 1x PBS, pH 7.4. Cells were scraped into 2mL of 1x PBS, pH 7.4 using sterile cell scrapers.
Scraped cells were collected and transferred into a pre-weighed 15mL conical tube (BD Falcon).
Cells were pelleted by centrifugation at approximately 900xg (2,200rpm) for 5min at 4°C in the
Beckman J6-MI centrifuge. PBS was aspirated off, and the pellet was weighed. The cell pellet
was resuspended in a volume of SDS lysis buffer ten times the pellet weight. Whole cell lysates
were passed through a sterile 21G needle fitted with a 1mL syringe approximately 20 times to
shear the gDNA and create a homogeneous mixture. Lysates were aliquoted and stored at -80°C.
SDS-PAGE and Immunoblotting
Protein concentrations were calculated using a Bradford Protein assay, as described in
Chapter 2. 40µg of total protein from each whole cell lysate was diluted in an equal volume of
Laemmli sample buffer plus 5% β-mercaptoethanol, boiled for 5 minutes, and quickly spun to
collect the samples. Boiled lysates were loaded onto a 4-15% gradient SDS-PAGE gel unless
otherwise mentioned and resolved by electrophoresis in a Mini-PROTEAN electrophoretic box
unit at 150V for approximately 1hr.
Gels were transferred onto Immobilon PVDF membranes using the wet transfer method
and Transfer Buffer containing SDS. 100mL of 10x Wet transfer buffer with SDS (16.879g TrisHCl, 17.299g Tris Base, 144.134g Glycine, 10g SDS in 1L total volume) was added to a 1L
graduated cylinder, and combined with 200mL of 100% MeOH, and 700mL H2O. Transfer
buffer, sponges, along with the transfer tank and assembly were pre-chilled at 4°C for
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approximately 1hr prior to setting up the transfer. Six pieces of Whatman 3MM Chromatography
paper and one piece of PVDF membrane were cut to the size of the gel. Once the gel had
finished running, it was removed from its cassette, and rinsed in Milli-Q distilled H2O for
approximately 2-3 minutes to remove residual running buffer. The pre-cut PVDF membrane was
soaked in 100% MeOH for 1min to activate it, and then rinsed in Milli-Q distilled H2O for 2min.
Both gel and membrane were then equilibrated in chilled 1x Wet transfer buffer with rocking at
room temperature for approximately 15min. After equilibration, the transfer sandwich was
assembled by placing one of the black and clear transfer plates on the benchtop such that the
black plate is facing down. One sponge, soaked in 1x transfer buffer was added on top of the
black plate, and rolled to remove any bubbles. Then, the first three sheets of pre-soaked
Whatman 3MM paper were added on top of the wet sponge, one at a time, rolling out any
bubbles after each paper is placed. The equilibrated gel was then carefully placed on top of the
transfer stack, and rolled to remove bubbles. The equilibrated PVDF membrane was placed on
top of the gel, ensuring that it covered the entire gel. The last three sheets of pre-soaked
Whatman 3MM paper were added on top of the membrane, one at a time, being careful not to
shift the membrane. The transfer stack was topped with a second sponge, also soaked in 1x
transfer buffer, and the transfer plate was closed and locked shut. The transfer plate was fitted
into the black and red holder, with the black side of the plate facing the black side of the holder.
The holder was lowered into the transfer tank, and the tank was filled with 1x wet transfer buffer
with SDS. The transfer unit was plugged into a BioRad power supply and set to run at 100V for
approximately 50min.
Membranes were blocked, washed and developed as described in Chapter 2. Blots were
probed with various antibodies specific to DNMT1: Abcam N-DNMT1 (cat # ab16632), Sigma
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N-DNMT1 (cat # D4692), Sigma C-DNMT1 (cat # D4567) using conditions as outlined in Table
3-2. An antibody directed against the CBP domain of the TAP-tag was used to detect the
DNMT1-TAP allele, referred to as simply the “TAP-tag” antibody (Open Biosystems, cat #
CAB1001).
Total RNA isolation
Total RNA was isolated from non-tagged HCT116neoS cells and HCT116-TAP cells
using the TRIzol reagent (Invitrogen, cat # 15596-026) as recommended by the manufacturer.
RNA was reverse-transcribed with the SuperScript III First-Strand Synthesis system (Invitrogen,
cat # 18080051) using oligo-d(T) primers, according to manufacturer’s instructions. No reverse
transcriptase (“No RT”) negative controls were included with each sample, and endpoint PCR
was performed with β-actin primers against all cDNA template samples to validate that no PCR
product could be amplified from any of the No RT negative controls before proceeding with RTqPCR, and that a product of the appropriate size and intensity was obtained, indicating that
cDNA synthesis was efficient across all samples.
RT-qPCR
RT-qPCR was performed using Quantitect SYBR Green mastermix and primers designed
to distinguish the non-tagged (WT) DNMT1 allele from the TAP-tagged DNMT1 allele. WT
DNMT1 primers consisted of a sense primer that crossed through the STOP codon (absent in the
TAP-tagged allele), and contained 11bp of sequence specific to the WT allele, paired with an
antisense primer located approximately 150bp downstream, within Exon 40 of DNMT1. TAPtagged DNMT1 primers consisted of a sense primer that spanned the LHA-TAP fusion site, with
9bp of sequence specific to the 5’ end of the TAP-tag, paired with an antisense primer located
approximately 200bp downstream, within the TAP-tag coding sequence. Human β-actin was
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Table 3-2: Optimal antibody conditions

Antibody
NDNMT1
CDNMT1
TAP

Manufacturer

Species

Blocking
Buffer

Sigma

rabbit

StartingBlock

1:1000

1:15,000

Sigma
Open
Biosystems

rabbit

StartingBlock

1:1000

1:15,000

rabbit

Blotto

1:500

1:10,000
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Primary
Dilution

Secondary
Dilution

Secondary
Antibody
goat antirabbit
goat antirabbit
donkey
anti-rabbit

Protein
Size
(kDa)
185
185
varies

used as a loading and normalization control for nearly all RT-qPCR studies, and these primers
amplify a product of approximately 120bp. Primers against the far C-terminal end of DNMT1
(Ex37sn and Ex38asn), common to both WT and TAP-tagged alleles, were used as an additional
normalization control, to rule-out any differences in primer efficiencies between the WT and
TAP primer sets. A 1:25 dilution of cDNA for each sample was read from a standard curve
generated by 1:5-1:125 serial dilutions of cDNA from non-tagged HCT116 cells.
PCR reactions were run on a BioRad DNA Engine Peltier thermal cycler fitted with a
Chromo4 Real-Time Fluorescence Detector attachment, and data was analyzed using
OpticonMonitor3 software. The PCR cycling program consisted of initial denaturation at 95°C
for 15min, followed by 40 cycles, each including: denaturation at 94°C for 30sec, annealing at
the pre-determined optimal temperature for each primer set (Table 3-1) for 30sec, extension at
72°C for 30sec, followed by final extension at 72°C for 5min. A melting curve was run at the
conclusion of each RT-qPCR reaction, in the range of 40-90°C, with reads every 1°C, and a hold
every 1sec. Table 3-1 lists all primer sequences and optimized annealing temperatures.
Primers were used to distinguish the WT and TAP alleles (Table 3-1), and a set of
internal DNMT1 primers spanning the ATG3/Ex1-2asn boundary were used as a normalization
standard, to rule-out any differences in efficiencies between WT and TAP-specific primers. βactin was used as an RNA loading control.

RNA Immunoprecipitation with α-AUF1 antibody
Immunoprecipitation and RNA isolation
In an adaptation of the protocol described by Torrisani et al. (92), approximately 4 x 106
non-tagged HCT116neoS and HCT116-TAP cells were seeded into three 100mm tissue culture
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dishes, with one dish for each of three conditions: No antibody negative control, non-specific
IgG negative control, and anti-AUF1 antibody. 24hrs after plating, cells were harvested by
trypsinization, and cells from all three 100mm dishes of each cell type were pooled into one
15mL conical tube. Cells were pelleted by centrifguation in the Beckman J6-MI centrifuge by
spinning at 2,500rpm for 5min at 4°C. Cell pellets were resuspended in 6.2mL 1x PBS, pH 7.4,
and 2mL of the cell resuspension was transferred into each of three 15mL conical tubes, one for
each condition as described above. Cells were again pelleted by centrifugation, but resuspended
this time in 2mL 1x PBS, pH 7.4, 2mL nuclear isolation buffer (1.28M sucrose, 40mM Tris-HCl,
pH 7.5, 20mM MgCl2, 4% Triton-X) and 6mL high-performance liquid chromatography-grade
(HPLC) H2O. Cell resuspensions were incubated on ice for 20min with frequent inversion to
mix and thoroughly lyse cells. Nuclei were pelleted by centrifugation at 2,500xg (3,483rpm in
the J6-MI centrifuge) for 15min at 4°C. Each nuclear pellet was resuspended in 1mL RIP buffer
(150mM KCl, 25mM Tris, pH 7.4, 5mM EDTA, 0.5mM DTT, 0.5% NP-40, 9µg/mL Leupeptin,
9µg/mL Pepstatin, 3µg/mL Aprotinin, 1mM PMSF and 100U/mL SUPERASin RNase inhibitor
(Ambion, cat # AM2694), transferred to 1.5mL eppendorf tubes, and incubated on ice for 5min.
Resuspended nuclei were sonicated using the Diagenode Bioruptor water bath sonicator for 25
cycles at the highest pulse, with 5sec on, and 5sec off, to ensure complete lysis of nuclei. Nuclear
lysates were clarified to remove membranes/debris by centrifugation at 16,000xg for 10min at
4°C. The nuclear supernatant was transferred to new 1.5mL eppendorf tubes for the IP.
250µL of Protein G sepharose beads (GE Healthcare, cat # 17-0618-01) were pipeted
using a 2-200µL tip with the end cut off. The protein G beads were equilibrated by washing three
times in 250µL RIP buffer, spinning at 1000xg for 2min at 4°C between each wash to pellet the
beads. After equilibration, the beads were resuspended in 250µL RIP buffer to make a 50% bead
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slurry. 40µL of 50% Protein G bead slurry, together with antibody to AUF1 (Millipore, cat # 03111), nonspecific IgG (supplied with AUF1 antibody) or no antibody, were added to each 1.5mL
tube containing clarified nuclear supernatant. The immunoprecipitation samples were incubated
at 4°C in the cold room, overnight with gentle end-over-end rotation.
Fresh RIP Buffer was made without the addition of SUPERASin, to use for washing. The
beads were pelleted at 2,000xg for 1min at 4°C. Supernatant/flowthrough was collected for each
sample, and retained in 1.5mL tubes labeled “input”. The beads were washed in 500µL RIP
Buffer (without SUPERASin) a total of three times, each time pelleting the beads by
centrifugation at 2,000xg for 5min at 4°C. After the last wash was removed, the beads were
resuspended in 1mL of TRIzol (Invitrogen) and 2mL of TRIzol was added to input samples.
Both sets of samples were stored at -80°C until RNA could be isolated.
RNA was isolated from both IP and input samples according to manufacturer’s
instructions included with the TRIzol reagent. All reagent volumes were scaled to the initial
volume of TRIzol used to resuspend the samples. RNA from IP samples was dissolved in 18µL
DEPC-treated water; RNA from input samples was dissolved in 30µL DEPC-treated water.
Samples were quantitated on the NanoDrop spectrophotometer, and the integrity of 1.5µg of
RNA from input samples was checked on a 1% TAE-EtBr gel.
cDNA synthesis was performed using the SuperScript III RT First-Strand Synthesis
system (Invitrogen) with oligo-d(T) primers, according to manufacturer’s instructions. A no
reverse transcriptase negative control was included for each RNA template. An endpoint PCR
was performed using WTsn/WTasn primers to validate that the resultant cDNA was of sufficient
quality to amplify DNMT1 by PCR, and to ensure that the primers could not generate products
from the “No RT” negative control samples.
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RT-qPCR
RT-qPCR was performed as described above for DNMT1 and DNMT1-TAP expression
analyses, using the same primer sets and cycling conditions. However, for this set of studies,
quantitation of a 1:5 dilution of cDNA for each IP sample was determined from a standard curve
generated by 1:10-1:1000 serial dilutions of cDNA from the non-tagged HCT116 no antibody
input sample.

TAP-tag purification from whole HCT116-TAP cells
Cortney Heyer in Dr. Moran’s laboratory adapted a TAP-tag purification protocol based
on several methods described in the literature (Figure 3-2) (107, 108). Approximately 500x106
HCT116-TAP CreA42 cells, plated in twenty-six 150mm dishes were harvested by
trypsinization, five dishes at a time. Cells were transferred and pooled into 50mL conical tubes,
and pelleted by centrifugation. Cell pellets were resuspended in 10mL of 1x PBS, pH 7.4
containing complete EDTA-free protease inhibitor cocktail (Roche) twice to wash, and each time
re-pelleted by centrifugation. Pellets were lysed in 4mL of Tween 20 lysis buffer (50mM
HEPES, pH 7.5, 150mM NaCl, 1mM EDTA, 2.5mM EGTA, 0.1% Tween 20, 1mM PMSF,
1mM NaF, 1mM NaVO4 and complete protease inhibitor cocktail), and pooled into a 15mL
conical tube (8mL total volume). The cell lysate was sonicated using a Diagenode Bioruptor
water bath sonicator for 25 cycles of 1 sec on, 1 sec off at the highest pulse, and incubated on ice
for 30min to ensure complete lysis. A small volume (50µL) of unclarified whole cell lysate was
retained and stored at -80°C. The lysate was clarified by centrifugation at 16,100xg for 15min at
4°C and the clarified supernatant was pooled into a 15mL conical tube. A small volume of
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clarified supernatant (20µL) and 1/6th of the insoluble pellet were both retained and stored at 80°C.
IgG sepharose beads (GE Healthcare, cat # 17-0969-01) were pipeted using a 2-200µL
tip with the very end cut off. 100µL of IgG beads were washed with 250µL Tween 20 lysis
buffer three times, spinning at 250xg for 2 minutes at 4°C between washes. Equilibrated IgG
beads were added to the 15mL conical tube containing the clarified cell lysate, and incubated at
4°C overnight with end-over-end rotation.
Following overnight incubation, the IgG beads were pelleted by centrifugation at 250xg
for 2min at 4°C. Approximately 1mL of the unbound flowthrough fraction was retained and
stored at -80°C. The IgG beads were washed three times with 500µL of Tween 20 lysis buffer,
pelleting the beads at 250xg for 2min at 4°C after each wash. The supernatant from all IgG
washes was collected and pooled into a 15mL conical tube and stored at -80°C. IgG beads were
washed with 1x TEV buffer (3920µL HPLC H2O, 36µL of 0.1M DTT, and 175µL of 20x TEV
Buffer supplied with the AcTEV protease enzyme (Invitrogen, cat # 12575015)) three times,
pelleting the beads at 250xg for 2min at 4°C after each wash. The supernatant from all TEV
washes was collected and pooled into a 15mL conical tube and stored at -80°C. Equilibrated
beads were resuspended in 300µL of 1x TEV buffer, and 100U (10µL) of AcTEV protease was
added to the tube. TEV protease cleavage was allowed to proceed for 2hrs at 4°C with end-overend rotation, then the reaction was spiked with 50U (5µL) additional AcTEV protease and
incubated for 2hrs at room temperature (the optimal temperature for the enzyme).
Calmodulin sepharose beads (GE Healthcare, cat # 17-0529-01) were pipeted using a 2200µL tip with the very end cut off. 100µL of Calmodulin beads were washed three times with
250µL of Calmodulin binding buffer (10mM Tris-HCl, pH 8.0, 10mM β-mercaptoethanol,
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150mM NaCl, 1mM magnesium acetate, 1mM imidazole, 2mM CaCl2, 0.1% NonidetP-40 and
complete protease inhibitor cocktail), pelleting the beads by centrifugation at 250xg for 2min at
4°C after each wash. IgG beads from the TEV protease cleavage reaction were pelleted by
centrifugation at 250xg for 2min at 4°C. The supernatant, containing DNMT1-TAP cleaved from
the IgG beads, was transferred to a fresh 1.5mL microcentrifuge tube, and labeled the “TEV
Eluate”. The leftover IgG beads were washed twice with 300µL of Calmodulin binding buffer,
and the beads were pelleted at 250xg for 2min at 4°C after each wash. The supernatant from
these washes was added to the TEV Eluate tube, and a small aliquot of the TEV Eluate was
retained and stored at -80°C. 1/250th volume of 1M CaCl2 (2.4µL) was added to the TEV Eluate
and the tube was inverted several times to mix. The TEV Eluate sample was centrifuged at
250xg for 2min at 4°C to remove any residual traces of IgG beads, and the supernatant was
transferred into the microcentrifuge tube containing the equilibrated Calmodulin beads. The TEV
Eluate was incubated with Calmodulin beads at 4°C overnight with end-over-end rotation, in the
presence of high CaCl2 to promote the calmodulin-calmodulin binding peptide (CBP) interaction.
Following overnight incubation, the Calmodulin beads were pelleted by centrifugation at
250xg for 2min at 4°C. The unbound flowthrough was transferred to a clean 1.5mL
microcentrifuge tube and stored at -80°C to determine the efficiency of capture by WB. The
beads were washed three times with 500µL of Calmodulin binding buffer, pelleting the beads at
250xg for 2min at 4°C after each wash. All calmodulin washes were retained and stored at 80°C. After washing, the Calmodulin beads were resuspended in 100µL of Calmodulin elution
buffer (10mM Tris-HCl, pH 8.0, 10mM β-mercaptoethanol, 150mM NaCl, 1mM magnesium
acetate, 1mM imidazole, 2mM EGTA, 0.1% NP-40 and complete protease inhibitor cocktail) and
inverted four times to mix. The beads were incubated in Calmodulin elution buffer for 3min on
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ice, then pelleted by centrifugation at 250xg for 2min at 4°C, and the supernatant was collected
in a clean 1.5mL microcentrifuge tube. The last incubation/centrifugation step was repeated
seven more times, to generate a total of eight 100µL elution fractions.
The leftover IgG beads and Calmodulin beads were boiled to remove any remaining
bound proteins. 100µL of Laemmli sample buffer (BioRad, cat # 161-0737) plus 5% βmercaptoethanol was added to resuspend each bead pellet. Beads were boiled for 5min, and
pelleted by centrifugation at 250xg for 2min at 4°C. The supernatants were transferred to clean
1.5mL microcentrifuge tubes and stored at -80°C.

SDS-PAGE, immunoblotting and silver staining of purified DNMT1-TAP fractions
Protein concentrations for all samples retained during the purification procedure were
determined by Bradford assay against standard curves generated using each buffer (i.e., Tween
20 lysis buffer, TEV elution buffer, etc.) and known concentrations of BSA. Two 4-15% gradient
gels were loaded identically with fractions of the samples retained during each step in the
purification protocol. Similarly, two 4-15% gradient gels (BioRad, cat # 161-1158) were loaded
identically with each of the eight purified DNMT1-TAP elution fractions. 37.5µL of each elution
fraction was combined with 12.5µL of 4x Laemmli sample buffer plus 5% β-mercaptoethanol,
and boiled for 5min. One gel was probed with the anti-TAP-tag antibody (Open Biosystems, cat
# CAB1001) as described previously. The other identical gel was processed immediately with
the Silver Stain Plus kit (BioRad, cat # 161-0449), according to manufacturer’s instructions.
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DNMT1 Activity assay (3H incorporation)
HCT116-TAP cells were harvested as described above for the TAP-tag purification.
Tween 20 lysis buffer was prepared as described and supplemented with 100µg/mL RNase A
(Sigma, cat # R6513). The cell lysates were sonicated for 10 cycles, instead of 25, and
quantitated by Bradford assay. Recombinant human DNMT1 (cat # M0230S) and M.SssI CpG
methyltransferase (cat # M0226S) were purchased from New England BioLabs, and supplied
with S-adenosylmethionine, 50x BSA and 10x DNA methyltransferase reaction buffer. Lambda
DNA and Poly(dI-dC) substrate DNA were both obtained from Scott Rothbart in Dr. Moran’s
laboratory. 3H-S-adenosylmethionine was purchased from MP (cat # 24051H).
25µL positive control reactions containing 0.5U of M.SssI methylase with 1µg lambda
DNA substrate, or 1.0U recombinant hDNMT1 enzyme with 15ng poly(dI-dC) DNA substrate,
each with 1µCi 3H-S-adenosylmethionine, 0.5µL of 50x BSA, and 2.5µL of 10x reaction buffer.
Similarly, increasing amounts of purified DNMT1-TAP lysate (0.05-4µg) were added into 25µL
reactions, also containing 15ng poly(dI-dC) substrate, 1µCi 3H-S-adenosylmethionine, 0.5µL of
50x BSA, and 2.5µL of 10x reaction buffer. No enzyme and no substrate negative controls were
also included to measure background. All reactions were mixed thoroughly in 1.5mL
microcentrifuge tubes by vortexing, quickspun to collect all contents at the bottom of the tube,
and incubated at 37°C for 30min. The reactions were stopped on ice. Samples were spotted onto
2.5cm Whatman 3MM filter paper circles (cat # 1030-025) to bind DNA by anion exchange. The
filter paper discs were placed into the bottom of a Büchner funnel fitted with a large Erlenmeyer
flask and washed twice with 10mL of 0.5M NaPO4, once with 2mL 70% EtOH and once with
2mL 100% EtOH under vaccum. The filters were allowed to air dry briefly on Kimwipes placed
on the benchtop. Once dry, the filter papers were added to small 5mL plastic scintillation vials
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along with 5mL of Safety Solve High Flash Point liquid scintillation cocktail (Research Products
International, cat # 111177), and the radioactivity was counted using a liquid scintillation
counter. The amount of methyltransferase activity was represented by the degree of
incorporation of 3H-labeled methyl groups onto the DNA substrate, and measured as counts per
million (cpm).

Subcellular fractionation
Non-tagged HCT116neoS cells and HCT116-TAP cells were fractionated into whole cell
and mitochondrial lysates by dounce homogenization and differential centrifugation as described
in Chapter 2.

SDS-PAGE and immunoblotting of subcellular fractions
Each subcellular fraction was lysed, quantitated and its constituent proteins were resolved
by SDS-PAGE as described in Chapter 2. Gels were transferred to Immobilon PVDF membranes
as described above, using the wet transfer protocol. An antibody directed against the far Nterminal epitope (amino acids 1-10) of DNMT1 (Abcam, cat # ab16632) was used for subcellular
localization studies because it provided the strongest signal for full-length DNMT1 in the
mitochondrial fraction. Antibodies against compartment-specific markers were used to
demonstrate the purity of each subcellular fraction: VDAC (Sigma) as a mitochondrial marker
and H3K4me3 (Upstate Biotechnology) as a nuclear marker.
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RESULTS
Creation of the HCT116 DNMT1-TAP cell line by AAV-mediated gene targeting and
homologous recombination
A tandem affinity purification tag was inserted into the C-terminus of a single
endogenous human DNMT1 allele by adeno-associated viral (AAV) vector-mediated
homologous recombination (Figure 3-4). The targeting construct contained a NeoR cassette for
selection of positively-recombined clones. Neomycin-resistant HCT116-TAP clones were
screened first by PCR to check for correct insertion of the TAP-tag into the genomic locus of
DNMT1. A PCR screen of the LHA showed that a total of three clones (A4, B3 and B7)
produced bright bands of the correct size (~1.7kb), indicating that they contain the DNMT1-TAP
targeting construct in the proper orientation, and represent products of successful homologous
recombination between the pAAV-MCS-DNMT1-TAP targeting vector and the endogenous
DNMT1 locus (Figure 3-6A, and 3-6B LHA). Additionally, a PCR screen of the RHA showed
that a total of two original TAP clones (A4, and B3) and two Cre subclones (CreA42, and
CreB33) produced bands of the correct size (~4.2kb with NeoR cassette, and ~2kb without NeoR
cassette, respectively) (Figure 3-6B RHA). The original TAP B7 clone appeared to be a mixed
population of cells (Figure 3-7), containing at least one colony representing a proper integration
of the DNMT1-TAP targeting construct (hence the initial positive result by PCR screen of the
LHA in Figure 3-6), and at least one colony representing perhaps a random integration of the
DNMT1-TAP targeting construct (hence the failure to maintain expression of the TAP-tagged
DNMT1 allele in Figure 3-7).
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Figure 3-7: Mixed populations of NeoR clones are detected by immunoblot. This is a
representative immunoblot from numerous protein expression analyses performed on the
HCT116-TAP clones. Whole cell lysates from each of these eight cell lines was separated by
SDS-PAGE and probed with antibodies to DNMT1 and the TAP-tag. The TAP 5B5, 5C2 and
5C2 clones also represent mixed populations of cells, as it shows no expression of the TAP-tag
(lower panel). The three clones labeled in red font represent true positive recombinant clones,
containing proper integration of the TAP-tag in its correct orientation, and exhibiting a strong
signal for TAP-tag expression (lower panel).
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Subcloning of positive recombinants was required to obtain a homogeneous cell population
Because the highly efficient rAAV method for delivery of our DNMT1-TAP targeting
construct produced a higher recombination frequency than expected (5.2%, see below), it
became apparent that simply plating the NeoR clones by limiting dilution was not sufficient to
select for colonies arising from a single progenitor cell. Instead, many of the initial “positive”
clones turned out to be mixed populations, as described above for the original TAP B7 line
(Figure 3-7). An additional subcloning step was performed to ensure that any further analysis
was limited to homogeneous NeoR clones that represent a single recombination event.

Southern Blot confirms correct genotype of three final DNMT1-TAP Cre cell lines
A Southern blot with LHA and RHA probes verified the genotype of the two original
TAP clones (A4 and B3), and the two TAP Cre subclones (CreA42 and CreB33), among others
(Figure 3-8). A double digest with restriction endonucleases BamHI and PpuMI, which cut the
DNMT1 genomic locus outside of the insertion sites of the DNMT1-TAP targeting vector,
produced a 4.9kb fragment from the WT DNMT1 allele. BamHI also cuts once within the TAPtag, and PpuMI cuts once within the NeoR marker, so a double digest of the original DNMT1TAP allele produced three fragments: ~1kb, ~2.4kb and ~4.2kb in size (Figure 3-8A). Because
the TAP Cre clones should lack the NeoR cassette, a double digest of the DNMT1-TAP Cre
allele was expected to produce two fragments: ~2.4kb and ~3.1kb in size. The blot probed with a
LHA probe (Figure 3-8B) shows a total of 13 HCT116-TAP clones with the proper fragment
sizes: one band at ~2.4kb representing the DNMT1-TAP allele, and one band at ~4.9kb,
representing the WT DNMT1 allele. The blot probed with a RHA probe (Figure 3-8C) shows a
total of 12 HCT116-TAP clones with the proper fragment sizes: one band at ~4.9kb representing
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Figure 3-8: Southern blots confirm genotype and proper integration of TAP-tag targeting
construct. Total gDNA was purified from all HCT116-TAP clones of interest; both original
TAP lines and cell lines that had been transfected with Cre recombinase. The DNA was digested
with BamHI and PpuMI restriction endonucleases, cutting at sites marked by red arrows. Probes
directed against all four components of the TAP-tag (red bars) were labeled with 32P. Expected
sizes of bands detected with each probe, for each type of DNMT1 allele are listed in the table.
(B) A total of 13 clones produced bands of the correct sizes when visualized with a probe against
the LHA. (C) Only 12 clones produced the correct fragments when probed with the RHA probe.
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the WT DNMT1 allele, and either one band at ~4.2kb representing the original DNMT1-TAP
allele with the NeoR marker, or one band at ~3.1kb representing the DNMT1-TAP Cre allele
without the NeoR cassette. Technical issues, including bubbles in the transfer occluding the
visualization of key bands, and non-specific binding of the Neo probe to plasmid sequences used
to generate the 1kb+ DNA ladder, prevented the blots probed with TAP-tag and Neo probes from
being interpreted. Overall, out of the 232 Neo-resistant subclones examined, a total of 12
HCT116-TAP clones were verified to contain the correct genotype, resulting in a recombination
frequency of 5.2%.

Expression of the DNMT1-TAP protein
Immunoblots probed with two of the commercially-available DNMT1 antibodies (Sigma
N-terminal, and Sigma C-terminal, see Figure 3-9A) showed a substantial difference in DNMT1
expression between the non-tagged HCT116 cells and HCT116-TAP cells (Figure 3-9B). The
Sigma N-terminal antibody is epitope-specific, directed against amino acids 72-78 of the nuclear
DNMT1 protein; the Sigma C-terminal antibody is also an epitope-specific antibody, directed
against amino acids 1581-1595. The difference in DNMT1 protein between non-tagged HCT116
cells and HCT116-TAP cells was striking. On immunoblots probed with either of these two
antibodies, DNMT1 appeared to be at least 10-20-fold more abundant in the TAP-tagged cells
(Figure 3-B).
In contrast to these results, an antibody obtained from Abcam (cat # ab16632) and
directed against a far N-terminal epitope of DNMT1 (amino acids 1-10), showed an equivalent
level of DNMT1 expression across non-tagged and TAP-tagged cells (Figure 3-9B).
Furthermore, when the WT and DNMT1-TAP alleles were resolved on a 5% SDS-PAGE gel, the
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Figure 3-9: Immunoblot analyses of WT and TAP-tagged DNMT1 expression. (A)
Molecular structure of DNMT1, showing the locations of conserved domains within the protein.
The green half-circles represent specific epitopes detected by several antibodies against DNMT1.
(B) Immunoblots of whole cell lysates from non-tagged HCT116s and three of the validated TAP
Cre subclones separated on 4-15% gradient SDS-PAGE gels were probed with antibodies
directed against different epitopes of the DNMT1 protein. (C) Whole cell lysates from each cell
line of interest were separated on a 5% SDS-PAGE gel to resolve the 20kDa in size between the
WT DNMT1 (lower band) and the DNMT1-TAP (upper band) alleles.
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relative levels of DNMT1 expression between the two alleles was equal (Figure 3-9C). It is still
unclear why we consistently observe two different pictures using antibodies that detect the same
protein, but further studies are necessary to resolve this discrepancy, including looking at the
relative level of WT and DNMT1 expression with antibodies directed against other epitopes of
the protein.

Expression of the DNMT1-TAP allele is 6- to 8-fold higher than the endogenous WT
DNMT1 allele
RT-qPCR studies using primers specific for either the WT allele or the DNMT1-TAP
allele (Figure 3-5B) and random hexamer-primed cDNA examined the relative levels of DNMT1
mRNA expression across non-tagged HCT116 cells and three of the TAP Cre subcloned lines
(Figure 3-10). An internal set of primers against DNMT1 was used as a normalization control, to
account for any differences in primer efficiencies. β-actin was used as a second normalization
control, to account for any variability in the amount of mRNA put into cDNA synthesis. The
reported dilution values for either the WT- or TAP-specific primers were normalized first to the
internal DNMT1 primer set, and then those ratios were normalized to β-actin. The average for
WT DNMT1 expression in the non-tagged HCT116 cells was set to one, and all other values
were adjusted accordingly. We observed no non-specific amplification with DNMT1-TAPspecific primers in the non-tagged HCT116 cells. Expression of the WT DNMT1 allele in all
three TAP Cre subclones was approximately 0.5ng, which would be expected for cells
containing only one WT allele. However, expression of the DNMT1-TAP allele was
approximately 6-8-fold higher (3-4ng) than expression of the WT DNMT1 allele in all three TAP
Cre subclones. Because only the TAP-tagged allele was affected, this result suggested that C-
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Figure 3-10: Quantitation of DNMT1-TAP overexpression by RT-qPCR. Total RNA was
isolated from non-tagged and TAP-tagged HCT116 cells and used to synthesize cDNA with
random hexamers. RT-qPCR using primers that distinquish the WT and TAP-tagged DNMT1
alleles were used to quantitate differences in expression of these two loci. Dilution values for
each primer set were first normalized to internal DNMT1 primers to account for any differences
in primer efficiencies. These values were then normalized to β-actin as an RNA input control.
Graphed values represent the average of at least three technical repeats per sample from a
representative experiment, with error bars signifying the standard deviation about the mean,
calculated using the formula described in Chapter 2.
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terminal insertion of the TAP-tag into the DNMT1 genomic locus may have disturbed a normal
regulatory mechanism, affecting mRNA stability.

AUF1 binding and destabilization of DNMT1 is reduced in the TAP-tagged cells,
contributing to increased stability of the DNMT1-TAP allele
Precedent literature identified a conserved AU-rich element in the 3’UTR of DNMT1 that
is bound by AU-rich element/poly(U)-binding/degradation factor 1 (AUF1), subsequently
targeting the transcript for destabilization and degradation by the exosome (92). This 54
nucleotide AU-rich element is located just 200bp downstream of the insertion site for the
DNMT1-TAP targeting construct (Figure 3-11), so it stood to reason that insertion of the TAPtag at the C-terminus of DNMT1 may have disrupted the AUF1 interaction, and caused an
increase in stability of the DNMT1-TAP message. We therefore carried out RNA
immunoprecipitation studies to assess the binding of AUF1 to the 3’UTR of the two DNMT1
transcripts. RT-qPCR demonstrated a 50% reduction in the level of AUF1 bound to DNMT1
mRNA in the HCT116-TAP cells, relative to non-tagged HCT116 cells (Figure 3-12). A β-actin
negative control represents the level of background signal detected for these experiments. The
observed decrease in AUF1 binding in the HCT116-TAP cells is consistent with a failure to
destabilize the DNMT1-TAP mRNA, resulting in a higher steady-state level of the DNMT1-TAP
transcript. While not quantitatively proportional with the level of DNMT1-TAP mRNA overexpression (we might expect a 6-8-fold reduction in AUF1 binding), this observation also likely
explains the over-expression of DNMT1-TAP seen at the protein level.
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Figure 3-11: Schematic diagram of DNMT1 3’UTR, site of TAP-tag insertion, and
conserved AUF1 binding site. A 54-nucleotide highly-conserved AU-rich element lies just
200bp downstream of the targeted insertion site for the DNMT1-TAP targeting vector. This AUrich element has been shown to be bound and destabilized by AUF1.
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Figure 3-12: AUF1 binding to its conserved site within the DNMT1 3’UTR is disrupted in
the TAP-tagged cells. RNA immunoprecipitation with an AUF1 antibody was performed in
non-tagged HCT116 and HCT116-TAP cells. Nonspecific rabbit IgG was used as a negative
control for the IP. Immunoprecipitated RNA was used as a template for cDNA synthesis with
oligo d(T) primers. RT-qPCR using primers against DNMT1 demonstrate that the amount of
DNMT1 mRNA pulled down with AUF1 is reduced by half in the HCT116-TAP cells. Primers
against β-actin were used as a negative control for RT-qPCR. Graphed values represent the
average of three replicates per sample, with error bars signifying the standard deviation about the
mean, calculated using the formula in Chapter 2.
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Purification of DNMT1-TAP isolates multiple protein species for DNMT1
Whole cell lysates from HCT116-TAP cells were subjected to tandem affinity
purification, as depicted in Figure 3-2. This procedure involved two affinity binding steps and a
TEV protease cleavage step, and allowed for rapid and efficient purification of the DNMT1-TAP
protein. We separated fractions of the DNMT1-TAP purification elutions on SDS-PAGE gels,
and either visualized all proteins present by silver stain (Figure 3-13, top panels), or probed with
specific antibodies by immunoblot (Figure 3-13, bottoms panels). As expected, the silver stained
gel showed numerous bands, representing purified DNMT1-TAP, as well as any interacting
protein partners that co-purified with DNMT1 (Figure 3-13B, top panel). Interestingly, when an
identical gel was probed with an antibody directed against the CBP-domain of the TAP-tag
(Figure 3-13B, lower panel), a similar multiple-banding pattern was observed. This suggests that
not only do multiple protein species exist for DNMT1 in an endogenous context, but also that we
had TAP-tagged and purified several different protein species for DNMT1.
This phenomenon was reproduced in Figure 3-14, when aliquots from several different
elution fractions were pooled, separated by SDS-PAGE and probed with antibodies detecting
either the extreme N- or C-terminus of the DNMT1 protein (Figure 3-9A). The TAP-tag
antibody showed a familiar picture, with several protein species detected in the ~60-190kDa
range. The most predominant band migrated at approximately 190kDa, representing the fulllength DNMT1 (185kDa) with a fused CBP (5kDa), the part of the TAP-tag remaining after TEV
protease cleavage. Likewise, an antibody against a far C-terminal epitope of DNMT1 (amino
acids 1581-1595) detected multiple proteins; many, although not all, appear to correlate with
bands detected with the anti-TAP-tag antibody. However, purified DNMT1-TAP probed with an
antibody directed against an N-terminal epitope of DNMT1 (amino acids 72-78) only showed the
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Figure 3-13: Silver stain and immunoblot analysis of the TAP-tag purified DNMT1TAPCreA42 subclone. (A) TAP-tag purification was performed on the HCT116-TAP CreA42
cell line, samples from each purification fraction were collected and proteins were separated on
two identical 4-15% gradient gels. One gel was processed with silver stain (top panel), the other
was analyzed by immunoblot using an antibody against the TAP-tag. (B) Samples from each of 8
elution fractions collected from calmodulin beads were separated on two identical 4-15%
gradient gels and processed as in (A).
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Figure 3-14: Multiple protein species are detected for purified DNMT1-TAP. Elution
fractions collected from a similar TAP-tag purification as in Figure 3-12 were pooled, resolved
on 4-15% SDS-PAGE gradient gels and silver stained (far lefthand panel), or probed with
various antibodies against DNMT1 (three righthand panels). A similar multiple protein-banding
pattern was observed in the two righthand panels, using antibodies against the C-terminus of the
DNMT1-TAP allele, suggesting that multiple protein species for DNMT1 were purified by the
TAP-tag purification method. When probed with an antibody against a more N-terminal epitope
of DNMT1, only a single band, representing the full-length DNMT1 protein appears, suggesting
that only full-length DNMT1 contains both the TAP-tag and an N-terminal epitope (aa72-78)
detected by the antibody.
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presence of full-length DNMT1-TAP (~190kDa). This suggests that the multiple bands detected
in the two righthand panels represent species of DNMT1 lacking the N-terminus, and may arise
as a result of alternative downstream start sites for DNMT1, or alternative splicing or proteolytic
processing of DNMT1.

Purified DNMT1-TAP is functional as a methyltransferase
Because the entire TAP-tag purification is carried-out under mild, non-denaturing
conditions, it is generally assumed that both the functionality of the target protein and its proteinprotein interactions are preserved. In order to be sure that the purified DNMT1-TAP protein was
functional and had retained methyltransferase activity, we performed an in vitro DNA
methyltransferase enzyme assay, based on established methods (118, 119), and using a protocol
adapted from Scott Rothbart in Dr. Moran’s laboratory. The bacterial CpG methyltransferase,
M.SssI, in a reaction with its preferred substrate, lambda DNA, was used as a positive control.
Increasing amounts of purified DNMT1-TAP protein (0.05-4µg) were added to reactions
containing an unmethylated poly(dI-dC) substrate (Figure 3-15). 3H-S-adenosylmethionine was
used as the methyl group donor in all reactions, allowing a specific labeling of 3H-methyl groups
incorporated into DNA. The DNA was subsequently purified and incorporation of 3H was
measured by scintillation counting, as a direct measurement of DNA methyltransferase activity.
Background counts were obtained from no enzyme and no template negative control reactions
and an average background count was subtracted from the values reported for each enzyme. As
expected, we observed a relatively high level of 3H incorporation into purified lambda DNA
substrate, catalyzed by M.SssI. Also as expected, we observed an approximately linear increase
in methyltransferase activity with increasing amounts of purified DNMT1-TAP added to the
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Figure 3-15: Purified DNMT1-TAP is functional as a methyltransferase. A classical in vitro
3
H-incorporation assay for DNA methyltransferase activity was performed on extracts of TAPtag purified DNMT1. M.SssI was used as a positive control. Increasing amounts of purified
DNMT1-TAP produced an approximately linear increase in 3H-methyl groups incorporated into
a defined DNA substrate, demonstrating that the purified DNMT1-TAP allele is catalytically
active. Graphed values represent the average of two replicate reactions minus background from a
representative experiment, with error bars signifying the standard deviation about the mean.
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reaction (Figure 3-15). Thus, the purified DNMT1-TAP enzyme is catalytically active, and
capable of methylating a DNA substrate in vitro.

The DNMT1-TAP allele localizes properly to the mitochondria and is expressed at nearendogenous levels
To validate our use of the HCT116-TAP cell line in studies involving mitochondrial
methylation, we needed to be sure that the DNMT1-TAP allele could indeed translocate to the
mitochondria. Both non-tagged HCT116 and HCT116-TAP cells were fractionated into whole
cell and mitochondrial extracts, and resolved by SDS-PAGE. Gels were loaded with different
amounts of total protein from whole cell and mitochondrial fractions, representing equal cell
equivalents. An N-terminal DNMT1 antibody (aa1-10, Figure 3-9A) shows that the level of
DNMT1 in the mitochondrial fraction is approximately the same across non-tagged HCT116
cells and HCT116 cells carrying a TAP-tagged DNMT1 allele (Figure 3-16A). The appearance
of a doublet in the mitochondrial fraction from the TAPCre3 cells represents the 20kDa
difference in size between the WT (lower band) and TAP-tagged (upper band) DNMT1 alleles
that cannot be fully resolved on a 4-15% gradient gel (Figure 3-16A). VDAC was used as both a
mitochondrial marker and a loading control, and H3K4me3 was used as a nuclear marker to
demonstrate the purity of these mitochondrial preparations (Figure 3-16A).
Identical immunoblots of whole cell and mitochondrial fractions from non-tagged
HCT116 and HCT116-TAP cells were also probed with the Sigma N-terminal and Sigma Cterminal antibodies (Figure 3-16B). Although full-length DNMT1 could not be detected in the
mitochondrial fractions of cells probed with either antibody, two smaller protein species, which
we suspect are proteolytic cleavage products of the full-length enzyme, were detected. These
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Figure 3-16: Subcellular localization of DNMT1-TAP. Non-tagged HCT116 cells and
HCT116 TAPCre3 cells were fractionated into whole cell and mitochondrial lysates. These
extracts were resolved on 4-15% SDS-PAGE gels, and probed with four of the DNMT1-specific
antibodies (See Figure 3-9A for epitopes). (A, B) Both full-length DNMT1 and smaller
immunoreactive protein species appear to be equally expressed in the mitochondrial fractions of
both cell types. (C) Full-length DNMT1 along with a smaller protein species are detected in the
mitochondrial fraction of HCT116-TAP cells. Subcellular fractions from non-tagged HCT116
cells probed with the TAP-tag antibody show non-specific detection of a protein of ~35kDa.
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proteins (~60kDa, seen with the N-terminal antibody, and ~30kDa with the C-terminal antibody)
were equally expressed across both cell lines (Figure 3-16B).
Whole, cytosolic and mitochondrial lysates from HCT116 and HCT116-TAP cells were
separated on 4-15% gradient SDS-PAGE gels and probed with an antibody to the CBP-domain
of the TAP-tag (Figure 3-16C). Full length DNMT1 was detected in the mitochondrial fraction
of HCT116-TAP cells, validating our use of this cell line for mitochondrial studies. A smaller,
~30kDa protein band was also visible in the mitochondrial fraction, but because a band of similar
size was also detected in the mitochondria of non-tagged HCT116 cells, it likely represents either
a non-specific protein or an endogenous calmodulin binding protein, several of which have been
detected in mitochondria purified from rat liver (120).
Consistent with the immunoblot data, RT-qPCR studies measured the abundance of
mtDNMT1 using primers that distinguish the mitochondrial DNMT1 transcript from total
DNMT1 (Figure 3-17). Primers against human β-actin were used as a normalization control. We
observed no significant difference in the level of mtDNMT1 mRNA between non-tagged
HCT116 and HCT116-TAP cells.

DISCUSSION
Strategy and rationale behind generation of the HCT116 TAP-tagged DNMT1 cell line
The TAP-tagged DNMT1 cell line was originally created as a way to track the
localization and protein-protein interactions of DNMT1 within its respective subcellular
compartments. None of the commercially-available antibodies against DNMT1 gave a clear
picture as to where this protein partitioned within the cell, so having a way to tag and isolate
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Figure 3-17: Quantitation of mtDNMT1-TAP abundance. Total RNA isolated from nontagged HCT116 and HCT116-TAPCre3 cells was used to synthesize cDNA using random
hexamers. RT-qPCR was performed using primers that distinguish the mitochondrial DNMT1
transcript from total DNMT1, as described in Chapter 2. Values were normalized to β-actin, and
represent the average of triplicate samples from a representative experiment, with error bars
signifying the standard deviation about the mean.
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DNMT1 under native conditions became critical for our studies. Additionally, because the
discovery of the mitochondrial isoform of DNMT1 lacked precedent, we needed a way to isolate
mtDNMT1 interacting proteins without any prior knowledge of their identity. On the cutting
edge of research at the time was the use of adeno-associated viral vector technology to generate
human somatic cell knock-outs (115). Leading scientists in the field were reporting higher
targeting frequencies by homologous recombination than ever achieved before. Rather than
knock-out DNMT1, we decided to knock-in a clever configuration of a fusion tag that would
allow us to isolate DNMT1 from is subcellular compartments, in complex with its native binding
partners.
The C-terminus of DNMT1 was chosen for targeting because the precise details of the
transcriptional start site for the mitochondrial targeting sequence upstream of the coding region
for DNMT1 had not been mapped. Furthermore, a C-terminal tag would allow expression of the
DNMT1-TAP fusion protein from its endogenous promoter, and presumably, maintain natural
levels of expression of the tagged allele. As an extra precaution, the targeting construct was
designed to contain a loxP-floxed NeoR selection cassette, so that if it became desirable to
remove the NeoR marker, it could be easily excised by transfection with a plasmid expressing
Cre recombinase.

Unexpected disruption of AUF1 binding and destabilization of the TAP-tagged DNMT1
mRNA
Studies aimed at understanding the level of expression of DNMT1-TAP relative to WT
DNMT1 generated some surprising results. Both RT-qPCR analyses of DNMT1 expression at the
mRNA level (Figure 3-10) and immunoblot analyses of DNMT1 protein levels with two
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different antibodies (Sigma N-terminal DNMT1, Sigma C-terminal DNMT1, Figure 3-9) seemed
to agree that the TAP-tagged DNMT1 allele was highly over-expressed relative to the
endogenous DNMT1 allele. This over-expression was observed despite the fact that the
DNMT1-TAP targeting construct was inserted into the genomic DNMT1 locus so that
expression would be driven by the native DNMT1 promoter and the targeted allele would be
subject to regulation by the same mechanisms as the WT allele. The WT allele in the HCT116TAP cells was expressed at approximately half the level of DNMT1 in the non-tagged HCT116
cells (Figure 3-10), as expected for only one copy of the WT locus (one copy WT DNMT1, one
copy DNMT1-TAP). The data suggested that manipulation of the targeted allele was the cause of
this over-expression. Several reports in the literature described a conserved AU-rich element
located within the 3’UTR of the DNMT1 mRNA that could be bound by a highly-characterized
destablilizing protein, AUF1 (92, 116, 117). When bound by AUF1, the DNMT1 transcript was
targeted for destabilization by the exosome, and turned over rapidly (92). We hypothesized that,
by insertion of the TAP-tag just 200bp upstream of the AUF1 binding site (Figure 3-11), we had
introduced sufficient sequence or secondary structure to disrupt the AUF1-DNMT1 interaction.
Our RNA IP data shows substantial reduction in the association of AUF1 with DNMT1 mRNA
in HCT116-TAP cells (Figure 3-12), suggesting that, by preventing its destabilization, we
induced an accumulation of the DNMT1-TAP transcript, consistent with our RT-qPCR results,
and this increased stabilization resulted in over-expression of the DNMT1-TAP protein, as
evidenced by our immunoblots.
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Snapshots of purified DNMT1-TAP and speculations about other DNMT1 isoforms
In our hands, immunoblots probed with any of the commercially-available DNMT1
antibodies reproducibly demonstrated multiple protein species for DNMT1. Erica Peterson and
Dr. Dolores Arjona, former members of our laboratory, performed numerous experiments aimed
at revealing the true identity of these proteins, and to understand how they changed under various
experimental conditions. We had hoped that, upon generation of a cell line carrying an
endogenously-tagged DNMT1 allele, some of those lingering questions could finally be
answered. Unfortunately, the data we have obtained using the HCT116-TAP cell line has been
complicated to interpret, and in many cases, it has generated more questions than answers. What
does appear to be true is that multiple proteins containing the C-terminal domain of DNMT1 are
immunoreactive with several different DNMT1 antibodies; these proteins are expressed
endogenously and can be purified with the TAP-tag (Figure 3-13, lower panels). Immunoblots of
the purified DNMT1-TAP allele suggest that the only protein species containing both the TAPtag and the N-terminal epitope between amino acids 72-78 is the full-length DNMT1-TAP
protein (Figure 3-14). Taken together, our results are suggestive that these other, smaller proteins
are N-terminally truncated versions of DNMT1, perhaps generated using downstream alternative
translation start sites. We know from the data presented in Chapter 2 that an upstream in-frame
start site is used to generate the mitochondrial isoform of DNMT1 (Figure 2-6). Several other
ATGs in-frame with the published translational start site within the DNMT1 genomic sequence
exist downstream, including ATGs at Exons 21, 25 and 34. An in-frame ATG within Exon 4 of
the DNMT1 coding sequence was thought to be the primary translational start site for many
years (121) until the current site was identified by 5’ RACE (93). Thus, it is not unreasonable to
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hypothesize that other isoforms (122, 123) of DNMT1 may still remain to be characterized, and
their discovery could provide explanation for some of our most intriguing data.

Protein binding partners predicted to have co-purified with DNMT1-TAP
Figure 3-13B (top panel) shows that numerous protein bands were detected in the
purified DNMT1-TAP elution fractions on a silver stained SDS-PAGE gel. These proteins were
predicted to represent multiple species/isoforms of DNMT1, as well as proteins interacting with
these species of DNMT1. Sizes for the most predominant bands could be estimated using the
Alpha Imager molecular weight prediction tool, and speculations were made as to the identity of
these proteins, based on known interactions for DNMT1 in the nucleus (Figure 3-18). A band
migrating at ~95kDa is predicted to be ubiquitin-like with PHD and ring finger domains 1
(UHRF1), a protein described to bind and tether DNMT1 to actively-replicating chromatin,
assisting its faithful maintenance of the DNA methylation profile (79, 124). A protein detected at
~56kDa could be one of four known interacting partners of DNMT1 with that approximate
molecular weight: histone deacetylase 1 (HDAC1), histone deacetylase 2 (HDAC2), DNA
methyltransferase 1 associated protein 1 (DMAP1) or E2F transcription factor 1 (E2F1). Each of
these interactions is thought to serve as a mechanism for recruitment of DNMT1 to replication
foci within dividing cells, where it participates in maintenance methylation of hemi-methylated
DNA (125, 126). A 27kDa protein band is predicted to represent proliferating cell nuclear
antigen (PCNA), which has been shown to function as a clamp that helps to unwind DNA, and
facilitate the methyltransferase activity of DNMT1 on hemi-methylated DNA (127, 128).
Although supported by previous literature, these interactions are only putative; the true identities
of these co-purified proteins remain to be revealed.
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Figure 3-18: Proteins predicted to have co-purified with DNMT1-TAP. A sample of the
TAP-tag purified elution fractions processed by silver stain was used to estimate the molecular
weight of proteins that co-purified in complex with DNMT1-TAP. Predictions were made as to
the identity of these proteins, based on what is known about protein-protein interactions for
DNMT1 in the nucleus. The true identity of these protein partners remains to be tested by
immunoblot.
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Subcellular localization of DNMT1-TAP
Immunoblots of subcellular fractions from non-tagged HCT116 and HCT116-TAP cells
demonstrate that TAP-tagged DNMT1 localizes to the mitochondria. Furthermore, expression of
mtDNMT1-TAP approximates the level of endogenous mtDNMT1 expression, regardless of the
antibody used for detection. We have hypothesized that the smaller protein species detected in
the mitochondrial fractions using either of the Sigma antibodies are products of proteolytic
cleavage of the full-length enzyme, processed upon entry into mitochondria (Chapter 2, Figure 210). It is not uncommon for nuclear-encoded mitochondrial proteins to undergo such
modification upon translocation into the mitochondrial compartment (6, 7, 85). N-terminal
presequences are regularly removed by proteolysis once the imported preprotein enters the
mitochondrial matrix (6). Furthermore, several imported proteins have been shown to serve as
substrates for additional processing by enzymes either bound to the inner membrane, or residing
in the matrix (6). Thus, although the exact composition of the mitochondrial proteins detected at
60kDa (N-terminal antibody) or 30kDa (C-terminal antibody) is not known, it is not
unreasonable to postulate that they could represent smaller forms of DNMT1. Alternatively, they
could represent non-specific proteins that cross-react with the DNMT1 antibodies. In either case,
they are equally expressed in both HCT116-TAP and non-tagged HCT116 cells.

Advantages and disadvantages of using the HCT116 TAP-tagged DNMT1 cell line
One major disadvantage of using the TAP-tag for purification of DNMT1 is the presence
of the CBP domain. Protein recovery using calmodulin-coated beads, as described in the original
TAP procedure for S. cerevisiae (107) was only 50%, while in other mammalian cells the
recovery has been noted to be significantly lower (109, 110). Factors accounting for this could
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include binding of endogenous calmodulin to the CBP-tagged DNMT1, thereby blocking the
CBP site, and preventing its efficient binding to calmodulin-coated beads, or binding of
endogenous CBP directly to calmodulin-coated beads, preventing their interaction with the
tagged DNMT1. This major drawback can potentially be prevented, however, through the
addition of a calcium chelator (EGTA or EDTA) in the first round of purification. This would
help to strip the IgG binding buffer of any available Ca2+ that would allow an unwanted CBPcalmodulin interaction, and the endogenous calmodulin could be washed away and discarded
prior to incubation with calmodulin beads.
Another significant disadvantage for any tagged protein is that the tag itself may disrupt
complex formation, and/or potentially generate false positive interactions. By cleaving off the
larger ProtA domain with TEV protease during the second purification step, this risk is
diminished somewhat, but it is still an issue for consideration. In our case, however, it may be
that the TAP-tag serves as more of a hindrance, limiting import of the DNMT1-TAP protein
through the translocase machinery and into the mitochondrial compartment. In immunoblots
where the WT mtDNMT1 and mtDNMT1-TAP alleles could be resolved, it appears as though
the level of mtDNMT1-TAP protein is slightly under-represented relative to the non-tagged
allele (Figure 3-16A), suggesting that the TAP-tag may prevent import of some mtDNMT1-TAP.
Complete resolvation of the WT and DNMT1-TAP alleles in mitochondrial fractions was
attempted several times on 5% SDS-PAGE gels without success. However, on well-resolved 415% gradient gels, like Figure 3-16A, a doublet could be visualized at ~185kDa, representing
what we believe to be the WT and TAP-tagged DNMT1 alleles. In such instances, signal for the
upper band, signifying the mtDNMT1-TAP allele, was less intense than the lower band,
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representing the WT mtDNMT1 allele. Further experimentation is needed to verify this
observation.
The TAP-tag was chosen for its rapid and efficient recovery of a fusion protein, and its
relative ease of use in small-format purifications. Among its other advantages are that it allows
for the purification of protein complexes in their native context, and because the purification is
performed under mild, non-denaturing conditions, the purified protein is expected to retain
activity. Since we have TAP-tagged the endogenous DNMT1 locus, we have a unique tool for
characterizing the activity and protein-protein interactions that occur at endogenous levels, and
not those that are created nonspecifically or unnaturally due to overexpression of cDNA or the
presence of foreign vector sequences. Additionally, because we have employed an entirely
eukaryotic system by expressing the DNMT1-TAP fusion protein in mammalian cells, it is
subjected to normal regulatory mechanisms and post-translational modifications, which could be
functionally important to DNMT1 (76).
Our data demonstrates that purification of the DNMT1-TAP allele is possible (Figures 313 and 3-14), and that the isolation procedure does not disrupt enzymatic activity of DNMT1
(Figure 3-15). We have also shown that the DNMT1-TAP allele translocates to the mitochondria
(Figure 3-16), and is expressed at near-endogenous levels within this cellular subcompartment
(Figure 3-17). These observations not only validate our use of the HCT116-TAP cell line for
studies examining mitochondrial function, but they also support our use of this unique reagent to
understand what other mitochondrial accessory proteins interact with mtDNMT1 at endogenous
levels.
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Chapter 4: DNA Binding and Enzymatic Activity of Mitochondrial DNMT1

INTRODUCTION
I.

Preferential DNA binding by DNMT1 in the nucleus
DNMT1 has been shown to localize with discrete sites of new DNA synthesis, called

replication foci, in cells undergoing S-phase (72, 129, 130). This association is mediated by a
replication foci targeting sequence (RFTS) located within the N-terminal regulatory domain of
the protein (Figure 3-9A) (72). Its role in faithfully propagating the methylation patterns in a
post-replicative fashion earned DNMT1 the title of “maintenance methyltransferase”.
DNMT1 exhibits a preference for hemi-methylated DNA on the range of 3-50-fold,
depending on the experimental conditions, the length of the DNA substrate, the sequence
context, and the preparation of the enzyme (130-132). However, DNA methylation rates do not
usually correlate with DNA binding affinity or preference of the enzyme; the kinetics of the
methylation reaction catalyzed by DNMT1 is highly dependent on the sequence context and
structure of the substrate. For instance, a target CpG site embedded in a CG-rich context is
methylated more slowly than a target CpG site within an AT-rich sequence (133). Similarly,
single-stranded DNA and double-stranded DNA have remarkable effects on DNMT1 activity. A
single-stranded sequence with one 5mCpG site within a CG-rich sequence can serve as a potent
allosteric inhibitor of DNMT1 activity, whereas the same un-methylated single-stranded CG-rich
sequence is a substrate for DNMT1, but binding affinity and methylation rates are slow (133).
Double-stranded DNAs, however, can support methylation regardless of whether they are un-
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methylated or hemi-methylated, but the binding preference and catalytic activity of DNMT1 is
much higher on double-stranded hemi-methylated DNA substrates (74, 130-133).
At least two specific sites within DNMT1 have DNA-binding abilities: the active site,
within the catalytic domain of the enzyme, and the allosteric (Zn-binding) site, located in the Nterminal regulatory domain (Figure 3-9A). These sites are thought to bind DNA independently,
and the type of DNA bound at each site dictates the progress of enzymatic activity (74). The Nterminal DNA binding domain is thought to suppress de novo methylation, contributing to the
preference of the enzyme toward hemi-methylated DNA, and its role as a maintenance
methyltransferase (74).

II.

Enzymatic activity and mechanism of action for nuclear DNMT1
Methylation of DNA occurs via transfer of a methyl group from a cofactor, S-adenosyl-ʟ-

methionine (SAM), to the C5 position of a target cytosine residue by one of the DNA (cytosine5) methyltransferases. The mechanism can be described as having five steps: 1) binding, 2) baseflipping, 3) covalent catalysis, 4) methyl group transfer, and 5) β-elimination (130, 134, 135).
The schematic shown in Figure 4-1 starts with Step 3 for simplicity. The first step involves
binding of the DNMT to its target CpG site in duplex DNA, which induces base-flipping of the
target cytosine out of the DNA helix. During this step, the cytosine is flipped 180° out of the
DNA helix, and into the active site pocket of the DNMT (136). The thiol group of the Cys
residue within the DNMT ProCys active site forms a covalent thioester bond with the C6
position of the base ring of the target cytosine (134, 135). Methyl group transfer from the
cofactor SAM to the C5 position of the target residue occurs by way of an S N2 nucleophilic
substitution mechanism, and is the rate-limiting step of the sequential reaction. Finally, β-
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Figure 4-1: Mechanism of DNA methylation. DNA methylation involves covalent complex
formation between the target cytosine residue and the sulfhydryl group of the cysteine within the
ProCys active site. The methyl group transfer reaction occurs with the aid of methyl group
donor, S-adenosyl-L-methionine (SAM) (upper right). DNMT1 is released from the 5mCmodified cytosine residue by β-elimination.
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elimination releases the DNMT enzyme from the 5mC-modified base, and S-adenosylhomocysteine (SAH) is yielded as a by-product of the reaction.
Studies by Bestor and Ingram (136) were the first to suggest that DNMT1 operates in a
processive manner. They, and others, have shown that DNMT1 exhibits a higher methylation
rate on DNA of greater length, with levels of processivity nearing 99% on hemimethylated DNA
substrates (131, 137). DNMT1 remains in intimate contact with the target DNA strand as it slides
along, which helps the enzyme maintain its orientation with respect to DNA, as evidenced by its
low frequency of skipping target sites (131, 137).
Interestingly, DNMT1 does not behave according to Michaelis-Menten kinetics (118,
132, 138, 139). Rather, the enzyme is capable of more complex kinetics, whereby DNA can act
as both a substrate for and a regulator of the reaction (138). This observation implies that the Nterminal part of the enzyme influences the catalytic (C-terminal) domain through allosteric
activation, involving two distinct DNA-binding sites, as described above (74, 138, 139). This
coordinated interaction between the N-terminus and C-terminus of DNMT1 simultaneously with
DNA is supported by evidence that expression of the catalytic domain of DNMT1 alone is
incapable of methylating DNA (74). Studies characterizing the allosteric (N-terminal) DNAbinding site uncovered some interesting findings. Deletion of first 580 amino acids within the Nterminal domain has no negative effect on catalytic activity; in fact, expression of an Nterminally truncated protein, lacking the first 501 amino acids, has a 3-10-fold faster catalytic
rate than the full-length enzyme against all DNA substrates tested (139). This suggests that the
enzymatic activity of DNMT1 is tolerant of limited proteolysis to the N-terminus, which we
predict, from data presented in Chapter 2, happens to the mitochondrial isoform of DNMT1 upon
translocation into the organelle.
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III.

Pharmacologic inhibition of total DNMT1 activity
5-aza-cytidine (5-aza-C) and 5-aza-2’-deoxycytidine (5-aza-dC) are nucleoside analogs

of cytidine, containing modifications in the 5 position of the pyrimidine ring (Figure 4-2A) (40).
Both analogs are potent mechanism-based inhibitors of DNA methylation that function by virtue
of their incorporation into DNA (Figure 4-2B). These compounds have been widely used to
induce re-expression of genes silenced by methylation and to stimulate cellular differentiation.
However, because 5-aza-dC is as effective at one-tenth the dose of 5-aza-C, and because 5-aza-C
is considerably more cytotoxic, the deoxy analog is favored as a therapeutic agent (40, 140).
These drugs alter the DNA methylation status of DNA by affecting the expression and
activity of the DNA methyltransferases. There are thought to be two modes of action for 5-azadC on DNMT1: 1) covalent trapping and 2) proteasomal degradation (141). The first mechanism
affects only DNMT1 that is bound by DNA (Figure 4-2B). Modification at the N5 position of an
aza-substituted cytidine residue prevents substitution of CH3 from SAM and β-elimination of the
bound DNMT1 enzyme. Since DNMT1 acts processively, covalent trapping of the enzyme
results in a dramatic decrease in maintenance methylation activity (141, 142). The second
mechanism of action for 5-aza-dC is less understood. The soluble (free) form of DNMT1 is
believed to be the primary target for 5-aza-dC-induced proteasomal degradation, although the
precise mechanisms underlying degradation are not clear (141).

IV.

Objectives
The data presented in Chapter 2 identified a mitochondrial isoform of DNMT1, validated

the existence of 5mC modifications within mtDNA, and suggested that expression of mtDNMT1
induced changes in mitochondrial transcription. Using the analogy of the nucleus, we
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Figure 4-2: Structures of cytidine analogs and mechanism of inhibition of DNMT1 by
covalent trapping. (A) Structures for cytidine and nucleoside analogs 5-azacytidine (5-aza-C)
and 5-aza-2’-deoxycytidine (5-aza-dC) are shown. (B) Mechanism for DNMT1 inhibition by
covalent trapping of the enzyme at 5-aza-C or 5-aza-dC substituted residues.
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hypothesized that mtDNMT1 was functioning as a methyltransferase enzyme, modifying
actively-replicating mtDNA, and in a role secondary to methylation, also ultimately regulating
mitochondrial transcription. Thus, the goal of the studies described below was to provide the
missing link between the observations made in Chapter 2, and determine whether mtDNMT1 is
catalytically active, and therefore capable of generating the 5mC modification in mtDNA.

MATERIALS AND METHODS
Materials
Cell lines, reagents, antibodies and other materials were obtained as described in Chapter
2. Fluorescently-labeled, internally-modified DNA oligos for the DNMT1 enzyme assay were
purchased from Integrated DNA Technologies (IDT, Coralville, IA), and sequences are listed in
Table 4-1. GlaI enzyme (cat # E494) was purchased from SibEnzyme (West Roxbury, MA).
Bacterial CpG methyltransferase M.SssI (cat # M0226L) and recombinant human DNMT1
enzyme (cat # M0230S) were purchased from New England BioLabs (Ipswich, MA).
Fluorescence readings in enzyme assays were measured using a BioRad DNA Engine Peltier
thermal cycler fitted with a Chromo4 Real-Time Fluorescence Detector attachment. Enzyme
assay data was analyzed with Opticon Monitor 3 software.

Methods
Cell culture
HCT116neoS cells and HCT116-TAP cells were grown at 37°C in 5% CO2 and fed RPMI
1640 (Gibco/Invitrogen) medium, supplemented with 10% FBS, 100U/mL Penicillin and
100mg/mL Streptomycin. HEK293 cells were grown at 37°C in 10% CO2 and fed DMEM
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Table 4-1: Sequences for fluorescently-labeled oligos used in enzyme assay and additional
mtIP primers

Species
Human

Primer Set
ND1
ND6
No CpG

Oligo1
Oligo2

Forward

Reverse

Mitochondrial Immunoprecipitation (mtIP)
5'-TGCGAGCAGTAGCCAAACAAT-3'
5'-TGATGGCAGGAGTAATCAGAGG-3'
5'-AAACACTCACCAAGACCTCAACCC-3'
5'-ATTGATTGTTAGCGGTGTGGTCGG-3'
5'-CTGGTGATAGCTGGTTGTCCAAGA-3'
5'-CCTAGTGTCTAAAGAGCTGTTCCT-3'
mtDNMT1 Catalytic Activity Assay
5'-/6-FAM/CCTATGCG/5mC/ATCAGTTTTCTGATG/5mC/G/5mC/ATAGG/BHQ_1/-3'
5'-/6-FAM/CCTATG/5mC/G/5mC/ATCAGTTTTCTGATG/5mC/G/5mC/ATAGG/BHQ_1/-3'
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(Gibco/Invitrogen) medium, supplemented with 10% FBS, 100U/mL Penicillin and 100mg/mL
Streptomycin. Cell cultures were fed every other day, and stock cultures were maintained at
subconfluent cell densities.
For experimental consistency and because DNMT1 is cell-cycle regulated (78, 92) all
cells were treated the same way in the days leading up to an experiment. Cells were fed 48 hrs
prior to harvest, split and seeded 24 hrs prior to harvest, and harvested approximately 24 hrs after
plating to ensure that the vast majority of cells were still in S-phase, and expressing the maximal
level of DNMT1.

Subcellular fractionation and immunoblotting of HCT116-TAP cells
Each subcellular fraction was lysed, quantitated and its constituent proteins were resolved
by SDS-PAGE as described in Chapter 2. Gels were transferred to Immobilon PVDF membranes
using the wet transfer protocol, as described in Chapter 3. An antibody directed against the far Nterminal epitope (amino acids 1-10) of DNMT1 (Abcam, cat # ab16632) was used for subcellular
localization studies because it provided the strongest signal for full-length DNMT1 in the
mitochondrial fraction. Antibodies against compartment-specific markers were used to
demonstrate the purity of each subcellular fraction: VDAC (Sigma) as a mitochondrial marker
and H3K4me3 (Upstate Biotechnology) as a nuclear marker.

Mitochondrial DNA nucleoid extraction
mtDNA nucleoids were isolated from purified mitochondria using an adaptation of the
protocol decribed by Garrido, et al. (8). Mitochondria were isolated from HCT116-TAP cells as
described in Chapter 2. The intact mitochondrial pellet was treated with trypsin (see below)
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before being resuspended in 1.5x NE2 buffer (0.25M sucrose, 20mM Tris-HCl, pH 7.5, 2mM
EDTA, 7mM β-mercaptoethanol and complete protease inhibitors), and diluted with an equal
volume of 0.5X NE2 buffer to a final concentration of 5-7mg/mL of mitochondrial protein.
Mitochondria were lysed by adding 20% NP-40 to a final concentration of 0.5%. 1M Spermidine
(Sigma, cat # S0266) was added to a final concentration of 3mM to bind and precipitate the
mtDNA. Mitochondrial extracts were incubated on ice for 15min to ensure complete lysis, then
split evenly between two 1.5mL microcentrifuge tubes: one for immunoblot analysis, the other
for enzyme assay.

The mitochondrial lysate was sub-fractionated into soluble (“S”) and

insoluble pellet (“P”) fractions by centrifugation at 12,000xg for 20min at 4°C. The soluble (“S”)
supernatants were divided evenly between two clean 1.5mL microcentrifuge tubes. One aliquot
of the “S” fraction was stored as-is at -80°C for immunoblot. The NaCl concentration was
adjusted to 200mM and glycerol was added to 50% of the total volume of the other “S” aliquot.
25µL of SDS lysis buffer (62.5 mM Tris pH 6.8, 5% glycerol, 2% SDS, 5% β-mercaptoethanol,
and 1x complete protease inhibitor cocktail (Roche)) was added to one aliquot of the “P” fraction
for immunoblot analysis. The aliquot of the “P” fraction for enzyme assay was resuspended in
25µL of mtDNMT1 Lysis buffer (50mM Tris-HCl, pH 7.5, 1mM DTT, 1mM EDTA, 5%
glycerol and 0.1% Tween 20, 2x complete protease inhibitor cocktail), and the NaCl
concentration was adjusted to 200mM and glycerol was added to 50% of the total volume.

Mitochondrial DNA immunoprecipitation (mtIP)
Mitochondrial DNA immunoprecipitation was performed using an adaptation of the
protocol described by Lu, et al. (143). The ProtA domain of the TAP-tag was employed to
isolate mtDNMT1-TAP from crosslinked mitochondrial extracts to ask if and where mtDNMT1
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was bound to mtDNA. Mitochondrial extract from non-tagged HCT116 cells was included as a
negative control.
Isolation and cross-linking of mitochondria
Mitochondria were isolated from non-tagged HCT116 and HCT116-TAP cells by dounce
homogenization and differential centrifugation as described in Chapter 2. Mitochondrial pellets
were washed twice with 1mL of mitochondrial homogenization buffer in the presence of
complete protease inhibitors (cOmplete EDTA-free Protease Inhibitor Cocktail tablets, Roche,
cat # 11873580001), and once with 1mL of mitochondrial homogenization buffer in the absence
of protease inhibitors. To washed mitochondrial pellets, Formaldehyde crosslinking solution
(11% formaldehyde, 50mM HEPES, pH 8.0, 100mM NaCl, 1mM EDTA, 0.5mM EGTA) was
added to 1/10th the final volume, and incubated for 15min at 37°C. Cross-linking was terminated
by adding glycine to a final concentration of 125mM and incubating at room temperature for
10min. Crosslinked mitochondria were pelleted by centrifugation at 10,000xg for 5min at 4°C,
and washed once with 1mL of cold 1x PBS, pH 7.4. Mitochondrial pellets were split into two
1.5mL microcentrifuge tubes and re-pelleted by centrifugation, then lysed in 1mL mtIP Lysis
buffer (0.5% Triton X-100, 300mM NaCl, 50mM Tris-HCl, pH 7.4, 100µg/mL leupeptin,
200µM PMSF, complete protease inhibitor cocktail). The mitochondrial lysate was pipeted up
and down several times to mix thoroughly, and incubated on ice for 15min with occasional
inversion of the tubes, to allow complete lysis.
Sonication of mtDNA
The crosslinked mitochondrial DNA was sonicated using the Diagenode Bioruptor water
bath sonicator at the highest pulse, cycling between 30 sec on and 30 sec off, for two rounds
15min each. DNA fragmentation was assessed on a 1% TAE-EtBr agarose gel to verify proper
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shearing to 200-700bps. 10µL of sonicated DNA was run alongside 1µg of unsonicated gDNA.
The total protein concentration contained within the mitochondrial lysates was determined by
Bradford method using a BioRad protein dye (cat # 500-0006), against a standard curve
generated by absorbance values measured for known concentrations of BSA (Fisher, cat #
23210) read at 595nm.
Immunoprecipitation of DNMT1-TAP with IgG beads
IgG sepharose beads (GE Healthcare, cat # 17-0969-01) were pipeted using a 2-200µL
tip with the very end cut off. 125µL of IgG beads were washed with 1mL mtIP lysis buffer in the
absence of complete protease inhibitors three times, spinning at 2000rpm for 2 minutes at 4°C
between washes. Equilibrated IgG beads were resuspended into a 50% bead slurry with mtIP
lysis buffer in the presence of complete protease inhibitors, and 100µL was aliquoted into two
1.5mL microcentrifuge tubes. 750µg of crosslinked mitochondrial lysate from each cell type was
added to the tube containing IgG beads, and incubated at 4°C overnight with end-over-end
rotation.
After overnight incubation, IgG beads were spun down at 2000rpm, for 2min at 4°C, and
the flowthrough supernatant was collected and retained in a separate 1.5mL microcentrifuge tube
labeled “input”. The beads were washed as follows: three times with 1mL of RIPA-140 buffer
(10mM Tris-HCl, pH 8.0, 1% Triton X-100, 0.1% SDS, 0.1% deoxycholate, 1mM EDTA, 1mM
EGTA, 140mM NaCl); three times with 1mL of RIPA-500 buffer (10mM Tris-HCl, pH 8.0, 1%
Triton X-100, 0.1% SDS, 0.1% deoxycholate, 1mM EDTA, 1mM EGTA, 500mM NaCl); three
times with 1mL of LiCl buffer (10mM Tris-HCl, pH 8.0, 0.25M LiCl, 0.5% NP-40, 0.5%
deoxycholate, 1mM EDTA); and twice with 1mL of TE buffer (10mM Tris-HCl, pH 8.0, 1mM
EDTA), pelleting the beads by centrifugation at 2000rpm for 2min at 4°C between each wash.
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200µL TE buffer containing 0.5% SDS was added to all tubes and the samples were incubated at
65°C overnight to reverse the crosslinks.
DNA purification
After the reversal of crosslinks, IgG beads were pelleted by centrifugation at 2000rpm for
2min at 4°C. This time, the supernatant contains the immunoprecipitated material, released from
the beads after reversing the crosslinks, so the supernatant from each sample was collected and
retained. DNA was precipitated by adding 1/10th the total volume of 3M NaOAc, 20µg UltraPure
glycogen (Invitrogen, cat # 10814010) and 2-3 volumes of 100% ethanol. Tubes were mixed
well by vortexing, and stored at -80°C for approximately 2hrs. The DNA was pelleted by
centrifugation at 13,000xg for 15min at room temperature. Pelleted material was washed once
with 1mL 70% ethanol and the pellets were allowed to air dry on the benchtop for approximately
10-15min. DNA pellets were resuspended in 200µL of HPLC H2O containing 50µg/mL RNase
A (Sigma, cat # R5503-100MG) and incubated at 37°C for 1hr. 100µg/mL of Proteinase K
(20mg/mL stock, Bioline, cat # BIO-37037) was added to each tube, along with 10% SDS to a
final concentration of 0.25%, and samples were vortexed and quickspun to mix thoroughly.
Samples were incubated at 37°C overnight to degrade all proteins present.
After overnight incubation, the DNA was subjected to Phenol/Chloroform extraction
twice, followed by chloroform/isoamyl alcohol extraction and ethanol precipitation with
UltraPure glycogen, as described in Chapter 2. Precipitated DNA pellets were washed once with
1mL of 70% ethanol, and resuspended in 50µL of 10mM Tris, pH 8.0. DNA samples were
incubated at 37°C for approximately one hour to help solubilize the pellets.
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qPCR with mitochondrial-specific primers
Input DNA samples were quantitated on the NanoDrop spectrophotometer and diluted to
make 100µL working stocks of 10ng/µL, 1ng/µL and 0.1ng/µL each to be used as a standard
curve. Endpoint PCR was used to confirm that the experiment worked by demonstrating a clear
difference in band intensity for products representing a specific interaction with mtDNA over
non-specific or negative controls. Endpoint PCR was performed using HotStarTaq Plus Master
Mix (Qiagen, cat # 203645), the mtIP3 primer set (Table 4-1) and 1µL of immunoprecipitated
DNA from each sample. PCR products were visualized on a 1% TAE-EtBr agarose gel by UV
transillumination. Quantitative PCR was performed to quantitate the difference between a
specific mtDNMT1-mtDNA interaction over signal from non-specific background. 25µL
reactions were prepared using Quantitect SYBR Green PCR Mastermix, 0.6µM of each
mitochondrial-specific primer (Table 4-1) and 1µL of immunoprecipitated DNA, and tubes were
tapped to mix and quickspun to collect all contents at the bottom of the tube. qPCR was
performed using BioRad Peltier thermal cyclers, with PCR cycling conditions specific to each
primer set (Table 4-1). Reactions were run in triplicate and reported dilution values averaged to
obtain the mean and standard deviation.

Preparation of whole cell and purified nuclear enzyme samples
Approximately 45x106 HCT116-TAP cells were washed twice with ice-cold 1x PBS, pH
7.4 and harvested by scraping. 5% of the whole cell pellet was resuspended in mtDNMT1 Lysis
buffer (50mM Tris-HCl, pH 7.5, 1mM DTT, 1mM EDTA, 5% glycerol and 0.1% Tween 20),
NaCl was added to 200mM final concentration, and glycerol was added to 50% of the total
volume.
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Nuclei were isolated from the nuclear/unbroken cell pellet obtained after dounce
homogenization during mitochondrial isolation, as described in Chapter 2. The nuclear/unbroken
cell pellet was resuspended in 3mL of Buffer S1 (10mM KCl, 10mM HEPES, pH 7.5, 10mM
MgCl2, 10% glycerol, 0.25M sucrose, 0.1% Triton X-100, 1mM DTT, 5µg/mL aprotinin,
5µg/mL leupeptin, 5µg/mL pepstatin, 1mM PMSF, 1mM sodium orthovanadate, and 5mM NaF)
and overlaid on top of 3mL of Buffer S3 (10mM KCl, 10mM HEPES, pH 7.5, 0.5mM MgCl2,
10% glycerol, 0.88M sucrose, 0.1% Triton X-100, 1mM DTT, 5µg/mL aprotinin, 5µg/mL
leupeptin, 5µg/mL pepstatin, 1mM PMSF, 1mM sodium orthovanadate, and 5mM NaF) in a
15mL conical tube. Nuclei were pelleted by centrifugation at 3000rpm in the Beckman J6-MI
centrifuge for 15min at 4°C. The nuclear pellet was washed once with 1mL Buffer S3 and
divided evenly between two tubes. The nuclear sample in one tube was pelleted, weighed and
resuspended in 10x the pellet weight in SDS lysis buffer (62.5 mM Tris pH 6.8, 5% glycerol, 2%
SDS, 5% β-mercaptoethanol, and 1x complete protease inhibitor cocktail (Roche)). The other
nuclear sample was pelleted, resuspended in mtDNMT1 Lysis buffer, the NaCl concentration
was adjusted to 200mM and glycerol was added to 50% of the total volume.

Preparation of mitochondrial DNMT1 enzymes
The storage conditions for purified mitochondrial DNMT1 enzyme preparations were
modeled after the recombinant hDNMT1 enzyme (New England BioLabs, cat # M0230S). All
mitochondrial DNMT1 enzymes were stored at -20°C as 50% glycerol stocks in 50mM TrisHCl, pH 7.5, 200mM NaCl, 1mM DTT, 1mM EDTA and 0.1% Tween 20, in the presence of
complete protease inhibitors.
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Crude mitochondrial extracts
Crude mitochondria were prepared as described in Chapter 2. Mitochondrial pellets were
lysed in mtDNMT1 Lysis buffer (50mM Tris-HCl, pH 7.5, 1mM DTT, 1mM EDTA, 5%
glycerol and 0.1% Tween 20) in the presence of complete protease inhibitors. Prior to storage,
the NaCl concentration was adjusted to 200mM, and glycerol was added to 50% of the total
volume. Enzymes were stored at -20°C until analyzed by enzyme assay.
Percoll-purified mitochondrial extracts
Percoll-purified mitochondrial extracts were prepared as described in Chapter 2. These
highly-purified mitochondrial pellets were lysed and stored as described above for crude
mitochondrial enzymes.
Trypsin treatment of intact mitochondria
Mitochondria were isolated from HCT116 cells by dounce homogenization and
differential centrifugation as described in Chapter 2. The crude intact mitochondrial pellet was
washed twice with 1mL of mitochondrial homogenization buffer in the presence of complete
protease inhibitors (Roche), and pelleted by centrifugation at 10,000xg for 10 minutes at 4°C
after each wash. The mitochondrial pellet was washed once with 1mL of mitochondrial
homogenization buffer in the absence of protease inhibitors, and resuspended in Trypsin
Digestion buffer (10mM HEPES-KOH, pH 7.4, 250mM sucrose, 0.5mM EGTA, 2mM EDTA,
1mM DTT) in a volume 20x the pellet weight. Trypsin-EDTA (Gibco, cat # 25200-056, stock
concentration: 100µg/mL, diluted in 1x PBS, pH 7.4), was added to achieve a final concentration
of 10µg/mL, and samples were incubated at room temperature for 20 minutes with occasional
inversion to mix the tube contents. Bovine trypsin inhibitor (Sigma, cat # T0256, stock
concentration: 1mg/mL) was added to a final concentration of 10µg/mL, tubes were inverted
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several times to mix, and incubated on ice for approximately 10 minutes. Intact mitochondria
were pelleted by centrifugation at 10,000xg for 10 minutes at 4°C, and washed twice more with
1mL of mitochondrial homogenization buffer, this time in the presence of both complete
protease inhibitors, and 10µg/mL bovine trypsin inhibitor. Washed mitochondrial pellet was
weighed and lysed in a volume of SDS Lysis Buffer 10x the pellet weight.
IgG capture of mtDNMT1-TAP
mtDNMT1-TAP was isolated from crude and/or trypsin-treated mitochondrial extracts
using IgG beads to selectively bind the ProtA domain of the TAP-tag. Trypsin-treated
mitochondrial pellets were resuspended in 0.5mL of mtDNMT1 Lysis buffer and sonicated using
a Diagenode Bioruptor water bath sonicator at the highest pulse for 2.5min, cycling between 5sec
on and 5sec off. Sonicated lysate was incubated on ice for 15min to ensure complete lysis.
The MgCl2 concentration was adjusted to 10mM final concentration, which is optimal for
the AgeI restriction endonuclease. 5U of AgeI enzyme (New England BioLabs, cat # R0552S)
was added to the mitochondrial lysate and incubated at 37°C for 20min to digest mtDNA and
make the mtDNMT1-TAP enzyme more available for capture by IgG beads.
50µL of IgG beads were pipeted using a 2-200µL tip with the end cut off, and washed
three times with 200µL of mtDNMT1 lysis buffer, each time pelleting the beads by
centrifugation at 250xg for 2min at 4°C. Washed and equilibrated beads were resuspended into a
50% slurry with 50µL of mtDNMT1 lysis buffer. 50µL of IgG bead slurry was added to the
15mL conical tube containing mitochondrial lysate, and the tube was incubated at 4°C overnight
with end-over-end rotation.
After overnight incubation, IgG beads were pelleted by centrifugation at 300xg for 3min
at 4°C. 1mL of the unbound flowthrough was collected in a 1.5mL microcentrifuge tube and
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stored for analysis. IgG beads containing bound mtDNMT1-TAP were washed three times with
0.5mL mtDNMT1 Lysis buffer, each time incubating for 10min at 4°C with end-over-end
rotation, and spinning at 300xg for 3min at 4°C. During the last wash, the lysate was split evenly
between two 1.5mL microcentrifuge tubes, one for immunoblot analysis, the other for enzyme
assay. The aliquot for immunoblot analysis was spun to pellet the beads, and 25µL of SDS lysis
buffer was added. The aliquot for enzyme assay was also spun to collect the beads; 25µL of
mtDNMT1 Lysis buffer was added, and the NaCl concentration was adjusted to 200mM and
glycerol was added to 50% of the total volume.
TAP-tag purification of mtDNMT1-TAP
HCT116-TAP cells grown at approximately 75% confluence (~15x106 cells per dish) in
sixty 150mm dishes were harvested by scraping. Mitochondria were isolated as described in
Chapter 2. Mitochondrial pellets were lysed with 1mL of mtDNMT1 Lysis Buffer, then pooled
into a 50mL plastic beaker, and the total volume was adjusted to 15mL with mtDNMT1 Lysis
buffer. The mitochondrial lysate was sonicated using a Misonix Sonicator 3000 fitted with the
probe attachment, cycling between 1sec on, 5sec off, for a total of 25 cycles. The lysate was
incubated on ice for 15min to ensure complete lysis. The 15mL total lysate volume was divided
evenly between two 15mL conical tubes (~7.5mL each) for immunoprecipitation.
125µL of IgG beads were pipeted using a 2-200µL tip with the end cut off, and washed
three times with 250µL of mtDNMT1 lysis buffer, each time pelleting the beads by
centrifugation at 250xg for 2min at 4°C. Washed and equilibrated beads were resuspended into a
50% slurry with 125µL of mtDNMT1 lysis buffer. 100µL of bead slurry was added to each of
two 15mL conical tubes containing the mitochondrial lysate, and the tubes were incubated
overnight at 4°C with end-over-end rotation.
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1x TEV buffer was prepared as described in Chapter 3. Following overnight incubation
with IgG beads, the beads were pelleted by centrifugation at 250xg for 2min at 4°C.
Approximately 1mL of the unbound flowthrough was collected and retained for analysis. IgG
beads were transferred to a 1.5mL microcentrifuge tube and washed three times with 1mL of
mtDNMT1 Lysis buffer, each time pelleting the beads at 250xg for 2min at 4°C. The beads were
then washed three times with 0.5mL 1x TEV buffer, spinning at 250xg for 2min at 4°C inbetween each wash.
Washed IgG beads were resuspended in 300µL of 1x TEV buffer, and 100U (10µL) of
AcTEV Protease (Invitrogen, cat # 12575015) was added to the tube. The reaction was incubated
at room temperature for 2.5hrs, rotating end-over-end. After 2.5hrs, the reaction was spiked with
50U (5µL) additional AcTEV Protease enzyme. The TEV cleavage reaction was allowed to
proceed overnight at 4°C with end-over-end rotation to permit complete cleavage of bound
mtDNMT1-TAP from the IgG beads.
After overnight incubation in the presence of AcTEV Protease, the IgG beads were
pelleted by centrifugation at 250xg for 2min at 4°C. The supernatant, containing the cleaved
mtDNMT1-TAP, was transferred to a clean 1.5mL microcentrifuge tube. The concentrations of
EDTA and NaCl within the 1x TEV buffer were adjusted to more closely match the storage
conditions for the recombinant hDNMT1 enzyme (1mM EDTA, 200mM NaCl, respectively),
and glycerol was added to 50% of the total volume. IgG beads containing residual (uncleaved)
bound material were boiled in SDS Lysis buffer for 5min, pelleted by centrifugation, and the
supernatant was collected and saved for analysis.
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mtDNMT1 catalytic activity assay
Using the fluorescence-based enzymatic assay described by Wood, et al. (144) as a
model, we developed and optimized a similar assay compatible with the Chromo4 fluorescence
detection system fitted on our BioRad Real-Time PCR machines. A schematic diagram of the
assay is shown in Figure 4-3.
All enzyme assays were prepared in a total volume of 100µL, consisting of 10mM TrisHCl, pH 7.5, 5mM MgCl2, 1mM DTT, 5% glycerol, 0.1mg/mL BSA, 25-100mM NaCl and 01mM S-adenosylmethionine (SAM). Two stocks of Buffer A were prepared and aliquoted for
these experiments: one stock of Buffer A-25, containing 25mM NaCl, and Buffer A-100, which
contains 100mM NaCl. Fresh stocks of 1x SEB Buffer (SIBEnzyme, 10mM Tris-HCl, pH 8.5,
5mM MgCl2, 10mM NaCl, 1mM β-mercaptoethanol), 0.8U/µL GlaI in 1x SEB Buffer, 1mM
SAM, as well as Oligo1 and Oligo2 (various concentrations) were made before each reaction
was assembled.
All reactions were run in duplicate, using low-profile, white PCR strips (BioRad, cat #
TLS0851), sealed with flat cap strips (BioRad, cat # TCS0803). Reaction tubes were quickspun
using the 96-well plate rotor in the Beckman J2-HC centrifuge to collect all contents at the
bottom of the tubes. A BioRad Peltier Thermal Cycler was pre-warmed to 37°C prior to loading
reactions into the machine. The length of reactions ranged from 1-6hrs, with fluorescence
readings taken every 1min.
Oligo design
Two fluorescently-labeled oligo probes (hemi-methylated Oligo1 and fully-methylated
Oligo2) were designed that are identical except for a single methylation site at an internal CpG
(Table 4-1). Both oligos were labeled at their 5’ end with the fluorescein fluorophore 6-FAM and
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Figure 4-3: Schematic diagram of fluorescence-based assay for methyltransferase activity.
Oligos 1 and 2 are fluorescently-labeled at the 5’ end with the fluoroscein fluorophore 6-FAM,
and at the 3’ end with BlackHole Quencher 1 (BHQ1). The oligos form a hairpin, locking the
fluorophore moiety in close proximity with the quencher, preventing fluorescence. Within the
hairpin structure is a stretch of duplex DNA containing a single methylation site (CpG). When an
active methyltransferase is incubated with the hemi-methylated Oligo1, it becomes methylated to
form Oligo 2, which is the optimal substrate for GlaI restriction endonuclease. Cleavage by GlaI
releases the fluorophore from the quencher, resulting in an increase in fluorescence that is
directly proportional to methylation activity.
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at the 3’ end with Black Hole Quencher 1 (BHQ1). Because the excitation/emission wavelengths
for the 6-FAM fluorophore mimic that of SYBR Green dye used in qPCRs, the fluorescence
could be measured on our real-time PCR machine.
Assay validation and optimal conditions
The fully-methylated Oligo2 was used as a positive control, to determine the optimal
concentration of Oligo and GlaI enzyme needed to stay within the linear range of DNMT1
activity. Oligo2 calibration curves were prepared with 0mM SAM, +/- 1U GlaI, Buffer A-100
and a range of Oligo2 concentrations between 0-20nM.
Selectivity of GlaI enzyme between Oligo1 (non-optimal) and Oligo2 (optimal)
substrates was measured in duplicate 100µL reactions, with 50µM SAM, 2.4U GlaI, Buffer A100 and Oligo1 concentrations between 0.028-1µM. An identical range of concentrations was
tested for Oligo2, in duplicate 100µL reactions containing 50µM SAM, 0.05U GlaI and Buffer
A-100.
Non-specific GlaI cleavage of the hemi-methylated Oligo1 substrate was measured in
duplicate 100µL reactions, with 50µM SAM, 0.8U GlaI, +/- 10nM M.SssI, Buffer A-100 and
Oligo1 concentrations between 0.13-0.6µM. All validation assays were incubated at 37°C for
1hr, with fluorescence readings taken every 1min.
Methylation activity using recombinant methyltransferases
M.SssI
Kinetic analysis of M.SssI methylation activity was performed using Oligo1
concentrations ranging from 0.078-0.6µM, in 100µL reactions containing 50µM SAM, 0.8U
GlaI, 10nM M.SssI, and Buffer A-100. Reactions were incubated for 2hrs at 37°C, with
fluorescence readings taken every 1min.
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Recombinant hDNMT1
Kinetic analysis of recombinant hDNMT1 methylation activity was performed using
Oligo1 concentrations ranging from 30-240nM, in 100µL reactions containing 1mM SAM,
100µ/mL BSA, 0.8U GlaI, 2.8nM hDNMT1, and Buffer A-25. Reactions were incubated for
2hrs at 37°C, with fluorescence readings taken every 1min.
Methylation activity of mitochondrial DNMT1 enzymes
Mitochondrial enzyme preparations were quantitated by Bradford assay, against a
standard curve of known concentrations of BSA read spectrophotometrically at 595nm. Between
0.5-2µg of total mitochondrial lysate was used as the source of mtDNMT1 enzyme when lysates
could be quantitated. When protein concentrations were too low to be quantitated accurately, a
fixed volume (5-10µL) of mitochondrial enzyme was added to each reaction.
All mitochondrial DNMT1 enzyme preparations were assayed in duplicate 100µL
reactions containing the following: 1mM SAM, 0.8U GlaI, 240nM Oligo1 and Buffer A-25.
Reactions were incubated at 37°C for 3-6hrs, with fluorescence readings taken every 1min.

Manipulation of mtDNMT1 activity and mtDNA methylation
Treatment with 5-aza-2’-deoxycytidine (5-aza-dC)
HCT116-TAP cells were grown at approximately 50-60% confluence in two 150mm
dishes for each condition, per timepoint. Cells were treated with 3µM 5-aza-dC 24hrs after
plating, and harvested at 24, 48 and 72hrs after the first 5-aza-dC treatment. Fresh growth
medium (RPMI 1640 supplemented with 10% FBS, 100U/mL Penicillin and 100mg/mL
Streptomycin) containing fresh drug (3µM 5-aza-dC) was replenished each day. 5-aza-dC
treatment was ceased after 48hrs. Cells were harvested from both 150mm dishes per condition at
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each timepoint and pooled. Mitochondria were isolated as described in Chapter 2, mitochondrial
pellets were further subjected to trypsin treatment and mtDNA nucleoid extraction, as described
above. Sub-mitochondrial fractions were divided evenly between two 1.5mL microcentrifuge
tubes: one half for analysis by immunoblot, the other half for analysis in an enzymatic assay.
SDS-PAGE and immunoblotting of sub-fractionated mitochondrial extracts
Protein concentrations of “S” and “P” fractions collected from 5-aza-dC-treated
mitochondria were determined by Bradford assay, but because the total protein concentrations in
these samples was so low, the maximal volume (25µL) of each sample was loaded onto 4-15%
gradient SDS-PAGE gels for analysis by immunoblot, as described previously.
Methylation activity of sub-fractionated mitochondrial extracts
Again, because the total protein concentrations for “S” and “P” enzyme preparations for
were so low, a fixed volume (5-10µL) of each sample was used as the enzyme source in
mtDNMT1 catalytic activity assays, as described above.
“S” and “P” enzyme preparations from 5-aza-dC-treated mitochondria were kept in a
small enough volume that they could be quantitated by Bradford assay, so a fixed 2.0µg of each
fraction was added to those enzyme activity assays (Figure 4-12 B, C, D).

RESULTS
GlaI activity against Oligo1 and Oligo2
A fluorescently-labeled DNA oligo (Oligo1, Figure 4-3) was designed lacking
methylation at a single CpG site, such that a single methylation event by an active
methyltransferase would result in the separation of fluorophore and and quencher, and could be
directly measured as an increase in fluorescence. A second oligo (Oligo2), identical in sequence,
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but with all four CpG sites pre-modified by 5mC, contains the optimal restriction site for GlaI
(5’-GCMGCM-3’). The tetra-methylated Oligo2 allowed us to optimize the conditions of the
assay to work with our fluorescence detection method prior to testing any enzyme samples.
To first assess whether the assay was working in our hands, a calibration curve was run to
measure GlaI cleavage across increasing concentrations of the fully-methylated Oligo2 substrate.
No DNA methyltransferase was needed in these reactions. Endpoint fluorescence values,
representing GlaI cleavage of Oligo2, were measured across a range of Oligo2 concentrations
(6.33-20nM). Fluorescence units per unit of GlaI (AU/U) were fitted to a linear function, and the
goodness of fit was calculated at R2 = 0.9685 (Figure 4-4A).
The selectivity of GlaI between sequences containing either fully-methylated (Oligo2) or
hemi-methylated (Oligo1) target restriction sites was measured across various concentrations of
either substrate (Figure 4-4B). No methyltransferase was added to these reactions, as we
intended to assess just the activity of GlaI against each of the DNA substrates. Reported
fluorescence values over time were used to calculate the rate of GlaI cleavage against either
Oligo1 (using a maximal 2.4U GlaI per reaction), or Oligo2 (using only 0.05U GlaI per
reaction). To obtain a stringent assessment of how GlaI behaves with both oligo substrates, these
reactions were biased in favor of non-specific cleavage by adding nearly 50 times more GlaI to
the reactions with the hemi-methylated Oligo1. This gave us confidence that the levels of
unwanted Oligo1 cleavage we would be detecting in later mitochondrial enzyme assays using
only 0.8U GlaI per reaction was minimal, and would not interfere with our activity
measurements. The initial rates for both sets of reactions were graphed along oligo concentration
(Figure 4-4B), and show that with 0.05U GlaI the reaction is only linear across 0.028-0.13µM
concentrations of Oligo2, and quickly becomes saturated by substrate at Oligo2 concentrations
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Figure 4-4: Validation of fluorescence-based enzymatic assay and quantitation of nonspecific GlaI cleavage. (A) A calibration curve with increasing amounts of the fully-methylated
Oligo2 was used to examine the efficiency of GlaI cleavage. Initial methylation rates (AU/U
GlaI/min) were graphed over substrate concentration, and demonstrate strong linearity with R2 =
0.9685. (B) GlaI activity against Oligo1 and Oligo2 were compared. Initial rates of methylation
(AU/U GlaI/min) were plotted across substrate concentration. GlaI cleavage of Oligo2 was as
much as 26-fold higher than cleavage of Oligo1.
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above that. GlaI activity against the non-optimal Oligo1 substrate is linear throughout the entire
range of concentrations, however, the rate is well below (by as much as 26-fold) the level of GlaI
activity against Oligo 2.
Wood, et al. (144) determined 0.8U GlaI per 100µL reaction to be the optimal
concentration of GlaI in standard enzyme assays, so this is the amount of GlaI used in all of our
analyses, unless otherwise mentioned. They also determined that 240nM Oligo1 was the optimal
substrate concentration for the kinetic analysis of the commercially-available recombinant
DNMT1 enzyme (144), so this is the amount of Oligo1 used in all of our analyses, unless
otherwise mentioned.
To get a more accurate measurement for the level of background signal we could expect
using the conditions chosen for our mitochondrial DNMT enzyme assays, we measured GlaI
activity across a range of Oligo1 concentrations (0.13-0.6µM) in both the presence and absence
of an active methyltransferase enzyme (M.SssI). The rates were calculated for both reactions, and
are shown in Table 4-2. The levels of GlaI activity generated by non-specific cleavage of the
hemi-methylated Oligo1 in the absence of M.SssI accounted for less than 10% of the total assay
signal achieved with M.SssI (Table 4-2), and was less than levels reported by Wood, et al. (144).
Together, this data demonstrates that GlaI exhibits a strong preference for a fully-methylated
DNA substrate, and non-specific cleavage of Oligo1 should not impact the quality of our enzyme
assay results.
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Table 4-2: Non-specific cleavage of the hemi-methylated Oligo1 by GlaI enzyme

Concentration
of Oligo1 (µM)
0.13
0.22
0.36
0.6

Methylation Rate
(AU/U GlaI/min)
Positive
Negative
Control
Control
(+M.SssI)
(-M.SssI)
0.0006
-0.0006
0.0069
0.0006
0.0075
0.0000
0.0256
0.0025
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%
Background
Cleavage
-100.00
9.09
0.00
9.76

Methylation activity of M.SssI and recombinant hDNMT1 enzymes is linear across
substrate concentration and time
The activities of a two well-characterized CpG methyltransferases were measured using
the fluorescence-based enzymatic assay across a range of Oligo1 concentrations. Plotting the
steady-state rates for both M.SssI and recombinant hDNMT1 against the concentration of Oligo1
shows a proportional linear increase in rate for both enzymes. The dependence of recombinant
hDNMT1 activity on the concentration of Oligo1 substrate is shown in Figure 4-5A, and
demonstrates a strong fit to a linear function (R2 = 0.9918). Similarly, the effect of Oligo1
concentration on the activity of M.SssI is shown in Figure 4-5B, and also demonstrates strong
linearity (R2 = 0.9995). In addition, Figure 4-5C shows that methylation by M.SssI is linear over
time. The observations that both of these enzymes exhibit a linear increase in the rate of
methylation as a function of substrate concentration is important because it indicates that we
have neither saturated nor limited either enzyme (GlaI or DNMT1/M.SssI), allowing the
reactions to proceed maximally.
Furthermore, as these are coupled reactions, measuring the rates of two separate enzymes
(DNMT and GlaI), it is important to note that we observed no “lag phase” in fluorescence prior
to reaching the linear steady-state of reaction, as Wood, et al. (144) described. This indicates that
GlaI cleavage of the oligo substrate is immediate, and that the reported fluorescence values can
be taken to represent true steady-state methylation rates, not rates of GlaI activity.
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Figure 4-5: Kinetic analyses of M.SssI and recombinant hDNMT1 positive control enzymes.
(A) Methylation activity for the recombinant human DNMT1 enzyme is also strongly linear over
a range of Oligo1 concentrations, with R2 = 0.9918. (B) Methylation activity for the bacterial
M.SssI methyltransferase was measured relative to Oligo1 concentration, and is strongly linear
with R2 = 0.9995. (C) Methylation activity for 4U of the bacterial M.SssI enzyme was plotted
over time and also exhibits linearity.
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Methyltransferase activity from whole cells and purified nuclei is linear over time
The methyltransferase activity of a 1:100 dilution of whole cell extract was measured and
exhibits a linear increase in GlaI cleavage over time (Figure 4-6A). This indicated that the
storage and assay conditions we had chosen worked well, not only for purified enzymes
purchased from New England BioLabs, but also for enzymes that we prepared in-house. To get
an estimate for the level of DNA methyltransferase activity found in purified nuclei, and to
approximate the levels we might expect from purified mitochondrial extracts based on previous
calculations that mtDNMT1 only represents 1-2% of total DNMT1 in the cell, we measured
dilutions of our nuclear enzyme preparations. Purified nuclei demonstrated methyltransferase
activity that was linear over time, and proportional to the amount of total nuclear extract assayed
(Figure 4-6B).

mtDNMT1 localizes to the insoluble, mtDNA-containing sub-mitochondrial pellet
To observe where mtDNMT1 partitions within the mitochondrial compartment, trypsintreated mitochondria were sub-fractionated into soluble (“S”) and insoluble pellet (“P”) fractions
using a protocol adapted from Garrido, et al. (8). An aliquot (75µg) of whole cell lysate and
18µg of each: mitochondrial, S and P sub-fractions were resolved on a 4-15% gradient gel by
SDS-PAGE (Figure 4-7A). The membrane was probed with control antibodies to VDAC and
H3K4me3 to demonstrate the purity of each fraction, and with an antibody to DNMT1 to track
its sub-mitochondrial localization. At first glance, it is clear that full-length DNMT1 is detected
in total mitochondrial extract (M), and both the soluble (S) and insoluble (P) fractions. However,
we examined the relative proportion of mtDNMT1 present in either sub-mitochondrial fraction
semi-quantitatively, with the hope of gaining insight into how this protein exists in mitochondrial
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Figure 4-6: Methyltransferase activity assays with whole cell and purified nuclear extracts.
Enzyme preparations from whole cells (A) and purified nuclei (B) were diluted to approximate
levels of mitochondrial DNMT activity, based on previous estimates that mtDNMT1 represents
only 1-2% of the total DNMT1 within a cell. Using standard assay conditions (0.8U/well GlaI
and 240nM Oligo1), both whole cell and purified nuclear enzymes demonstrate linear
methyltransferase activity as a function of time.

203

Figure 4-7: mtDNMT1 partitions with the insoluble mtDNA-containing pellet. (A)
Mitochondrial DNA nucleoids were isolated as described by Garrido, et al. (21) to determine
where mtDNMT1 partitions on a sub-mitochondrial level. The soluble (free) supernatant was
separated from the insoluble pellet, which contains mtDNA and mtDNA binding proteins. Using
an antibody to DNMT1, mtDNMT1 was seen to localize with both soluble “S” and insoluble “P”
fractions. Densitometric readings of the immunoblot with protein concentrations determined by
Bradford assay allowed calculation of the relative proportion of mtDNMT1 in each submitochondrial fraction: 89.3% of mtDNMT1 is soluble; 10.7% of mtDNMT1 is insoluble. (B)
Both soluble and insoluble forms of mtDNMT1 exhibit catalytic activity in vitro. Values
represent fluorescence readings normalized to the relative proportion of mtDNMT1 in each
fraction, as determined by densitometry of the immunoblot in (A).
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space, and what levels of methylation activity we might expect from an enzyme that is predicted
to be bound to mtDNA. In Figure 4-7A, the protein loaded in the first two lanes represents 75µg
of whole cell lysate (W) and 18µg of trypsin-treated mitochondrial lysate (M), respectively,
which is standard for all of our subcellular fractionation immunoblots. The S and P lanes were
also loaded with 18µg of the total protein collected for either fraction, but this amount of total
protein is disproportionate between the two fractions, and this impacts our interpretation of the
relative levels of soluble versus insoluble mtDNMT1. The protein loaded in lane “S” represents
only 5% of the total S fraction collected, and only 0.33% of the total mitochondrial protein.
However, lane “P” represents 51% of the entire insoluble pellet, and 0.91% of the total
mitochondrial protein. Using densitometric readings of the signals detected for DNMT1 in either
lane, the relative amount of mtDNMT1 in the soluble fraction was calculated to be 89.3%,
whereas only 10.7% of mtDNMT1 partitioned with mtDNA. So, despite a more intense signal
for mtDNMT1 in the P fraction, the vast majority of mtDNMT1 was soluble and freely available
to bind mtDNA, or participate in some other, unknown function. Enzyme assays were run using
S and P samples, and as shown in Figure 4-7B, enzymes extracted from both soluble and
insoluble mitochondrial pools contain active methyltransferase. Fluorescence readings were
normalized to the relative proportion of mtDNMT1 within each sub-mitochondrial fraction, and
show that the form of mtDNMT1 purified bound to mtDNA exhibits slightly greater activity than
the soluble form.

mtDNMT1 binds mtDNA in a manner that is proportional to CpG density
Data presented in Chapter 3 clearly demonstrated that the DNMT1-TAP allele
translocates properly to the mitochondrial compartment. Data presented in Figure 4-6A showed
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that mtDNMT1 co-localizes with the insoluble mitochondrial pellet containing mtDNA. We
therefore asked whether mtDNMT1 binds to mtDNA in order to understand the function of
mtDNMT1. The HCT116-TAP cell line was an ideal tool for asking whether mtDNMT1
interacted with mtDNA.
Using an adaptation of a mitochondrial DNA immunoprecipitation protocol described by
Lu, et al. (143), we exploited the DNMT1-TAP allele and employed IgG beads to selectively
bind the ProtA domain of the TAP-tag. Formaldehyde-crosslinked mitochondrial lysates were
immunoprecipitated with IgG beads and qPCR with primers specific for mtDNA (Table 2-2) was
used to quantitate the interaction between mtDNMT1 and mtDNA. Immunoprecipitates from
HCT116-TAP

cells

were

substantially

enriched

for

mtDNA

in

comparison

with

immunoprecipitates from non-tagged parental HCT116 cells, except for an amplicon containing
no CpG dinucleotides, which gave an equally low signal from both cell lines (Figure 4-8). These
data suggest a CpG-dependent interaction between mtDNMT1 and the mitochondrial genome,
and confirm the localization of this protein to the mitochondrial matrix. The mtDNMT1-mtDNA
interaction was evident in the D-loop control region, which carries the mitochondrial origin of
replication and promoters, as well as in several rRNA and protein coding regions. The level of
enrichment was dependent on the target amplicon; five of the six regions probed showed a threeto five-fold enrichment of mtDNA sequences in immunoprecipitated material from HCT116TAP cells, compared to control. However, qPCR of the region spanning the junction between
12S and 16S rRNA genes (primer set 2) showed only a two-fold enrichment in binding of
mtDNMT1-TAP. Interestingly the density of CpG dinucleotides within this amplicon is less than
50% of that in all other amplicons analyzed, suggesting that the interaction of mtDNMT1 with
mtDNA is proportional to CpG density.

206

Figure 4-8: mtDNMT1 specifically binds mtDNA in a manner that is proportional to CpG
density. mtDNMT1-TAP interacts specifically with various regions along mtDNA. Nonspecific
background was assessed using mitochondrial lysates from non-tagged HCT116 cells.
Enrichment of mtDNA in immunoprecipitates from each cell type was measured against a
standard curve of purified mtDNA, and represent absolute values. Bars represent the mean +/SD of six replicate samples from two independent experiments.
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Highly purified mitochondrial extracts exhibit CpG-specific methyltransferase activity in
vitro
Mitochondrial extracts, both crude and Percoll-purified preparations, as well as the TAPtag purified mtDNMT1 enzyme were assayed for methyltransferase activity using 240nM
Oligo1. Enzyme activity in mitochondrial lysates (0.5µg) was linear with time for the duration of
the assay, as measured by GlaI cleavage in fluorescence units (AU) (Figure 4-9A). Linearity of
the reactions over time indicates that the reactions progressed maximally, without limitation by
substrate concentration. The curves for both crude and Percoll-purified mitochondrial extracts
are not remarkably different, suggesting a high degree of purity for our “crude” preparations.
Because Percoll purification is regarded as the “gold standard” for isolation of pure
mitochondria, the observation that DNA methyltransferase activity in Percoll-purified
mitochondrial lysates is not substantially different from crude mitochondrial DNMT activity
indicates that the enzyme preparations are similar in purity. The TAP-tag purified mtDNMT1
enzyme also exhibited a linear increase in methylation activity over time; however, the rate for
this reaction (0.0083 AU/U GlaI/min) was roughly half that for Percoll-purified total
mitochondrial lysate (0.0194 AU/U GlaI/min). All enzyme preparations demonstrated
methyltransferase activity that was also linear as a function of enzyme concentration (Figure 49B, C).

mtDNMT1 activity in intact mitochondria is resistant to trypsin treatment
To address concerns that the methylation activity measured from our purified
mitochondrial extracts might be nuclear in origin, the intact mitochondrial pellet isolated from
non-tagged HCT116 cells was subjected to trypsin digestion, or a mock treatment as described

208

Figure 4-9: Enzyme assays detect CpG-specific methyltransferase activity in highlypurified mitochondrial extracts. (A) 0.5µg of crude or Percoll-purified mitochondrial extracts,
along with 0.5µg of TAP-tag purified mtDNMT1-TAP enzyme were assayed for methylation
activity using the coupled fluorescence-based enzymatic assay shown in Figure 4-3.
Fluorescence values (AU) were graphed relative to time, are linear for the duration of the assay,
and represent substantial methylation activity over the boiled enzyme negative control. (B, C)
Catalytic activity was also linear with enzyme concentration. Values for crude and Percollpurified enzymes were separated from the TAP-tag purified mtDNMT1-TAP enzyme for clarity.
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by Szczesny, et al. (145) prior to lysis. Whole cell lysate (75µg) and 18µg of each mitochondrial
lysate were resolved on a 4-15% gradient gel by SDS-PAGE. The membrane was probed with an
antibody to VDAC as a loading control, and an H3K4me3 antibody to demonstrate the purity of
mitochondrial fractions (Figure 4-10A). An N-terminal DNMT1 antibody showed that, although
signal decreased in mock and trypsin-treated mitochondria, DNMT1 could be still easily
detected. The continued presence of DNMT1 in mitochondrial extracts following trypsin
treatment confirmed its presence within the mitochondrial compartment.
Enzyme preparations were made from the trypsin-treated mitochondrial extracts, and
methylation activity was measured for equivalent total protein from each sample relative to time.
While there were only subtle differences in activity from untreated, mock and trypsin-treated
mitochondria, a sample of mitochondrial extract that was digested with trypsin after lysis showed
only background levels of activity (Figure 4-10B).

Mitochondrial extracts from non-tagged and TAP-tagged HCT116 cells demonstrate
nearly identical levels of methyltransferase activity
Given the data from Chapter 3, suggesting that total DNMT1-TAP is overexpressed in
the HCT116-TAP cells, we wanted to verify that we were not misrepresenting the level of
methylation activity in mitochondria by using the HCT116-TAP cell line. Thus, we directly
compared the activities of various amounts of either non-tagged or TAP-tagged mitochondrial
extracts over time. As shown in Figure 4-11, there is very little difference in the methylation
activity of mitochondria from non-tagged and TAP-tagged HCT116 cells. This data also suggests
that the TAP-tag is not interfering with activity of the mtDNMT1-TAP allele.
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Figure 4-10: Trypsin treatment of intact mitochondria does not affect mtDNMT1 enzyme
activity. (A) Immunoblots show the continued presence of full-length DNMT1 in mitochondria
subjected to trypsin digestion. VDAC was used as a loading control; H3K4me3 demonstrates
purity from contaminating nuclear material. (B) Methylation activity from 2µg of each enzyme
preparation was graphed over time, and show only minimal differences in the activity from
untreated, mock and trypsin-treated mitochondria.
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Figure 4-11: Non-tagged and TAP-tagged HCT116s exhibit nearly identical mitochondrial
methyltransferase activity. Mitochondria from non-tagged and TAP-tagged HCT116 cells were
assayed for methylation activity. (A) Fluorescence values (AU) were graphed over time (A) or
enzyme amount (B) at 30min. No substantial differences in catalytic activity were observed for
different concentrations of mitochondrial lysate from either cell type.
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IgG Capture is highly specific for the mtDNMT1-TAP allele
The specificity of the TAP-tag ProtA-IgG bead interaction was assessed by comparing
the enzyme activity within immunoprecipitated material from either non-tagged or TAP-tagged
HCT116 mitochondrial lysates, incubated with IgG beads. The level of nonspecific methylation
seen in immunoprecipitates from the non-tagged HCT116 cells is barely above the Boiled
enzyme negative control, while that for immunoprecipitated material from the TAP-tagged cells
is substantially greater (Figure 4-12). This suggests that IgG beads both specifically and
selectively bind the TAP-tag, allowing isolation of a functional mtDNMT1-TAP allele.

Restriction digest of mtDNA allows for capture of more mtDNMT1 protein without a
corresponding increase in mtDNMT1 activity
Trypsin-treated mitochondrial extracts were incubated with AgeI restriction endonuclease
to digest mtDNA that might be bound to mtDNMT1; a property we hypothesized was preventing
efficient capture and enzymatic analysis of the mtDNMT1 enzyme in previous experiments
(Figure 4-9). AgeI was chosen for the relatively high frequency of recognition sites within the
mitochondrial genome. Because the protein concentration for the AgeI IgG-captured sample was
below the limits of detection by Bradford assay, the maximum volume (25µL) of that sample
was loaded onto a 4-15% SDS-PAGE gel, alongside 18µg of either untreated or trypsin-treated
mitochondrial lysate. Immunoblot analysis using an antibody to DNMT1 shows a strong signal
for mtDNMT1 in all three mitochondrial extracts (Figure 4-13A). The intensity of the protein
band visible in lane 3, representing mtDNMT1-TAP captured on IgG beads after AgeI digest of
mtDNA, is substantially stronger than we have obtained using the IgG capture technique alone,
without its prior digestion. This suggests that mtDNMT1-TAP exists tightly bound to mtDNA,
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Figure 4-12: Specificity of IgG capture for the mtDNMT1-TAP allele. Mitochondria were
isolated from non-tagged and TAP-tagged HCT116 cells and immunoprecipitated with IgG
sepharose beads, which selectively bind the ProtA domain of the TAP-tag. A boiled enzyme
negative control measured background fluorescence. Non-specific binding between IgG beads
and mitochondrial lysate from non-tagged HCT116 cells showed only minimal levels of
methylation activity. The substantially greater methylation activity in immunoprecipitates from
HCT116-TAP cells demonstrates that IgG beads are selective for isolating the TAP-tag.
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Figure 4-13: AgeI digest of mtDNA allows greater recovery of mtDNMT1-TAP protein, but
no increase in enzyme activity. (A) Immunoblot of mitochondrial fractions from HCT116-TAP
cells, showing high level of mtDNMT1 in sample subjected to AgeI digestion and IgG capture of
the TAP-tag. The stronger signal in lane 3 demonstrates enrichment for mtDNMT1-TAP in that
sample. (B) Despite increased recovery of the mtDNMT1-TAP protein with AgeI digestion of
mtDNA, equal volumes (5µL) of the purified mtDNMT1-TAP enzyme showed no increase in
methyltransferase activity.
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and that enzymatic cleavage of mtDNA makes the TAP-tag epitope more available for binding
by IgG beads, allowing greater recovery of the protein. However, enzyme assays comparing the
activities of IgG captured mtDNMT1-TAP that had either been treated with AgeI or not showed
no substantial difference in methyltransferase activity (Figure 4-13B). This indicates that,
although digestion of mtDNA allows for a greater recovery of mtDNMT1-TAP, it does not
enhance its methyltransferase activity in vitro.

5-aza-dC inhibits mtDNMT1 expression and activity in vivo
To gain a better understanding of the role DNA methyltransferase activity plays in
mitochondria, we wanted to attempt to manipulate the level of DNMT1 protein and thus,
DNMT1 activity, in the mitochondria. 5-aza-dC has been shown to be a potent inhibitor of DNA
methylation in the nucleus, so we examined its efficacy on mitochondrial DNMT1. HCT116TAP cells were grown in the presence of the DNMT1 inhibitor, 5-aza-dC, for a total of 48hrs.
Cells were harvested and fractionated into whole cell and mitochondrial extracts at both 24hr and
48hr timepoints after treatment, and untreated cells were harvested at 24hrs as a control. Whole
cell and mitochondrial lysates were separated by SDS-PAGE on 4-15% gradient gels and probed
with antibodies to VDAC as a loading control, and H3K4me3 to demonstrate the absence of
contaminating nuclear material in the mitochondrial fractions. As shown in Figure 4-14 (top
panel), there is a dramatic reduction in DNMT1 protein in whole cell lysates from 5-aza-dCtreated cells relative to control, and this phenomenon occurs as early as 24hrs post-treatment.
Densitometry readings estimate an approximate 80-90% reduction in full-length DNMT1 seen in
whole cells treated with the DNMT1 inhibitor. Upon higher exposure, the effect of 5-aza-dC on
mtDNMT1 expression can be visualized (Figure 4-14, middle panel). It is evident that, while 5-
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Figure 4-14: Treatment of cultured cells with 5-aza-dC dramatically reduces mtDNMT1
protein. (A) Immunoblots of fractionated HCT116 cells treated with 5-aza-dC for 24 or 48hrs
show a striking reduction in DNMT1 expression in whole cell lysates, and a modest ~50%
reduction in mtDNMT1 protein. VDAC was used as a loading control; H3K4me3 demonstrates
the purity of mitochondrial lysates.
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aza-dC induces a clear reduction in mtDNMT1 protein, it is not as potent of an inhibitor in the
mitochondrial compartment (~50% reduction in mtDNMT1),
Based on the differential susceptibilities of chromatin-bound and soluble DNMT1 to
treatment with 5-aza-dC in the nucleus (141), we postulated that mtDNMT1 might also respond
differently to inhibition based on its sub-mitochondrial localization. Therefore we isolated
mitochondria from HCT116-TAP cells that had been grown in the presence of 3µM 5-aza-dC for
a total of 48 hours. Cells were harvested at 24hr, 48hr and 72hr timepoints after the first
exposure to 5-aza-dC to extend our analyses from above. Mitochondria were trypsin-treated, subfractionated into S and P fractions and assayed for enzymatic activity under standard conditions.
DNA methyltransferase activity from total mitochondrial extracts appeared to be remarkably
resistant to the inhibitory effects of 5-aza-dC (Figure 4-15A). However, methylation activity in S
and P sub-mitochondrial fractions was modestly affected by 5-aza-dC (Figure 4-15B, C and
Table 4-3). At both 24hr and 48hr timepoints, 5-aza-dC-treated S fractions showed little change
in methylation activity, relative to the untreated control (Figure 4-15B). By 72hrs, however, a
noticeable decrease in DNA methyltransferase activity could be seen in the S fraction of 5-azadC-treated cells, compared to control. The insoluble, mtDNA-bound form of mtDNMT1 was
affected at an earlier timepoint than the soluble form. Methyltransferase activity in 5-aza-dCtreated P fractions decreased at 24hr and 48hr timepoints, but appeared to rebound slightly by
72hrs (Figure 4-15C, Table 4-3). This dynamic difference in response to 5-aza-dC treatment
implies that while mtDNMT1 activity was affected within the first 48hrs, cessation of 5-aza-dC
treatment after this timepoint allowed mtDNA-bound DNA methyltransferase to recover and
resume more normal methylation activity by 72hrs.
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Figure 4-15: Treatment of cultured cells with 5-aza-dC differentially affects mtDNMT1
activity. Total mitochondrial extracts were prepared from untreated control and 5-aza-dC-treated
HCT116-TAP cells at 24, 48, and 72hrs after the first exposure to 5-aza-dC. (A) DNA
methyltransferase activity in total mitochondrial extracts appears resistant to the inhibitory
effects of 5-aza-dC. (B) Soluble mitochondrial extracts show no substantial 5-aza-dC-induced
inhibition of activity through 48hrs. By 72hrs, a modest decrease in DNMT activity can be seen
as a result of the drug. (C) The insoluble mitochondrial pellet shows more immediate decreases
in methyltransferase activity of cells treated with 5-aza-dC for 24 and 48hrs, but by 72hrs the
inhibitory effects of 5-aza-dC have worn-off, as methyltransferase activity shows a partial
recovery by 72hrs. All assays run using standard conditions (0.8U/well GlaI, 240nM Oligo1).
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Table 4-3: Rates of DNA methylation in sub-fractionated mitochondria, isolated from 5aza-dC-treated cells

Total M
S
P

CTRL
0.0150
0.0101
0.0111

24
0.0159
0.0111
0.0098
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5-aza-dC
48
-0.0120
0.0083

72
0.0155
0.0090
0.0095

DISCUSSION
Interaction between mtDNMT1 and mtDNA
Approaching these studies, we hypothesized that mtDNMT1 is functioning in
mitochondria much like it does in the nucleus, which if true, would require its interaction with
mtDNA. Data from our mitochondrial DNA immunoprecipitation (mtIP) experiments showed
that mtDNMT1-TAP indeed binds to various regions of the mitochondrial genome, however this
interaction alone was not enough to prove that it was responsible for methylating mtDNA.
Without further information, it could have been speculated that perhaps mtDNMT1 was
functioning as a scaffold protein, much like TFAM, which is thought to coat the mitochondrial
genome, and assist in unwinding of the mtDNA for better accessibility by the transcriptional
machinery (10, 12, 14). It is known that DNMT1 can bind a number of DNA molecules that
cannot support methylation, including poly(G) and poly(dG)-poly(dC), among others (130).
However, the observation that mtDNMT1 differentially binds specific regions within mtDNA in
proportion to their CpG content was more indicative of the protein’s function in DNA
modification. Because cytosines in the context of CpG dinucleotides are the major sites for DNA
methylation in mammals, the relative level of mtDNMT1 binding at regions containing these
sites was of particular importance. Since the mitochondrial genome does not contain clusters of
CpG dinucleotides surrounding gene promoters, termed “CpG islands”, we speculate that
methylation at even a single CpG could impact mitochondrial transcription of the gene housing
that site.
Perhaps even more interesting, our data shows that mtDNMT1 binds to the D-loop
control region of mtDNA (Figure 4-8), which is extensively modified by both 5mC and 5hmC
residues (Figure 2-3). This region carries the promoters driving transcription initiation of both
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heavy and light strands, and represents the assembly site for transcription initiation complexes.
The interaction detected between this region and mtDNMT1 further supports a role for
mtDNMT1 in directly regulating mitochondrial gene expression, and/or mtDNA replication.

Sub-mitochondrial localization of mtDNMT1
Studies by Patel, et al. (141) showing differential partitioning of DNMT1 in the nucleus
prompted us to investigate whether mtDNMT1 might also exist in two separate pools, and if so,
what relative percentage can be considered “bound” versus “free”. Although they gave no
estimates as to the proportions of nuclear DNMT1 that are chromatin-bound versus free, Patel, et
al. (141) stated that the majority of DNMT1 exists within the nucleus in soluble form, which is
precisely what we observed in the mitochondria. Utilizing Bradford assay protein quantitations
in combination with densitometry to estimate the relative signal for DNMT1 in each fraction on
an immunoblot, we can predict that over 8-fold more DNMT1 is soluble and freely available for
methylation in the mitochondria, relative to the amount of DNMT1 bound to mtDNA. This may
seem counterintuitive for the majority of DNMT1, an enzyme that functions by tightly
associating with and modifying DNA, to exist naturally in a state free from DNA. However, a
complete understanding of its role in the mitochondria has not yet been realized. It could be that
mtDNMT1 not engaged in methylation serves other non-enzymatic functions, such as indirectly
influencing the structure of mtDNA or participating in other protein complexes critical to
mitochondrial function. In any case, our data suggests that the mitochondrial compartment
contains considerably more DNMT1 than it needs for methylation of mtDNA alone.
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Why is the methylation activity for the TAP-purified mtDNMT1 enzyme so low in
comparison to other samples of reduced purity?
Holding constant the total amount of protein put into each assay, we expected to see the
greatest methyltransferase activity from the enzyme preparation with the highest proportion of
that total protein represented by mtDNMT1 (the TAP Purif mtDNMT1 sample) (Figure 4-9). It
was quite puzzling to observe the opposite effect. At least part of the difference seen in
methylation activity between the TAP-purified mtDNMT1 and either the crude or Percollpurified preparations can be attributed to the fact that only the activity of the mtDNMT1-TAP
allele is being measured in the TAP Purif mtDNMT1 sample. If both alleles are expressed
equally, then we would expect to see only 50% the level of activity from a single purified
DNMT1-TAP allele, compared to two alleles of WT DNMT1. In the crude and Percoll-purified
mitochondrial preparations, both copies of mtDNMT1 (WT and mtDNMT1-TAP) are
contributing to the assay signal.
However, these results raise a number of other concerns. They could suggest problems
with regard to the stability of the purified protein; perhaps the enzyme is unstable in the storage
buffer or under the reaction conditions we have chosen. Both the reaction and storage conditions
we used are identical to the recommended conditions for the recombinant hDNMT1 enzyme, as
described by New England BioLabs. However, these conditions were adapted from cytosolic
conditions, and the mitochondrial environment may be quite different with regard to ionic
strength and pH, among other factors. Perhaps the mtDNMT1-TAP enzyme would be more
functional in reaction conditions that more closely mimic the mitochondria.
Although the entire TAP-tag purification is performed under mild conditions, it is
possible that we are purifying the enzyme away from a cofactor or protein binding partner that is
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required for more efficient methylation. Since the Crude and Percoll-purified preparations
represent total mitochondrial lysate, the necessary factors or accessory proteins would be present
to assist with methylation activity in those samples.
It is also possible that restriction endonucleases exist within mitochondria that target a
recognition sequence within our fluorescently-labeled oligo substrate, generating an artificially
high signal in those reactions. If this is true, then any enzyme preparation made from total
mitochondrial lysate (either crude or Percoll-purified) would be affected by active endonuclease
activity, which could be misinterpreted as methyltransferase activity. It would also suggest that
the signal we detect for either our TAP-purified mtDNMT1 enzyme or the IgG Captured enzyme
represents the true methylation activity for mtDNMT1, and the “activity” from total
mitochondrial extracts is falsely represented.
Another consideration is that perhaps we are isolating mtDNMT1-TAP that is still so
tightly bound to mtDNA it will not release it to bind the artificial Oligo1 substrate. Attempts to
digest the mtDNA, either by AgeI restriction endonuclease or DNase I allowed for capture of
more mtDNMT1 protein, as visualized by immunoblot, but no increase in the methylation
activity of IgG-captured mtDNMT1-TAP enzyme (Figure 4-12). Likewise, incubation in a highsalt-containing buffer, to strip any bound mtDNA away aided in our efforts to purify mtDNMT1TAP, but the purified enzyme demonstrated no further increase in methylation activity.
It is possible that mtDNMT1 is not the only methyltransferase being assayed in the crude
and Percoll-purified mitochondrial extracts. We showed in Chapter 2 that neither of the de novo
methyltransferases, DNMT3a and DNMT3b, could be detected in highly purified mitochondrial
lysates, and we know from bioinformatics analyses that neither of these enzymes contains an
obvious mitochondrial targeting sequence. However, we have not rigorously excluded their
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possible presence in mitochondria. It is possible that either or both of these enzymes has a
mitochondrial counterpart, and could be contributing to the assay signal we see from whole
mitochondrial extracts. One characteristic of the enzyme assay used to measure mitochondrial
methylation activity is that it employs a hemi-methylated oligo substrate, which is highly
preferred (3-50-fold) over un-methylated DNA substrates by the maintenance enzyme, DNMT1
(131, 132). Therefore, we would not expect either DNMT3a or DNMT3b to exhibit a substantial
level of methyltransferase activity on an unfavorable template. However, if both de novo and
maintenance DNMT enzymes are involved in mtDNA methylation, then it is possible that they
share redundant functions and coordinate methylation of DNA substrates as they do in the
nucleus.

Pharmacologic inhibition of mtDNMT1 activity
Early studies with the nucleoside analog 5-aza-2’-deoxycytidine (5-aza-dC) demonstrated
that treatment of cells with this compound led to a loss of extractable DNA methyltransferase
activity (142). Data described throughout this Chapter consistently demonstrated the presence of
methyltransferase activity within mitochondria, although the exact details of the mechanism of
mtDNA methylation have not been elucidated. We hypothesized that by examining the 5-azadC-mediated inhibition of mtDNMT1 we may gain a better perspective of how the enzyme
functioned under non-inhibitory conditions.
The success of this experiment was based on a couple of assumptions: first, that 5-aza-dC
can gain access to the mitochondria, and second, that 5-aza-dC can be phosphorylated and
become incorporated into mtDNA. It was not unreasonable to assume either, as mitochondria are
capable of replication and repair of their own DNA. As our data shows, 5-aza-dC effectively
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reduces the amount of mtDNMT1 protein seen by immunoblot, although not nearly to the same
extent as its effect on total DNMT1 in whole cells (Figure 4-14).
There are thought to be two mechanisms of action for 5-aza-dC in the nucleus: 1)
covalent trapping of the DNA-bound form of DNMT1, and 2) proteasomal degradation of the
free form of DNMT1 (141). A recent study described differential effects of 5-aza-dC based on
whether the enzyme was soluble or insoluble in the nucleus (141). The majority of DNMT1 was
found to be soluble and more susceptible to degradation than the chromatin-bound form.
A sub-fractionation of mitochondria demonstrated that active mtDNMT1 is found in two
separate pools within the mitochondrial compartment: the soluble fraction, and the insoluble
mtDNA-bound fraction (Figure 4-7). We extended these findings to our 5-aza-dC studies, to see
if the state of mtDNMT1 affected its susceptibility to inhibition by 5-aza-dC. Surprisingly,
although there was a clear effect on mtDNMT1 protein following exposure of cells to 5-aza-dC,
the effect on methyltransferase activity could not be observed by looking at total mitochondrial
extracts (Figure 4-15A). Inhibition of DNMT activity by 5-aza-dC was only apparent after
separating the mtDNA-bound and soluble forms of mtDNMT1 (Figure 4-15 B, C and Table 4-3).
Interestingly, the soluble (S) and insoluble (P) forms of mtDNMT1 responded somewhat
differently to treatment with 5-aza-dC, which may suggest two possible mechanisms of action
for 5-aza-dC in the mitochondria as well as the nucleus. The S fraction exhibited an effect at a
later timepoint than the P fraction, as a reduction in activity was not observed until 72hrs after
the first exposure. In contrast, the effect of 5-aza-dC on mtDNA-bound mtDNMT1 was more
immediate, with noticeable decreases at 24 and 48hrs post-treatment, whereas by 72hrs after the
first exposure, methylation activity seemed to be rebounding to more normal levels. Overall, it
was evident that, although 5-aza-dC did appear to induce differential effects on mtDNMT1
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activity dependent on whether the enzyme was bound to mtDNA or freely soluble, the drug was
not nearly as efficient in mitochondria as it was in the nucleus. This could be representative of
the compound’s low-level incorporation into mtDNA, or the overall low levels of methylation
activity within mitochondria. In any case, we cannot conclude that 5-aza-dC would be a useful
tool for inducing changes in either the mtDNA methylation profile or the mitochondrial
transcription program.
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Chapter 5: Perspectives

I.

Summary
Cytosine methylation of mitochondrial DNA (mtDNA) was first described several

decades ago, but neither the mechanism generating this modification nor its functional
significance was known. Using MeDIP analyses, we show that mtDNA contains not only 5methylcytosine (5mC), but also 5-hydroxymethylcytosine (5hmC), suggesting that previous
reports likely underestimated the degree of epigenetic modification within the mitochondrial
genome. As the mitochondrial genome does not encode its own methyltransferase, we questioned
whether a nuclear-encoded enzyme might be responsible for initiating these modifications. We
found that an isoform of the most abundant mammalian methyltransferase, DNA
methyltransferase 1 (DNMT1) translocates to mitochondria, driven by an in-frame mitochondrial
targeting sequence (MTS) located upstream of the nuclear DNMT1 translational start site. This
MTS is highly conserved across mammalian species, and directs GFP to the mitochondria. Using
a gene targeting approach, we inserted a tandem affinity purification (TAP) tag into the
endogenous locus of a single human DNMT1 allele by homologus recombination. We have used
this cell line to show that mtDNMT1 specifically binds mtDNA in a manner that is proportional
to CpG density, and that mtDNMT1 exhibits CpG-specific methyltransferase activity in vitro.
Mitochondrial DNMT1 is resistant to trypsin-treatment of intact mitochondria, but susceptible to
pharmacologic inhibition by the nucleoside analog 5-aza-2’-deoxycytidine (5-aza-dC).
Mitochondrial DNMT1 is also responsive to a number of factors known to be intimately
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involved in mitochondrial function. NRF1 and PGC1α, transcription factors that activate nuclearencoded mitochondrial proteins in response to oxidative stress, up-regulate expression of
mtDNMT1. Loss of p53, a tumor suppressor gene known to help control mitochondrial
metabolism, also results in a striking increase in mtDNMT1 expression, and this up-regulation of
mtDNMT1 appears to modify mitochondrial transcription in a gene-specific fashion. Our data
suggests roles for mtDNMT1 in both the establishment and maintenance of cytosine methylation,
which we propose is involved in the regulation of mitochondrial transcription.

II.

Potential utility of the DNMT1-TAP cell line
We generated a unique cell line that carries a TAP tag fused to the C-terminus of a single

endogenous human DNMT1 allele. We opted to target the genomic DNMT1 locus, rather than
ectopically express a tagged cDNA construct, to avoid issues of overexpression from an
unnatural promoter, and artifactual interactions or off-target effects as a consequence of such
overexpression. The DNMT1-TAP targeting construct was designed against the C-terminus to
allow for expression of the TAP-tagged allele under control of its native promoter and in an
endogenous context. Among our reasons for creating the HCT116-TAP cell line using this
approach was to have an endogenously-expressed DNMT1-TAP allele that could easily be
tracked to its subcellular compartments using an antibody specific for the TAP-tag, instead of the
commercially-available antibodies for DNMT1, which are somewhat promiscuous and
consistently generate complicated patterns of multiple protein bands. We also desired a system
whereby we could isolate DNMT1-TAP from its subcellular compartments and ask questions
regarding its methyltransferase activity and its protein-protein interactions without any prior
knowledge as to their identity. The strategy we chose to generate the HCT116-TAP cell line has
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been used successfully by several groups, to tag and isolate a variety of proteins in both yeast
and mammalian cells (107, 108, 113, 114), and has proven an enormously useful tool in
understanding the functions and protein partners of those proteins. Thus, we were confident that
a DNMT1-TAP allele would be a valuable reagent for our studies on mitochondrial DNMT1,
and has already been used in a number of applications to determine mtDNA binding and
catalytic activity of mtDNMT1.
However, a potential complication in any experiments that analyze the function or
interactions of nuclear DNMT1 is our observation that the DNMT1-TAP allele is expressed at
levels 6-8-fold higher than the WT allele at the mRNA level, and DNMT1-TAP appears to be
up-regulated at the protein level with two commonly-used DNMT1 antibodies. If this overexpression is not simply an artifact of the antibodies used, then the over-expression of DNMT1
could severely impact the utility of this cell line in determining protein-protein interactions both
qualitatively, due to a risk of false-positive or artificial interactions, and quantitatively by
disrupting normal stoichiometric ratios of protein complex components. The HCT116-TAP cell
line was derived from human colon carcinoma cells, so it exists as a tumor cell line already,
which has been shown to exhibit over-expression of DNMT1 and contain regions of
hypermethylation (81, 82). In addition to the characteristics of the parental cells, the DNMT1TAP allele may be expressed as much as 6-8-fold over the WT allele, thus likely exacerbating
the already aberrant levels of DNMT1 and methylation within this cell line.
However, the mitochondrial form of DNMT1-TAP does not appear to be overexpressed
relative to WT DNMT1 at either steady-state protein or mRNA levels (Figures 3-16 and 3-17),
and mitochondria from HCT116-TAP cells demonstrate rates of methyltransferase activity
comparable to non-tagged HCT116 cells (Figure 4-11). Thus, while the HCT116-TAP cell line

230

may only cautiously be used to examine factors influencing DNMT1 in whole cells or nuclei, it
should be an invaluable reagent for understanding the function, protein-protein interactions, and
post-translational modifications of DNMT1 in the mitochondrial compartment, as discussed
below.
Among the distinct advantages of the HCT116-TAP cell line is that it allows for
purification of proteins in native complex with DNMT1-TAP. This can be done from whole
cells, as shown in Chapter 3 (Figures 3-12 and 3-18), or the analysis can be reduced to focus on
protein-protein interactions within a particular sub-cellular compartment, such as the nucleus or
the mitochondria. We attempted to purify mtDNMT1-TAP from isolates of highly purified
mitochondria and recovered a sufficient amount of mtDNMT1-TAP to analyze by enzymatic
assay, but we observed a poor recovery of the full-length protein after TAP-tag purification or
IgG Capture, as only a faint band could be visualized by immunoblot with a DNMT1 antibody or
silver stain (Figure 5-1). We determined that we can use restriction enzyme digestion and/or
DNaseI treatment of mtDNA to capture more full-length mtDNMT1-TAP in an
immunoprecipitation with IgG beads (Figure 4-12A). Thus, these methods can be used to pulldown mtDNMT1-TAP and begin to ask what other proteins co-purify with it. TAP-tag
purification, in combination with non-biased mass spectrometry (MS) or direct immunoblotting
experiments with antibodies to proteins presumed to interact, can be a powerful tool to identify
interacting protein partners of mtDNMT1-TAP.
Likely candidates for interacting partners include TFAM, POLG and mTERF1, which
could all be involved in complexes with mtDNMT1 at sites of mtDNA replication and active
transcription. Antibodies against all three proteins have been validated for application in both
immunoblot and immunoprecipitation experiments. The mTERF1 antibody, in particular, could
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Figure 5-1: TAP-tag purification of mtDNMT1-TAP. (A) Purification fractions were resolved
on a 4-15% gradient SDS-PAGE gel, and protein bands were visualized by silver stain. Only a
faint band is visible for full-length mtDNMT1 at ~185kDa (red arrow) in lane 5 for the purified
elution fraction, indicating poor yield of the purified mtDNMT1-TAP. (B) Immunoblots of
purification fractions probed with an N-DNMT1 antibody only faintly detect full-length
mtDNMT1 in the purified elution fraction (lane 5). Antibodies to compartment-specific markers
were used to demonstrate the purity of subcellular fractions: VDAC, mitochondrial marker;
tubulin, cytosolic marker; H3K4me3, nuclear marker.
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be used to start teasing apart the gene-specific effects observed in mitochondrial transcription
upon over-expression of mtDNMT1. A co-immunoprecipitated sample of mtDNMT1-TAP
pulled-down with IgG beads or the TAP-tag antibody could be resolved by SDS-PAGE and
probed with the mTERF1 antibody to observe if an interaction is first present in a situation where
mtDNMT1 is not overexpressed. Then, experiments to perturb the mTERF1-mtDNMT1
interaction with analyses of downstream mitochondrial transcriptional effects can be performed
as described in more detail below, in a proposed model for transcriptional control in
mitochondria. Similarly, co-immunoprecipitation experiments with the TFAM antibody could
further implicate mtDNMT1 as being involved in transcription, and extend the correlative
observations we made in Chapter 2. However, an association with TFAM could also suggest that
mtDNMT1 is involved in overall mtDNA architecture, influencing the structural unwinding of
mtDNA during transcription, as a role secondary to its methylation activity. If an interaction with
POLG were detected, it could suggest a replicative function for mtDNMT1 through participation
with a mtDNA replication complex, or simply, that it associates with sites of active mtDNA
synthesis as a consequence of its methyltransferase activity, much like it has been shown to
localize to replication foci in nuclear chromatin.
As an extension of the studies proposed above, the DNMT1-TAP allele purified from
both whole cells and within mitochondria was shown in Chapters 3 and 4 to exhibit catalytic
activity in vitro. This is a critical observation, because it implies that this cell line can be used to
examine factors that may influence methyltransferase activity, in either the nuclear or
mitochondrial compartments. Although the activity of DNMT1 in vivo is thought to require
assistance from accessory proteins, such as UHRF1, to localize properly to hemi-methylated
CpG sites within DNA for methylation fidelity, in vitro enzymatic reactions seem to proceed
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normally in the absence of these factors. Thus, using an in vitro system to draw conclusions
about how methylation occurs in an in vivo context might lead one to conclude that DNMT1 is
capable of methylating DNA on its own. However, among some of the most puzzling data
discussed throughout this dissertation was the observation that a highly purified preparation of
mtDNMT1-TAP enzyme exhibits lower activity than total mitochondrial extracts against the
same hemi-methylated DNA substrate. Attempts to make the mtDNMT1-TAP allele more
available and to strip away any bound mtDNA for higher recovery of activity proved futile.
Thus, it is possible that a protein binding partner or other co-factor, removed during purification,
might be necessary for more efficient methylation by mtDNMT1. In this instance, the in vitro
enzymatic assay, in combination with a means of systematically re-constituting the system, could
be essential tools in identifying what is missing from our original mtDNMT1 catalytic assays.
Perhaps there is a protein in the mitochondria that plays an analogous role to UHRF1 in the
nucleus, and its association with mtDNMT1 is required for methylation activity, even in an in
vitro setting. If that is the case, then we would expect to see a spike in methyltransferase activity
when that factor is incrementally added back to the reaction. An alternative possible explanation
for loss of activity following purification of the TAP-tagged mtDNMT1 is that the TAP-tag
interferes with catalytic activity. The TAP-tag insertion adds considerable sequence at the Cterminus of DNMT1, which could also introduce unnatural secondary or tertiary structure,
thereby limiting accessibility of the active site of the enzyme to its target cytosine substrate.
However, a direct comparison of methyltransferase activity in mitochondrial extracts isolated
from both non-tagged and TAP-tagged HCT116 cells did not show a remarkable difference. If
the TAP-tag was interfering with activity, we would expect to see an approximate 50% reduction
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in the level of activity measured in HCT116-TAP cells, with only one WT allele, compared to
non-tagged cells, with both WT alleles.
Purification of mtDNMT1-TAP from mitochondria, and further characterization of its copurified proteins could also shed light on the identities of the other smaller proteins we detect
with DNMT1 antibodies in the mitochondria. A 60kDa band is seen with an N-terminal DNMT1
antibody and a 30kDa immunoreactive species is visualized with the C-terminal antibody (Figure
3-16). We are still unsure whether these proteins are proteolytically processed products of the
full-length mtDNMT1 or non-specific proteins, detected due to promiscuity of the antibodies.
Although mass spectrometry usually cannot be used to obtain the full sequence of a protein, it is
more valuable instead as an identification tool; MS could provide enough information within
discrete peptide sequences to predict both the identities and the precursor proteins for those
smaller species. Alternatively, N-terminal sequencing could be performed to obtain full
sequences for the unknown protein bands co-purified with mtDNMT1. Knowing the identities
and compositions of these smaller protein species would help to explain, for instance, why we
see no change in the level of the 60kDa mitochondrial protein species upon loss of p53, while the
full-length mtDNMT1 is dramatically up-regulated (Figure 2-12). If this protein species is indeed
a proteolytic product of the full-length enzyme but still contains the N-terminal epitope, one
would expect it to be equally increased in cells lacking p53, unless the processing peptidase
within mitochondria (MPP) is saturated, thereby limiting digestion of the full-length enzyme.
In line with the studies described above to reveal the identities of the smaller protein
species in mitochondria, the HCT116-TAP line could be used to assay their methyltransferase
activities. If those smaller species represent proteolytically-processed forms of the full-length
mtDNMT1, then we can already speculate what roles they may play and whether or not they
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might contain catalytic activity based on what is known about the functional domains of DNMT1
in the nucleus. The epitope-specific antibodies against DNMT1 used for detection by
immunoblot are informative, such that they can be used to predict which conserved motifs might
be present in a product cleaved from the N- or C-terminus. For instance, the C-terminal catalytic
domain that is so highly conserved across both eukaryotic and prokaryotic CpG
methyltransferases (Figure 1-5) contains amino acid sequence that, itself, would produce a
protein approximately 60kDa in size. This means, however, that the 30kDa band detected with
the C-terminal antibody is not likely to demonstrate catalytic activity. Similarly, although the
60kDa band seen on immunoblots with an N-terminal DNMT1 antibody is of sufficient size to
contain the catalytic domain, its detection with an N-terminal epitope suggests that it likely only
comprises a region within the regulatory domain, and thus, would also not be expected to exhibit
methyltransferase activity. These hypotheses could be tested using the HCT116-TAP cell line by
first fractionating mitochondrial extracts by size-exclusion chromatography, and then performing
additional TAP-tag purification on those fractions. Because the TAP-tag is inserted into the Cterminus, we would only be able to purify the 30kDa band detected with a C-terminal antibody,
but the additional size exclusion step would allow us to distinguish between methyltransferase
activity coming from the smaller protein species versus the full-length enzyme. In the nucleus, it
has been shown that the catalytic domain of DNMT1 is not functional on its own; rather, a
generous portion of the N-terminal regulatory domain is required for efficient methyltransferase
activity (74). If this observation holds true in the mitochondria, then it is likely that only the fulllength enzyme (after cleavage of the MTS) is responsible for methylation of mtDNA.
As discussed in the introduction, nuclear DNMT1 is known to be regulated by posttranslational modification (PTM) at several key residues, but this area remains largely
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uninvestigated. Nothing is known about post-translational modification of mtDNMT1, so the
potential for these mechanisms to control the function of mtDNMT1 begs exploration. Again,
because the HCT116-TAP cell line carries a TAP-tag that has been inserted into the endogenous
DNMT1 locus, the resultant DNMT1-TAP fusion protein is expected to be subject to regulation
by PTMs just like the WT allele. It is well-established that mitochondria are highly responsive to
conditions of oxidative stress, which generates cysteinyl-NO (SNO) adducts on many proteins
(146), and triggers phosphorylation cascades (147), thus impacting OXPHOS pathways and
mitochondrial biology in general. If PTMs were identified for mtDNMT1, the HCT116-TAP cell
line could be the ideal reagent to measure changes in the profiles of PTMs to mtDNMT1 as a
function of oxidative stress. This would broaden our findings that mtDNMT1 is responsive to
stimulation by NRF1 and PGC1α (Chapter 2), which themselves are up-regulated by oxidative
stress, and provide direct insight into how mtDNMT1 itself is controlled and thereby elicits
downstream effects on mitochondrial physiology.
Just as the studies above propose investigating the alterations in specific PTMs of
mtDNMT1 under conditions of oxidative stress, the HCT116-TAP cell line can be used to study
changes in protein-protein interactions, methylation activity and presumed proteolytic products
of mtDNMT1 under various conditions. It is relatively easy to induce oxidative stress in cultured
cells; they can be grown in a hypoxic chamber under conditions of 2% O2, in tissue culture flasks
with non-vented caps, in the presence of cobalt chloride or through chronic exposure to alcohol.
Several of these methods are currently being employed by a graduate student, Joyce Balinang, in
our laboratory, and preliminary results show dynamic alterations in levels of mtDNMT1 under
hypoxic conditions, recapitulating the effect shown in Figure 2-11. Induction of oxidative stress
within the HCT116-TAP cell line, isolation of mitochondria and subsequent purification of the
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mtDNMT1-TAP allele would provide the cellular reagents necessary to assess changes in
mtDNMT1 levels, activity and co-purified protein partners in a single experiment.
We also used the HCT116-TAP cell line in mitochondrial DNA IP experiments to
demonstrate that mtDNMT1-TAP binds to mtDNA in a CpG-dependent manner (Figure 4-8).
These assays should also be performed in different cellular contexts, such as oxidative stress, to
determine whether changes in mtDNMT1 protein levels seen by immunoblot correlate with an
altered amount of mtDNMT1 bound to mtDNA. Although we would expect increases in
mtDNMT1 protein levels to coincide with increased binding of mtDNMT1 to sites along
mtDNA, and therefore increased mtDNA modification, this highlights an important point: it may
prove challenging to distinguish between effects caused by changes in mtDNMT1 protein levels
and those caused by changes in mtDNMT1 function. The mitochondrial form of DNMT1, as in
the nucleus, performs multiple tasks: it binds mtDNA, and exhibits methyltransferase activity.
However, it may serve other roles unique to its compartmentalization within mitochondria. We
will therefore need to rely on other methods, such as MeDIP, hydroxy-MeDIP, enzyme assays
and transcriptional analyses to precisely tease-apart the many possible roles mtDNMT1 could be
playing to impact mitochondrial function. In addition to methylation-mediated effects on
mitochondrial transcription, other potential functions include serving as a scaffold protein,
similar to the role of TFAM (10, 14), binding mtDNA, and recruiting or blocking the interaction
of specific mitochondrial transcription factors or the transcriptional machinery with mtDNA.

III.

Proposed model for transcriptional control in mitochondria
The mitochondrial transcriptional studies described in Chapter 2 led us to question

whether the changes in mitochondrial transcription patterns observed were strand-specific or
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gene-specific, and whether up-regulation of mtDNMT1 or loss of p53 was responsible for those
effects (Figure 2-13 and 2-14). It is clear that this issue needs to be addressed in a more defined
cellular context, where only mtDNMT1 activity has been altered and the confounding effects of
p53 status can be avoided.
Because the 5’ region that distinguishes the mitochondrial and nuclear forms of DNMT1
is so small (303bp in human, 159bp in mouse), and the precise transcription start site of
mtDNMT1 remains to be located, RNAi strategies to knock down expression of only the
mtDNMT1 isoform are not feasible. Thus, we have designed approaches to both knock-out and
overexpress mitochondrial DNMT1. The knockout strategy involves targeting of both alleles to
modify exon 1 by adding two termination codons between ATG2 and ATG3 (Figure 2-6). The
targeting construct contains either hygromycin or zeocin resistance cassettes, allowing
conditional deletion of each allele of mtDNMT1 individually. In similar conditional knockouts
of total DNMT1 in HCT116 cells, En Li and colleagues (148) reported that total loss of DNMT1
function led to mitotic catastrophe, characterized by G2 arrest, severe mitotic defects and cell
death. If this striking cellular reponse has a mitochondrial component, then it would suggest an
essential role for mtDNMT1 in cell survival. However, if the targeted cells were able to escape
these effects, then they could be useful in determining what effects loss of mtDNMT1, and
therefore loss of mtDNA methylation, has on mitochondrial transcription and function.
In an alternative approach, we have generated all of the reagents necessary to induce
overexpression of only the mitochondrial form of DNMT1. These include CMV-driven
expression constructs containing DNMT1 sequences starting at: ATG1, which would express
both mitochondrial and nuclear forms; ATG3, which expresses exclusively the nuclear form; and
a ΔATG3opt construct, in which ATG3 has been mutated to alanine, and the Kozak sequence
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surrounding ATG1 has been optimized, permitting high overexpression of only the
mitochondrial isoform. These expression constructs have been transferred into lentiviral vectors
for efficient transduction of even the hardest-to-transfect cell lines.
Either of these genetic approaches should provide an adequate system for more
specifically altering mtDNMT1 levels, enabling us then to look at direct consequences, including
mtDNA methylation and hydroxymethylation profiles, and changes in mitochondrial
transcription. Based on our initial findings, we predict that altering levels of mtDNMT1 will
have effects on mitochondrial transcription, particularly visible on the heavy strand, where there
are several protein-coding ORFs and two different promoters driving transcription. We
hypothesized from our original experiments that the increase in ND1 expression on the heavy
strand could be a result of interference with proper termination from HSP1, introduced either by
methylation of the terminator binding site, or through direct protein-protein interaction of
mtDNMT1 bound at that site (Figure 2-16). Using cell lines either lacking or overexpressing
only mtDNMT1, we can perform mtIP experiments to look for changes in the residence of
mtDNMT1 and/or mTERF1 at the termination site, and whether transcription of ND1 and the
rRNA genes is subsequently altered.
We have obtained several other cell lines that will be instrumental in our analysis of
functional outcomes of mtDNMT1, methylation and hydroxymethylation in mitochondria.
HCT116 cell lines carrying hypomorphic alleles of DNMT1 (DNMT1-/-), null alleles for
DNMT3b (DNMT3b-/-), or double knockout (DKO) were received from Dr. Bert Vogelstein
(Johns Hopkins University). The hypomorphic DNMT1 alleles were generated by replacing
exons 3-5 with a hygromycin resistance cassette, however, alternative splicing from exons 1-6
resulted in low-level production of a truncated protein that retains some hemimethylation activity

240

(66, 67). Although enough DNMT1 is still present in the DNMT1-/- hypomorphs to maintain
approximately normal levels of methylation, the value of these cell lines will be in determining
whether DNMT1 is solely responsible for the methylation observed in mitochondria. We have
not been able to justify why we observe greater methyltransferase activity in crude mitochondrial
preparations, in comparison to a more pure mtDNMT1-TAP enzyme (Figure 4-9). One possible
explanation for this is that mtDNMT1 may not be the only methyltransferase that gains access to
the mitochondrial compartment. Although we could not detect either of the de novo
methyltransferases, DNMT3a or DNMT3b, in the mitochondrial fractions of cells probed by
immunoblot, and we cannot locate obvious mitochondrial targeting sequences within the
genomic sequence for either enzyme through bioinformatics, it will be important to know
whether they are present or absent in mitochondria with certainty. If one or both of these
enzymes is present in mitochondria, then genetic deletion of either DNMT3a or DNMT3b, or
both together (3a-/- 3b-/- DKO), would induce changes in 5mC modification of mtDNA as
assessed by MeDIP, and mitochondrial methyltransferase activity as measured by enzymatic
assay. Furthermore, if one of the de novo methyltransferases is found to translocate to
mitochondria, then distinct roles for de novo and maintenance methylation, and preference for
hemi-methylated versus unmethylated DNA substrates, among other properties, will need to be
examined in mitochondria similar to studies that have been performed for the nuclear DNMTs.
Mouse embryonic stem (ES) cells containing deletions in DNMT1 exons 30-32, which
encode the PC and ENV motifs required for catalytic activity, were obtained from Drs. Masaki
Okano and En Li. (58). The J1 wild type ES cells were used to generate heterozygous (C/+) as
well as homozygous deletion (C/C) ES cell lines. Prashant Thakkar in our laboratory has been
working closely with these three ES cell lines, and has preliminary data showing an approximate
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50% reduction in the level of mtDNMT1 in C/+ cells compared to WT J1, and the C/C cells
show no detectable levels of mtDNMT1. These cell lines will be critical in a more stringent
analysis of mtDNMT1 function, as it relates to 5mC and therefore 5hmC modification in
mitochondria. Data generated through MeDIP and hydroxy-MeDIP analyses of these cell lines
should indicate whether the 5hmC modification in mtDNA depends on the presence of 5mC, or
if 5hmC can arise independently through some other mechanism, as discussed in Chapter 2. This
distinction is critical to the way we think about how the processes of methylation and
hydroxymethylation are themselves regulated, and how they can be used to modify
mitochondrial transcription.
If 5hmC is derived from 5mC, then the enzyme responsible for its conversion would be
extremely important to overall levels of mitochondrial epigenetic modification, potentially
through demethylation of mtDNA, and would probably play roles in influencing mtDNA
structure as well as mitochondrial transcription. Prashant Thakkar in our laboratory is already
examining whether TET1, the most abundant of the Tet proteins in ES cells and responsible for
conversion of 5mC to 5hmC in the nucleus, might also have a mitochondrial component. If a
mitochondrial TET1 protein is identified, it will be essential to understand whether it interacts
with mtDNMT1, and how the function of the TET1 enzyme is balanced by mtDNMT1
methylation to coordinate effects on mitochondrial gene expression. As described in Chapter 1,
the patterns for 5mC and 5hmC modifications have been mapped for the nuclear genome, and it
appears as though they exhibit opposite distributions with regard to CpG-rich (low 5mC, high
5hmC) and CpG sparse (high 5mC, low 5hmC) regions. Thus, it almost seems as though the high
presence of 5hmC within CpG-rich promoters may confer some degree of protection against the
5mC modification, and subsequent methylation-mediated silencing of the associated genes. If
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this “competition” between 5mC and 5hmC for the same CpG sites also occurs in mitochondria,
then factors dictating which modifications are present within mtDNA could serve as critical
regulators of mitochondrial gene expression.
Because CpG dinucleotides are under-represented and generally sparse throughout
mtDNA, it is possible that methylation of even a single residue could impact mitochondrial
transcription or binding by proteins associated with mtDNA. It is therefore particularly important
that we more precisely map the distribution of 5mC modification in the mitochondrial genome.
MeDIP analyses paired with qPCR can report relative quantitations for the level of 5mC
modification within a specific amplicon, but it cannot provide information as to the methylation
status of a particular site. There is a distinction to be made between overall levels of mtDNA
methylation and methylation status at a single cytosine residue; we will need to perform nextgeneration sequencing of bisulfite-modified mtDNA to determine the methylation status of
mtDNA at a single nucleotide resolution. We have already optimized the conditions necessary to
achieve complete bisulfite conversion, and preliminary reads of the mitochondrial genome detect
5mC modifications within D-loop regulatory region of mtDNA, which houses the promoters for
bi-directional transcription as well as the origin of replication for heavy strand synthesis (Figure
1-2). This data complements what we observed by mtIP showing mtDNMT1 bound in the Dloop region, and by MeDIP analysis with the 5mC antibody (Figure 2-3). Additionally, if 5mC is
a precursor for 5hmC, it could also further support data from the hydroxy-MeDIP and β-gt
assays, showing 5hmC modification in the D-loop (Figure 2-3 and Figure 2-5).
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IV.

mtDNMT1 as a possible therapeutic target
Mitochondrial dysfunction has been implicated in a wide variety of human diseases,

including heart disease, neurological disease, diabetes, aging and cancer. Central to each of these
disorders is an alteration in the production of cellular energy, mediated by mitochondrial
glycolysis and oxidative phosphorylation. Mitochondrial energy production could not be
achieved without assistance from the nuclear genome, which encodes the majority of proteins
required for OXPHOS complex formation, mitochondrial biogenesis, and mitochondrial DNA
transcription, which produces essential components of the respiratory chain complexes.
Two of the major nuclear-encoded factors that exert control over mitochondrial function
are NRF1 and PGC1α. These transcriptional co-activators stimulate transcription of nuclearencoded genes with protein products destined for import into mitochondria as part of a cellular
response to changing environmental conditions. Our data demonstrates that among the nuclearencoded mitochondrial proteins regulated by NRF1 and PGC1α is the novel mitochondrial
isoform of the maintenance mammalian DNA methyltransferase, DNMT1. Roles for DNMT1 in
methylation of nuclear DNA and methylation-mediated regulation of nuclear gene expression
have been well-established. Our data showed that up-regulation of mtDNMT1 was associated
with distinct changes in the mitochondrial transcriptional program, which suggests that
mtDNMT1 may serve to regulate mitochondrial gene expression through a mechanism
analogous to its role in the nucleus.
Pharmacologic inhibition of DNA methyltransferase activity through incorporation of the
nucleoside analog 5-aza-2’-deoxycytidine (5-aza-dC) into DNA was first demonstrated in
cultured cells (39, 40, 142), and has since been approved for clinical use in treating
myelodysplastic syndrome and acute leukemias. Combination clinical trials are currently
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underway, using 5-aza-dC paired with histone deacetylase inhibitors and interleukin-2 in the
treatment of renal cell carcinoma as well as melanoma (149). In the nucleus, DNMT1 protein
and activity are effectively shut down by treatment with 5-aza-dC, and genomic methylation
levels have been reported to decrease by 80% (142). We examined the effects of this compound
on mtDNMT1, and observed only a modest inhibition of DNMT1 in the mitochondrial
compartment, relative to its substantial effect on DNMT1 in whole cells (Figure 4-14). Thus 5aza-dC appeared to be relatively ineffective at inhibiting mtDNMT1 activity (Figure 4-15).
Studies using other nucleoside analogs of cytidine, including 2’-deoxy-2’,2’-difluorocytidine
(dFdC, gemcitabine), report that the phosphorylated form (dFdCTP) is incorporated into mtDNA
with a 432-fold lower efficiency than dCTP (150). Additionally, these bases were interpreted as
mtDNA lesions, causing POLG to pause and incorporate downstream nucleotides much more
slowly, and with 2-fold less fidelity at pause sites (150). Although no previous reports have used
5-aza-dC to inhibit mtDNA methylation, our results likely suggest that this compound, like
dFdC, is also not incorporated efficiently into mtDNA. Further experimentation is needed to
confirm this theory.
Although mtDNMT1 does not appear to be as sensitive to the effects of the mechanismbased inhibitor, 5-aza-dC, mtDNMT1 may still serve as a relevant therapeutic target using
compounds against one of its other proposed functions, such as mtDNA binding. Alternatively,
5-aza-dC could be used in combination therapy perhaps with analogs of 5hmC, which could be
effective if mtDNMT1 turns out to be directly involved in generating the 5hmC modification.
The possibility of targeting mtDNMT1 as a means of regulating mitochondrial function is
certainly present, but it will be important for future studies to further discern the specific roles of
mtDNMT1 in the mitochondria so that their therapeutic potential can be realized.
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V.

Conclusions
Mitochondria are intimately involved in normal cell function as they are responsible for

the production of the majority of cellular energy required for processes including cell signaling,
differentiation, and control of cell cycle and cell growth (1-3). Mitochondria contain their own
unique genome, but its content is not sufficient to allow for complete functioning of the
organelle. Most of the proteins found in mitochondria are encoded by the nuclear genome and
transported into the mitochondrial compartment using recognizable targeting sequences and
specific import machinery. Among the features that mitochondrial DNA shares with nuclear
DNA is the presence of cytosine methylation, which was first described in a couple of seminal
papers several decades ago (15-17). However, neither the mechanism generating the 5methylcytosine (5mC) modification, nor its functional significance was known. The studies
described

throughout

this

dissertation

addressed

whether

a

nuclear-encoded

DNA

methyltransferase may be responsible for generating 5mC in mtDNA, and what the functional
consequences of that modification might be, as they related to mitochondrial transcription.
Using MeDIP analyses we validated the presence of 5mC in various regions throughout
mtDNA, and we discovered that mtDNA also contains 5-hydroxymethylcytosine (5hmC)
modifications at specific sites throughout the mitochondrial genome. The presence of both
modifications suggests that previous estimates reporting 5mC at only 3-5% of CpG dinucleotides
were likely an underestimation (17). 5hmC has also been described to occur in the nuclear
genome and is thought be derived from 5mC, representing an intermediate in active
demethylation of DNA through an oxidative-deamination mechanism (47). We sought answers
to how these modifications were generated in mitochondria, and what roles they played in
regulating mitochondrial function, using epigenetic modification in the nucleus as an analogy.
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We found that an isoform of the most abundant mammalian methyltransferase, DNA
methyltransferase 1 (DNMT1) translocates to mitochondria, driven by an in-frame mitochondrial
targeting sequence (MTS) located upstream of the nuclear DNMT1 translational start site. This
MTS is highly conserved across numerous mammalian species, suggesting a functional relevance
for this protein in mitochondria. We showed that this MTS is capable of directing GFP to the
mitochondria, and operates across species, demonstrating its functional conservation.
To investigate the function of mitochondrial DNMT1 (mtDNMT1), we created a cell line
that carries a tandem-affinity purification (TAP) tag at the C-terminus of a single endogenous
human DNMT1 allele. The TAP-tag was inserted into the DNMT1 genomic locus through gene
targeting and rAAV-mediated homologous recombination, and all final cell lines were screened
by PCR, genotyped by Southern blot and characterized using immunoblot and RT-qPCR
analyses. The DNMT1-TAP allele was shown to localize properly to the mitochondria, and
insertion of the tag did not disrupt catalytic methyltransferase activity measured from whole
cells.
Using the DNMT1-TAP cell line, we showed that mtDNMT1 specifically binds mtDNA
in a manner that is proportional to CpG density, supporting a role for this isoform in methylation
of CpGs in mtDNA. Using a sensitive fluorescence-based enzyme assay and highly-purified
mitochondrial extracts, we showed that mtDNMT1 exhibits CpG-specific methyltransferase
activity in vitro. This activity is resistant to trypsin-treatment of intact mitochondria, indicating
that it originates from within the mitochondrial compartment. Mitochondrial DNMT1 protein
was down-regulated and methyltransferase activity was modestly inhibited by the nucleoside
analog 5-aza-2’-deoxycytidine (5-aza-dC), although to a lesser extent than the level of inhibition
observed for total DNMT1.
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Mitochondrial DNMT1 was up-regulated by over-expression of NRF1 and PGC1α,
transcription factors that activate nuclear-encoded mitochondrial proteins in response to
oxidative stress. Loss of p53, a tumor suppressor gene known to help control mitochondrial
metabolism, also induced a dramatic increase in mtDNMT1 expression at both the mRNA and
protein levels. The effect of this p53-mediated up-regulation of mtDNMT1 was examined for
influences on mitochondrial transcription. We observed gene-specific differences in transcription
of several mitochondrial genes upon over-expression of mtDNMT1, which we propose are the
results of methylation-mediated control of transcription in the mitochondria.
Our data suggests roles for mtDNMT1 in both the establishment and maintenance of
cytosine methylation, from which 5hmC is presumably derived, and in the regulation of
mitochondrial transcription. We propose that the enzymes responsible for epigenetic
modification of mtDNA have potential as therapeutic targets, with relevance to a broad spectrum
of human disorders.
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